Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16437302,peak plasma concentration (C(max)),"The peak plasma concentration (C(max))of 44.0+/-24.2 ng/ml occurred 39+/-19.3 h after subcutaneous administration, equivalent to the C(max) (43.76+/-18.23 ng/ml) previously reported for dairy cattle after a pour-on administration of 0.5 mg/kg eprinomectin.",Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),[ng] / [ml],44.0,436,DB00602,Ivermectin
,16437302,C(max),"The peak plasma concentration (C(max))of 44.0+/-24.2 ng/ml occurred 39+/-19.3 h after subcutaneous administration, equivalent to the C(max) (43.76+/-18.23 ng/ml) previously reported for dairy cattle after a pour-on administration of 0.5 mg/kg eprinomectin.",Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),[ng] / [ml],43.76,437,DB00602,Ivermectin
,16437302,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) after subcutaneous administration was 7354+/-1861 (ng h)/ml, higher than that obtained after pour-on delivery (5737.68+/-412.80 (ng h)/ml).",Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),[h·ng] / [ml],7354,438,DB00602,Ivermectin
,16437302,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) after subcutaneous administration was 7354+/-1861 (ng h)/ml, higher than that obtained after pour-on delivery (5737.68+/-412.80 (ng h)/ml).",Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),[h·ng] / [ml],5737.68,439,DB00602,Ivermectin
,16437302,mean residence time (MRT),The mean residence time (MRT) of the drug in plasma was 211+/-55.2 h.,Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),h,211,440,DB00602,Ivermectin
,16437302,milk to plasma ratio,"The concentration of drug in milk was parallel to that in plasma, with a milk to plasma ratio of 0.16+/-0.01.",Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),,0.16,441,DB00602,Ivermectin
,16437302,highest detected concentration,"The highest detected concentration of eprinomectin in milk was 9.0 ng/ml, below the maximum residue limit (MRL) of eprinomectin in milk established by the Joint FAO/WHO Expert Committee on Food Additives in 2000.",Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437302/),[ng] / [ml],9.0,442,DB00602,Ivermectin
,15725548,observed,The observed peak plasma concentration (Cmax) was 46.3+/-13.8 ng ml-1 and the time to reach Cmax (t(max)) was 0.9+/-0.2 day.,Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),[ng] / [ml],46.3,1386,DB00602,Ivermectin
,15725548,peak plasma concentration (Cmax),The observed peak plasma concentration (Cmax) was 46.3+/-13.8 ng ml-1 and the time to reach Cmax (t(max)) was 0.9+/-0.2 day.,Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),[ng] / [ml],46.3,1387,DB00602,Ivermectin
,15725548,time to reach Cmax (t(max)),The observed peak plasma concentration (Cmax) was 46.3+/-13.8 ng ml-1 and the time to reach Cmax (t(max)) was 0.9+/-0.2 day.,Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),d,0.9,1388,DB00602,Ivermectin
,15725548,absorption half-life (t1/2ab),"The values for the absorption half-life (t1/2ab) and the elimination half-life (t1/2el) were 0.3+/-0.2 and 2.8+/-0.7 days, respectively.",Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),d,0.3,1389,DB00602,Ivermectin
,15725548,elimination half-life (t1/2el),"The values for the absorption half-life (t1/2ab) and the elimination half-life (t1/2el) were 0.3+/-0.2 and 2.8+/-0.7 days, respectively.",Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),d,2.8,1390,DB00602,Ivermectin
,15725548,area under the concentration-time curve (AUC),The calculated area under the concentration-time curve (AUC) was 185.2+/-12.1 ng day ml-1 and the mean residence time (MRT) was 4.2+/-1.3 days.,Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),[d·ng] / [ml],185.2,1391,DB00602,Ivermectin
,15725548,mean residence time (MRT),The calculated area under the concentration-time curve (AUC) was 185.2+/-12.1 ng day ml-1 and the mean residence time (MRT) was 4.2+/-1.3 days.,Pharmacokinetics of ivermectin in zebu Gobra (Bos indicus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725548/),d,4.2,1392,DB00602,Ivermectin
,11106995,half-life,A 14.5 h half-life in the rumen prolonged the presence of [3H] in the abomasum.,"The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106995/),h,14.5,3589,DB00602,Ivermectin
,11106995,systemic availability,"Absorption of doramectin resulted in a systemic availability of 35%, of which 1.6 and 23.6% of the dose was contained in urine and biliary secretions, respectively.","The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106995/),%,35,3590,DB00602,Ivermectin
,11106995,systemic availability,"Absorption of doramectin resulted in a systemic availability of 35%, of which 1.6 and 23.6% of the dose was contained in urine and biliary secretions, respectively.","The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106995/),%,1.6,3591,DB00602,Ivermectin
,11106995,systemic availability,"Absorption of doramectin resulted in a systemic availability of 35%, of which 1.6 and 23.6% of the dose was contained in urine and biliary secretions, respectively.","The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106995/),%,23.6,3592,DB00602,Ivermectin
,31183888,elimination half-life (t1/2λz ),"The pharmacokinetic parameters of ivermectin following oral alone-administration were as follows: elimination half-life (t1/2λz ) 110 ± 11.06 hr, area under the plasma concentration-time curve (AUC0-∞ ) 7,805 ± 1,768 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),h,110,3920,DB00602,Ivermectin
,31183888,area under the plasma concentration-time curve (AUC0-∞ ),"The pharmacokinetic parameters of ivermectin following oral alone-administration were as follows: elimination half-life (t1/2λz ) 110 ± 11.06 hr, area under the plasma concentration-time curve (AUC0-∞ ) 7,805 ± 1,768 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),h,"7,805",3921,DB00602,Ivermectin
,31183888,maximum concentration (Cmax ),"ng/ml, maximum concentration (Cmax ) 137 ± 48.09 ng/ml, and time to reach Cmax (Tmax ) 14.0 ± 4.90 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),[ng] / [ml],137,3922,DB00602,Ivermectin
,31183888,time to reach Cmax (Tmax ),"ng/ml, maximum concentration (Cmax ) 137 ± 48.09 ng/ml, and time to reach Cmax (Tmax ) 14.0 ± 4.90 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),h,14.0,3923,DB00602,Ivermectin
,31183888,t1/2λz,"The pharmacokinetic parameters of praziquantel following oral alone-administration were as follows: t1/2λz 7.39 ± 3.86 hr, AUC0-∞ 4,301 ± 1,253 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),h,7.39,3924,DB00602,Ivermectin
,31183888,AUC0-∞,"The pharmacokinetic parameters of praziquantel following oral alone-administration were as follows: t1/2λz 7.39 ± 3.86 hr, AUC0-∞ 4,301 ± 1,253 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),h,"4,301",3925,DB00602,Ivermectin
,31183888,Cmax,"ng/ml, Cmax 897 ± 245 ng/ml, and Tmax 5.33 ± 0.82 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),[ng] / [ml],897,3926,DB00602,Ivermectin
,31183888,Tmax,"ng/ml, Cmax 897 ± 245 ng/ml, and Tmax 5.33 ± 0.82 hr.",Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183888/),h,5.33,3927,DB00602,Ivermectin
,18420349,Maximum concentration,"Maximum concentration in plasma was 2.22 and 5.25 microg/l, and AUC was 13.6 and 33.7 microg day/l for the 0.5 and 1.0mg/kg dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),[μg] / [l],2.22,4187,DB00602,Ivermectin
,18420349,Maximum concentration,"Maximum concentration in plasma was 2.22 and 5.25 microg/l, and AUC was 13.6 and 33.7 microg day/l for the 0.5 and 1.0mg/kg dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),[μg] / [l],5.25,4188,DB00602,Ivermectin
,18420349,AUC,"Maximum concentration in plasma was 2.22 and 5.25 microg/l, and AUC was 13.6 and 33.7 microg day/l for the 0.5 and 1.0mg/kg dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),[d·μg] / [l],13.6,4189,DB00602,Ivermectin
,18420349,AUC,"Maximum concentration in plasma was 2.22 and 5.25 microg/l, and AUC was 13.6 and 33.7 microg day/l for the 0.5 and 1.0mg/kg dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),[d·μg] / [l],33.7,4190,DB00602,Ivermectin
,18420349,Milk-to-plasma AUC ratio,"Milk-to-plasma AUC ratio was 0.79+/-0.12 and 1.12+/-0.43; the fraction of dose recovered in milk was 0.037+/-0.011 and 0.058+/-0.027% for the low and high dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),,0.79,4191,DB00602,Ivermectin
,18420349,Milk-to-plasma AUC ratio,"Milk-to-plasma AUC ratio was 0.79+/-0.12 and 1.12+/-0.43; the fraction of dose recovered in milk was 0.037+/-0.011 and 0.058+/-0.027% for the low and high dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),,1.12,4192,DB00602,Ivermectin
,18420349,fraction of dose recovered in milk,"Milk-to-plasma AUC ratio was 0.79+/-0.12 and 1.12+/-0.43; the fraction of dose recovered in milk was 0.037+/-0.011 and 0.058+/-0.027% for the low and high dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),%,0.037,4193,DB00602,Ivermectin
,18420349,fraction of dose recovered in milk,"Milk-to-plasma AUC ratio was 0.79+/-0.12 and 1.12+/-0.43; the fraction of dose recovered in milk was 0.037+/-0.011 and 0.058+/-0.027% for the low and high dose, respectively.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),%,0.058,4194,DB00602,Ivermectin
below,18420349,Maximum residual levels,"Maximum residual levels in milk were below the maximum acceptable level of 20 microg/kg; however, EPR was detected in all samples investigated.",Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420349/),[μg] / [kg],20,4195,DB00602,Ivermectin
,12093526,retention times,"The retention times of moxidectin and internal standard, ivermectin are approximately 10.7 and 18.6 min, respectively.",Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093526/),min,10.7,6009,DB00602,Ivermectin
,12093526,retention times,"The retention times of moxidectin and internal standard, ivermectin are approximately 10.7 and 18.6 min, respectively.",Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093526/),min,18.6,6010,DB00602,Ivermectin
,12093526,Recoveries,"Recoveries at concentrations 0.2, 400, 1000 ng/ml are 94, 75, and 71%, respectively.",Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093526/),%,94,6011,DB00602,Ivermectin
,12093526,Recoveries,"Recoveries at concentrations 0.2, 400, 1000 ng/ml are 94, 75, and 71%, respectively.",Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093526/),%,75,6012,DB00602,Ivermectin
,12093526,Recoveries,"Recoveries at concentrations 0.2, 400, 1000 ng/ml are 94, 75, and 71%, respectively.",Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093526/),%,71,6013,DB00602,Ivermectin
,30859185,C max,"C max and AUC increased in PSAC and SAC with ascending doses and were similar in both age groups when the current standard dose (200 μg/kg) was administered (∼23 ng/mL and ∼350 ng×h/mL, respectively).",Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30859185/),,∼23,8188,DB00602,Ivermectin
,30859185,AUC,"C max and AUC increased in PSAC and SAC with ascending doses and were similar in both age groups when the current standard dose (200 μg/kg) was administered (∼23 ng/mL and ∼350 ng×h/mL, respectively).",Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30859185/),,∼350,8189,DB00602,Ivermectin
,30859185,weight-adjusted CL/F,"AUC and Cmax were ∼2-fold lower in children compared with parameters previously studied in adults, whereas body weight-adjusted CL/F (∼0.35 L/h/kg) was significantly higher in children.",Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30859185/),[l] / [h·kg],∼0.35,8190,DB00602,Ivermectin
,30859185,Tmax,"Tmax (∼6 h), t1/2 (∼18 h), mean residence time (MRTINF) (∼28 h) and V/F (∼8 L/kg) were similar in all paediatric treatment arms.",Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30859185/),h,∼6,8191,DB00602,Ivermectin
,11558745,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) (IVM: 21.4 ng/ml; DRM: 21.3 ng/ml; MXD: 30.1 ng/ml) were obtained at (tmax) 7.9 h (IVM), 8 h (DRM) and 7.9 h (MXD).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),[ng] / [ml],21.4,8502,DB00602,Ivermectin
,11558745,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) (IVM: 21.4 ng/ml; DRM: 21.3 ng/ml; MXD: 30.1 ng/ml) were obtained at (tmax) 7.9 h (IVM), 8 h (DRM) and 7.9 h (MXD).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),[ng] / [ml],21.3,8503,DB00602,Ivermectin
,11558745,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) (IVM: 21.4 ng/ml; DRM: 21.3 ng/ml; MXD: 30.1 ng/ml) were obtained at (tmax) 7.9 h (IVM), 8 h (DRM) and 7.9 h (MXD).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),[ng] / [ml],30.1,8504,DB00602,Ivermectin
,11558745,tmax,"Maximum plasma concentrations (Cmax) (IVM: 21.4 ng/ml; DRM: 21.3 ng/ml; MXD: 30.1 ng/ml) were obtained at (tmax) 7.9 h (IVM), 8 h (DRM) and 7.9 h (MXD).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),h,7.9,8505,DB00602,Ivermectin
,11558745,tmax,"Maximum plasma concentrations (Cmax) (IVM: 21.4 ng/ml; DRM: 21.3 ng/ml; MXD: 30.1 ng/ml) were obtained at (tmax) 7.9 h (IVM), 8 h (DRM) and 7.9 h (MXD).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),h,8,8506,DB00602,Ivermectin
,11558745,area under the concentration time curve (AUC),"The area under the concentration time curve (AUC) of MXD (92.8 ng x day/ml) was significantly larger than that of IVM (46.1 ng x day/ml) but not of DRM (53.3 ng x day/ml) and mean residence time of MXD (17.5 days) was significantly longer than that of either avermectin, while that of DRM (3 days) was significantly longer than that of IVM (2:3 days).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),[d·ng] / [ml],92.8,8507,DB00602,Ivermectin
,11558745,area under the concentration time curve (AUC),"The area under the concentration time curve (AUC) of MXD (92.8 ng x day/ml) was significantly larger than that of IVM (46.1 ng x day/ml) but not of DRM (53.3 ng x day/ml) and mean residence time of MXD (17.5 days) was significantly longer than that of either avermectin, while that of DRM (3 days) was significantly longer than that of IVM (2:3 days).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),[d·ng] / [ml],46.1,8508,DB00602,Ivermectin
,11558745,area under the concentration time curve (AUC),"The area under the concentration time curve (AUC) of MXD (92.8 ng x day/ml) was significantly larger than that of IVM (46.1 ng x day/ml) but not of DRM (53.3 ng x day/ml) and mean residence time of MXD (17.5 days) was significantly longer than that of either avermectin, while that of DRM (3 days) was significantly longer than that of IVM (2:3 days).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),[d·ng] / [ml],53.3,8509,DB00602,Ivermectin
,11558745,mean residence time,"The area under the concentration time curve (AUC) of MXD (92.8 ng x day/ml) was significantly larger than that of IVM (46.1 ng x day/ml) but not of DRM (53.3 ng x day/ml) and mean residence time of MXD (17.5 days) was significantly longer than that of either avermectin, while that of DRM (3 days) was significantly longer than that of IVM (2:3 days).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),d,17.5,8510,DB00602,Ivermectin
,11558745,mean residence time,"The area under the concentration time curve (AUC) of MXD (92.8 ng x day/ml) was significantly larger than that of IVM (46.1 ng x day/ml) but not of DRM (53.3 ng x day/ml) and mean residence time of MXD (17.5 days) was significantly longer than that of either avermectin, while that of DRM (3 days) was significantly longer than that of IVM (2:3 days).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),d,3,8511,DB00602,Ivermectin
,11558745,mean residence time,"The area under the concentration time curve (AUC) of MXD (92.8 ng x day/ml) was significantly larger than that of IVM (46.1 ng x day/ml) but not of DRM (53.3 ng x day/ml) and mean residence time of MXD (17.5 days) was significantly longer than that of either avermectin, while that of DRM (3 days) was significantly longer than that of IVM (2:3 days).","Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558745/),d,2:3,8512,DB00602,Ivermectin
,26852126,systemic disposition,"Moreover, the systemic disposition of IVM in the LNC administered by the SC route was higher (p < 0.05) (1367 ng h/ml) compared to treatment with a commercial formulation (CF) (1193 ng.h/ml), but no significant differences in the biodistribution pattern were found.",Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26852126/),[h·ng] / [ml],1367,17578,DB00602,Ivermectin
,26852126,systemic disposition,"Moreover, the systemic disposition of IVM in the LNC administered by the SC route was higher (p < 0.05) (1367 ng h/ml) compared to treatment with a commercial formulation (CF) (1193 ng.h/ml), but no significant differences in the biodistribution pattern were found.",Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26852126/),[h·ng] / [ml],1193,17579,DB00602,Ivermectin
,3841151,terminal elimination rate constant (beta),"Compartmental analysis yielded mean parameters as follows: terminal elimination rate constant (beta) = 0.258 d-1, biological half-life (t 1/2 beta) = 2.7 d; apparent volume of distribution of the central compartment (Vd1) = 0.45 L/kg; apparent volume of distribution at steady state (Vdss) = 2.4 L/kg.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),1/[d],0.258,21868,DB00602,Ivermectin
,3841151,biological half-life (t 1/2 beta),"Compartmental analysis yielded mean parameters as follows: terminal elimination rate constant (beta) = 0.258 d-1, biological half-life (t 1/2 beta) = 2.7 d; apparent volume of distribution of the central compartment (Vd1) = 0.45 L/kg; apparent volume of distribution at steady state (Vdss) = 2.4 L/kg.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),d,2.7,21869,DB00602,Ivermectin
,3841151,apparent volume of distribution of the central compartment (Vd1),"Compartmental analysis yielded mean parameters as follows: terminal elimination rate constant (beta) = 0.258 d-1, biological half-life (t 1/2 beta) = 2.7 d; apparent volume of distribution of the central compartment (Vd1) = 0.45 L/kg; apparent volume of distribution at steady state (Vdss) = 2.4 L/kg.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),[l] / [kg],0.45,21870,DB00602,Ivermectin
,3841151,apparent volume of distribution at steady state (Vdss),"Compartmental analysis yielded mean parameters as follows: terminal elimination rate constant (beta) = 0.258 d-1, biological half-life (t 1/2 beta) = 2.7 d; apparent volume of distribution of the central compartment (Vd1) = 0.45 L/kg; apparent volume of distribution at steady state (Vdss) = 2.4 L/kg.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),[l] / [kg],2.4,21871,DB00602,Ivermectin
,3841151,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) was 254 ng X d/mL.,Pharmacokinetics of ivermectin administered intravenously to cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),[d·ng] / [ml],254,21872,DB00602,Ivermectin
,3841151,mean residence time (MRT),"Noncompartmental parameters, obtained by utilizing statistical moment theory, mean residence time (MRT), clearance (CL), and Vdss were calculated to be 2.8 d, 0.79 L/kg X d, and 2.2 L/kg, respectively.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),d,2.8,21873,DB00602,Ivermectin
,3841151,clearance (CL),"Noncompartmental parameters, obtained by utilizing statistical moment theory, mean residence time (MRT), clearance (CL), and Vdss were calculated to be 2.8 d, 0.79 L/kg X d, and 2.2 L/kg, respectively.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),[l] / [d·kg],0.79,21874,DB00602,Ivermectin
,3841151,Vdss,"Noncompartmental parameters, obtained by utilizing statistical moment theory, mean residence time (MRT), clearance (CL), and Vdss were calculated to be 2.8 d, 0.79 L/kg X d, and 2.2 L/kg, respectively.",Pharmacokinetics of ivermectin administered intravenously to cattle. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841151/),[l] / [kg],2.2,21875,DB00602,Ivermectin
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,52,24392,DB00602,Ivermectin
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,72,24393,DB00602,Ivermectin
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,80,24394,DB00602,Ivermectin
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,87,24395,DB00602,Ivermectin
,27641517,CMAX -1,"Eprinomectin plasma concentrations showed a biphasic peak (CMAX -1: 5.72 ± 3.25 ng/mL; CMAX -2: 6.06 ± 2.47 ng/mL) in all animals at 3.88 ± 5.16 days and 77 ± 12.52 days, respectively.",Pharmacokinetics of an extended-release formulation of eprinomectin in healthy adult alpacas and its use in alpacas confirmed with mange. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641517/),[ng] / [ml],5.72,25652,DB00602,Ivermectin
,27641517,CMAX -2,"Eprinomectin plasma concentrations showed a biphasic peak (CMAX -1: 5.72 ± 3.25 ng/mL; CMAX -2: 6.06 ± 2.47 ng/mL) in all animals at 3.88 ± 5.16 days and 77 ± 12.52 days, respectively.",Pharmacokinetics of an extended-release formulation of eprinomectin in healthy adult alpacas and its use in alpacas confirmed with mange. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641517/),[ng] / [ml],6.06,25653,DB00602,Ivermectin
above,27641517,plasma concentrations,Eprinomectin plasma concentrations remained above 1.27 ± 0.96 ng/mL for up to 120 days.,Pharmacokinetics of an extended-release formulation of eprinomectin in healthy adult alpacas and its use in alpacas confirmed with mange. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641517/),[ng] / [ml],1.27,25654,DB00602,Ivermectin
,8839664,maximum plasma concentration,"The plasma pharmacokinetic variables for patients were; maximum plasma concentration 52.0 ng ml-1; time to achieve maximum concentration, 5.2 h.; elimination half life, 35.0 h; and the area under the plasma concentration curve versus time, 2852 ng.h.ml-1.",Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839664/),[ng] / [ml],52.0,25672,DB00602,Ivermectin
,8839664,time to achieve maximum concentration,"The plasma pharmacokinetic variables for patients were; maximum plasma concentration 52.0 ng ml-1; time to achieve maximum concentration, 5.2 h.; elimination half life, 35.0 h; and the area under the plasma concentration curve versus time, 2852 ng.h.ml-1.",Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839664/),h,5.2,25673,DB00602,Ivermectin
,8839664,elimination half life,"The plasma pharmacokinetic variables for patients were; maximum plasma concentration 52.0 ng ml-1; time to achieve maximum concentration, 5.2 h.; elimination half life, 35.0 h; and the area under the plasma concentration curve versus time, 2852 ng.h.ml-1.",Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839664/),h,35.0,25674,DB00602,Ivermectin
,8839664,area under the plasma concentration curve versus time,"The plasma pharmacokinetic variables for patients were; maximum plasma concentration 52.0 ng ml-1; time to achieve maximum concentration, 5.2 h.; elimination half life, 35.0 h; and the area under the plasma concentration curve versus time, 2852 ng.h.ml-1.",Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839664/),[h·ng] / [ml],2852,25675,DB00602,Ivermectin
,32991142,lethal concentration,"In vitro, moxidectin had an activity that was similar to that of ivermectin, with median lethal concentration values for L3 and adults in the range of 0.08-1.44 μM, after 72 h of exposure.",Characterization of Moxidectin against Strongyloides ratti: In Vitro and In Vivo Activity and Pharmacokinetics in the Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32991142/),μM,0.08-1.44,26090,DB00602,Ivermectin
,32991142,maximal blood concentration,At the highest dose (750 μg/kg) we observed a maximal blood concentration of 50.3 ng/mL and an area under the curve of 895.2 ng × h/mL.,Characterization of Moxidectin against Strongyloides ratti: In Vitro and In Vivo Activity and Pharmacokinetics in the Rat Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32991142/),[ng] / [ml],50.3,26091,DB00602,Ivermectin
,32991142,area under the curve,At the highest dose (750 μg/kg) we observed a maximal blood concentration of 50.3 ng/mL and an area under the curve of 895.2 ng × h/mL.,Characterization of Moxidectin against Strongyloides ratti: In Vitro and In Vivo Activity and Pharmacokinetics in the Rat Model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32991142/),[h·ng] / [ml],895.2,26092,DB00602,Ivermectin
,32991142,half-life,"The half-life in rats was 9 h, and moxidectin was cleared to undetectable blood levels within 7 d (<10 ng/mL).",Characterization of Moxidectin against Strongyloides ratti: In Vitro and In Vivo Activity and Pharmacokinetics in the Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32991142/),h,9,26093,DB00602,Ivermectin
,1496816,elimination half-life,"The mean elimination half-life of the drug was 35.2 h, suggesting that the drug is cleared slowly from pigs with drug detectable in plasma for 6-10 days.",The distribution and some pharmacokinetic parameters of ivermectin in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496816/),h,35.2,28741,DB00602,Ivermectin
,32660993,50% inhibitory concentration [IC50],"Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (50% inhibitory concentration [IC50], 10.42 μM) and hypnozoites (IC50, 29.24 μM) in primary macaque hepatocytes when administered as a high dose prophylactically but not when administered in radical cure mode.","Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32660993/),μM,10.42,33911,DB00602,Ivermectin
,32660993,IC50,"Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (50% inhibitory concentration [IC50], 10.42 μM) and hypnozoites (IC50, 29.24 μM) in primary macaque hepatocytes when administered as a high dose prophylactically but not when administered in radical cure mode.","Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32660993/),μM,29.24,33912,DB00602,Ivermectin
,1496814,peak plasma level (Cmax),"The average peak plasma level (Cmax) of ivermectin administered in the standard tablet formulation at 6 and 100 micrograms/kg of body weight was 2.97 and 44.31 ng/g, respectively.",Bioavailability of ivermectin administered orally to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496814/),[ng] / [g],2.97,34582,DB00602,Ivermectin
,1496814,peak plasma level (Cmax),"The average peak plasma level (Cmax) of ivermectin administered in the standard tablet formulation at 6 and 100 micrograms/kg of body weight was 2.97 and 44.31 ng/g, respectively.",Bioavailability of ivermectin administered orally to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496814/),[ng] / [g],44.31,34583,DB00602,Ivermectin
,22673107,time of clearance,"The mean time of clearance of parasites was 24 ± 0.149 h for 1000 and 24 ± 0.210 h for 750 μg of doramectin/kg body weight fish, however, the dose of 1,000 μg resulted in adverse reactions and mortality in fish.","Efficacy of two avermectins, doramectin and ivermectin against Argulus siamensis infestation in Indian major carp, Labeo rohita. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22673107/),h,24,35115,DB00602,Ivermectin
,22673107,time of clearance,"The mean time of clearance of parasites was 24 ± 0.149 h for 1000 and 24 ± 0.210 h for 750 μg of doramectin/kg body weight fish, however, the dose of 1,000 μg resulted in adverse reactions and mortality in fish.","Efficacy of two avermectins, doramectin and ivermectin against Argulus siamensis infestation in Indian major carp, Labeo rohita. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22673107/),h,24,35116,DB00602,Ivermectin
,22673107,time of clearance,"The mean time of clearance of parasites from fish was 6 ± 0.210 and 12 ± 0.314 h for doramectin and ivermectin, respectively, when given at a lower dose of 150 μg/kg body weight.","Efficacy of two avermectins, doramectin and ivermectin against Argulus siamensis infestation in Indian major carp, Labeo rohita. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22673107/),h,6,35117,DB00602,Ivermectin
,22673107,time of clearance,"The mean time of clearance of parasites from fish was 6 ± 0.210 and 12 ± 0.314 h for doramectin and ivermectin, respectively, when given at a lower dose of 150 μg/kg body weight.","Efficacy of two avermectins, doramectin and ivermectin against Argulus siamensis infestation in Indian major carp, Labeo rohita. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22673107/),h,12,35118,DB00602,Ivermectin
,16515667,terminal half-life,"After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),h,2.4,40218,DB00602,Ivermectin
,16515667,apparent volume of distribution,"After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),[l] / [kg],0.8,40219,DB00602,Ivermectin
,16515667,total body clearance,"After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),[l] / [h·kg],0.8,40220,DB00602,Ivermectin
,16515667,bioavailability,After oral administration of fexofenadine at 10 mg/kg bw bioavailability was 2.6% (1.9-2.9%).,"Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),%,2.6,40221,DB00602,Ivermectin
,16515667,bioavailability,"Ivermectin pretreatment (0.2 mg/kg, p.o.) 12 h before oral fexofenadine decreased the bioavailability to 1.5% (1.4-2.1%).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),%,1.5,40222,DB00602,Ivermectin
,16515667,maximal duration,"Oral and i.v. fexofenadine significantly decreased histamine-induced wheal formation, with a maximal duration of 6 h.","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),h,6,40223,DB00602,Ivermectin
,16515667,EC50,A pharmacokinetic/pharmacodynamic link model indicated that fexofenadine in horse has antihistaminic effects at low plasma concentrations (EC50 = 16 ng/mL).,"Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),[ng] / [ml],16,40224,DB00602,Ivermectin
,27474036,absorption rates,The absorption rates for levamisole (0.71 ± 0.32 h-1) and abamectin (0.24 ± 0.08 day-1) from the MCMDG-based formulation were considerably slower than those of other studies conducted on the commercial products.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),1/[h],0.71,40236,DB00602,Ivermectin
,27474036,absorption rates,The absorption rates for levamisole (0.71 ± 0.32 h-1) and abamectin (0.24 ± 0.08 day-1) from the MCMDG-based formulation were considerably slower than those of other studies conducted on the commercial products.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),1/[d],0.24,40237,DB00602,Ivermectin
,27474036,tmax,The tmax was delayed for levamisole (2.20 ± 0.45 h) and abamectin (4.20 ± 1.64 days) compared with those in published studies.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),h,2.20,40238,DB00602,Ivermectin
,27474036,tmax,The tmax was delayed for levamisole (2.20 ± 0.45 h) and abamectin (4.20 ± 1.64 days) compared with those in published studies.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),d,4.20,40239,DB00602,Ivermectin
,27474036,MRT,Longer MRT values for levamisole (6.14 ± 1.14 h) and abamectin (8.80 ± 1.39 days) were found in this study compared to those reported.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),h,6.14,40240,DB00602,Ivermectin
,27474036,MRT,Longer MRT values for levamisole (6.14 ± 1.14 h) and abamectin (8.80 ± 1.39 days) were found in this study compared to those reported.,Pharmacokinetics of Abamectin/Levamisole Combination in a Medium Chain Mono and Diglyceride-Based Vehicle and an In Vitro Release and In Vitro In Vivo Correlation Study for Levamisole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474036/),d,8.80,40241,DB00602,Ivermectin
,17847063,Peak plasma concentrations (C(max)),Peak plasma concentrations (C(max)) of 234.0 +/- 64.3 ng/ml (mean +/- SD) were obtained for moxidectin and 132.6 +/- 43.0 ng/ml for ivermectin.,Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),[ng] / [ml],234.0,42581,DB00602,Ivermectin
,17847063,Peak plasma concentrations (C(max)),Peak plasma concentrations (C(max)) of 234.0 +/- 64.3 ng/ml (mean +/- SD) were obtained for moxidectin and 132.6 +/- 43.0 ng/ml for ivermectin.,Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),[ng] / [ml],132.6,42582,DB00602,Ivermectin
,17847063,terminal elimination half-life,The terminal elimination half-life was significantly (p<0.01) longer in the moxidectin treated group (621.3 +/- 149.3 h) than for ivermectin treated group (80.3 +/- 29.8 h).,Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),h,621.3,42583,DB00602,Ivermectin
,17847063,terminal elimination half-life,The terminal elimination half-life was significantly (p<0.01) longer in the moxidectin treated group (621.3 +/- 149.3 h) than for ivermectin treated group (80.3 +/- 29.8 h).,Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),h,80.3,42584,DB00602,Ivermectin
,17847063,V(ss)/F,A significantly (p< 0.01) larger V(ss)/F was obtained for moxidectin (19.21 +/- 3.61 l/kg) compared with ivermectin (5.35 +/- 1.29 l/kg).,Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),[l] / [kg],19.21,42585,DB00602,Ivermectin
,17847063,V(ss)/F,A significantly (p< 0.01) larger V(ss)/F was obtained for moxidectin (19.21 +/- 3.61 l/kg) compared with ivermectin (5.35 +/- 1.29 l/kg).,Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),[l] / [kg],5.35,42586,DB00602,Ivermectin
,17847063,CL/F,"The mean estimates of CL/F of moxidectin and ivermectin were 0.0220 +/- 0.00381 and 0.0498 +/- 0.0179 l/h/kg, respectively.",Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),[l] / [h·kg],0.0220,42587,DB00602,Ivermectin
,17847063,CL/F,"The mean estimates of CL/F of moxidectin and ivermectin were 0.0220 +/- 0.00381 and 0.0498 +/- 0.0179 l/h/kg, respectively.",Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847063/),[l] / [h·kg],0.0498,42588,DB00602,Ivermectin
,29378154,Maximum concentrations,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[ng] / [ml],10.2,44382,DB00602,Ivermectin
,29378154,Maximum concentrations,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[ng] / [ml],82.9,44383,DB00602,Ivermectin
,29378154,Maximum concentrations,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,1.05,44384,DB00602,Ivermectin
,29378154,mean residence time,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.38,44385,DB00602,Ivermectin
,29378154,mean residence time,"Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,1.05,44386,DB00602,Ivermectin
,29378154,time to maximum concentration,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.14,44387,DB00602,Ivermectin
,29378154,time to maximum concentration,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.25,44388,DB00602,Ivermectin
,29378154,elimination half-life,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,0.23,44389,DB00602,Ivermectin
,29378154,elimination half-life,"The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01).",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),d,1.45,44390,DB00602,Ivermectin
,29378154,Peak concentrations,"Peak concentrations of IVM were 15.7, 23.3 and 1.9 µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[μg] / [kg],15.7,44391,DB00602,Ivermectin
,29378154,Peak concentrations,"Peak concentrations of IVM were 15.7, 23.3 and 1.9 µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[μg] / [kg],23.3,44392,DB00602,Ivermectin
,29378154,Peak concentrations,"Peak concentrations of IVM were 15.7, 23.3 and 1.9 µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.",Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29378154/),[μg] / [kg],1.9,44393,DB00602,Ivermectin
,26553292,AUC,"Pharmacokinetic parameters were AUC = 85.1 ng·day/mL, Vdss = 4.43 L/kg, and T1/2el = 1.73 days.","Ivermectin Pharmacokinetics, Metabolism, and Tissue/Egg Residue Profiles in Laying Hens. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26553292/),[d·ng] / [ml],85.1,47437,DB00602,Ivermectin
,26553292,Vdss,"Pharmacokinetic parameters were AUC = 85.1 ng·day/mL, Vdss = 4.43 L/kg, and T1/2el = 1.73 days.","Ivermectin Pharmacokinetics, Metabolism, and Tissue/Egg Residue Profiles in Laying Hens. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26553292/),[l] / [kg],4.43,47438,DB00602,Ivermectin
,26553292,T1/2el,"Pharmacokinetic parameters were AUC = 85.1 ng·day/mL, Vdss = 4.43 L/kg, and T1/2el = 1.73 days.","Ivermectin Pharmacokinetics, Metabolism, and Tissue/Egg Residue Profiles in Laying Hens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26553292/),d,1.73,47439,DB00602,Ivermectin
,18835001,T(max),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),d,1.22,50220,DB00602,Ivermectin
,18835001,C(max),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),[ng] / [ml],16.75,50221,DB00602,Ivermectin
,18835001,k(ab),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),1/[day],2.62,50222,DB00602,Ivermectin
,18835001,t(1/2)(ab),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),d,0.27,50223,DB00602,Ivermectin
,18835001,k(el),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),1/[day],0.27,50224,DB00602,Ivermectin
,18835001,t(1/2)(el),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),d,2.53,50225,DB00602,Ivermectin
,18835001,V(d)/F,"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),[l] / [kg],9.81,50226,DB00602,Ivermectin
,18835001,Cl/F,"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),[l] / [d·kg],2.21,50227,DB00602,Ivermectin
,18835001,AUC(0-->infinity),"The pharmacokinetic parameters (mean+/-S.D.) derived from one-compartment model analysis were as follows: T(max) 1.22+/-0.49day, C(max) 16.75+/-4.04ng/mL, k(ab) 2.62+/-1.86day(-1), t(1/2)(ab) 0.27+/-0.25day, k(el) 0.27+/-0.14day(-1), t(1/2)(el) 2.53+/-2.24day, V(d)/F 9.81+/-5.41L/kg, Cl/F 2.21+/-0.69L/kg/day and AUC(0-->infinity) 98.31+/-30.52ngday/mL.",Pharmacokinetics of ivermectin in cats receiving a single subcutaneous dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835001/),[ngday] / [ml],98.31,50228,DB00602,Ivermectin
,33694173,maximum plasma concentration (Cmax ),The maximum plasma concentration (Cmax ) for abamectin was 135.52 ± 38.6 ng/ml at 3.16 ± 0.75 h.,Pharmacokinetic properties of abamectin after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33694173/),[ng] / [ml],135.52,50491,DB00602,Ivermectin
,33694173,elimination half-life (T1/2 elim,The elimination half-life (T1/2 elim (h)) was 26.51 ± 6.86 h.,Pharmacokinetic properties of abamectin after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33694173/),h,26.51,50492,DB00602,Ivermectin
,33694173,area under the curve (AUC 0-∞),The area under the curve (AUC 0-∞) was 3723.50 ± 1213.08 ng h/ml.,Pharmacokinetic properties of abamectin after oral administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33694173/),[h·ng] / [ml],3723.50,50493,DB00602,Ivermectin
,33694173,mean residence time (MRT),The mean residence time (MRT) was 38.82 ± 8.93 h.,Pharmacokinetic properties of abamectin after oral administration in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33694173/),h,38.82,50494,DB00602,Ivermectin
,30993667,clearance,"Median (90% confidence interval) clearance of 0.346 (0.12-0.73) L/hour/kg in pre-school-aged (2-5 years) children is similar to 0.352 (0.17-0.69) L/hour/kg in school-aged (6-12 years) children but higher than in adults (0.199 (0.10-0.31) L/hour/kg), resulting in significantly lower exposure in children following a 200 μg/kg dose.",Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993667/),[l] / [h·kg],0.346,51937,DB00602,Ivermectin
,30993667,clearance,"Median (90% confidence interval) clearance of 0.346 (0.12-0.73) L/hour/kg in pre-school-aged (2-5 years) children is similar to 0.352 (0.17-0.69) L/hour/kg in school-aged (6-12 years) children but higher than in adults (0.199 (0.10-0.31) L/hour/kg), resulting in significantly lower exposure in children following a 200 μg/kg dose.",Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993667/),[l] / [h·kg],0.352,51938,DB00602,Ivermectin
,30993667,clearance,"Median (90% confidence interval) clearance of 0.346 (0.12-0.73) L/hour/kg in pre-school-aged (2-5 years) children is similar to 0.352 (0.17-0.69) L/hour/kg in school-aged (6-12 years) children but higher than in adults (0.199 (0.10-0.31) L/hour/kg), resulting in significantly lower exposure in children following a 200 μg/kg dose.",Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993667/),[l] / [h·kg],0.199,51939,DB00602,Ivermectin
,33103252,area under the concentration versus the time curve from 0 to the last sampling point (AUC0→t ),"The area under the concentration versus the time curve from 0 to the last sampling point (AUC0→t ) and the maximum plasma concentration (Cmax ) were significantly higher in Toric than in Hutsul horses (1792.09 ± 246.22 μg × hr/L vs. 716.99 ± 255.81 μg × hr/L and 62.72 ± 17.97 ng/ml vs. 35.34 ± 13.61 ng/ml, respectively).",The pharmacokinetics and antiparasitic activity of ivermectin in Hutsul and Toric horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33103252/),[h·μg] / [l],1792.09,53132,DB00602,Ivermectin
,33103252,area under the concentration versus the time curve from 0 to the last sampling point (AUC0→t ),"The area under the concentration versus the time curve from 0 to the last sampling point (AUC0→t ) and the maximum plasma concentration (Cmax ) were significantly higher in Toric than in Hutsul horses (1792.09 ± 246.22 μg × hr/L vs. 716.99 ± 255.81 μg × hr/L and 62.72 ± 17.97 ng/ml vs. 35.34 ± 13.61 ng/ml, respectively).",The pharmacokinetics and antiparasitic activity of ivermectin in Hutsul and Toric horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33103252/),[h·μg] / [l],716.99,53133,DB00602,Ivermectin
,33103252,maximum plasma concentration (Cmax ),"The area under the concentration versus the time curve from 0 to the last sampling point (AUC0→t ) and the maximum plasma concentration (Cmax ) were significantly higher in Toric than in Hutsul horses (1792.09 ± 246.22 μg × hr/L vs. 716.99 ± 255.81 μg × hr/L and 62.72 ± 17.97 ng/ml vs. 35.34 ± 13.61 ng/ml, respectively).",The pharmacokinetics and antiparasitic activity of ivermectin in Hutsul and Toric horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33103252/),[ng] / [ml],62.72,53134,DB00602,Ivermectin
,33103252,maximum plasma concentration (Cmax ),"The area under the concentration versus the time curve from 0 to the last sampling point (AUC0→t ) and the maximum plasma concentration (Cmax ) were significantly higher in Toric than in Hutsul horses (1792.09 ± 246.22 μg × hr/L vs. 716.99 ± 255.81 μg × hr/L and 62.72 ± 17.97 ng/ml vs. 35.34 ± 13.61 ng/ml, respectively).",The pharmacokinetics and antiparasitic activity of ivermectin in Hutsul and Toric horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33103252/),[ng] / [ml],35.34,53135,DB00602,Ivermectin
,26172188,tmax,Drug absorption was significantly (p<0.05) slower (tmax: 21.89±11.43 h) in autumn than in spring (tmax: 9.78±8.97 h).,A comparison of the efficacy and pharmacokinetics of ivermectin after spring and autumn treatments against Cyathostominae in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172188/),h,21.89,54840,DB00602,Ivermectin
,26172188,tmax,Drug absorption was significantly (p<0.05) slower (tmax: 21.89±11.43 h) in autumn than in spring (tmax: 9.78±8.97 h).,A comparison of the efficacy and pharmacokinetics of ivermectin after spring and autumn treatments against Cyathostominae in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172188/),h,9.78,54841,DB00602,Ivermectin
,26172188,Maximum concentrations (Cmax),Maximum concentrations (Cmax) of ivermectin in the blood plasma of individual horses (8.40-43.08 ng/ml) were observed 2-24 h after drug administration during the spring treatment and 2-36 h (6.43-24.86 ng/ml) after administration during the autumn treatment.,A comparison of the efficacy and pharmacokinetics of ivermectin after spring and autumn treatments against Cyathostominae in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172188/),[ng] / [ml],8.40-43.08,54842,DB00602,Ivermectin
,26172188,Maximum concentrations (Cmax),Maximum concentrations (Cmax) of ivermectin in the blood plasma of individual horses (8.40-43.08 ng/ml) were observed 2-24 h after drug administration during the spring treatment and 2-36 h (6.43-24.86 ng/ml) after administration during the autumn treatment.,A comparison of the efficacy and pharmacokinetics of ivermectin after spring and autumn treatments against Cyathostominae in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172188/),[ng] / [ml],6.43-24.86,54843,DB00602,Ivermectin
,25728454,maximal concentrations,"Plasma and milk concentrations of eprinomectin increased to reach maximal concentrations of 5.45 ± 2.84 and 2.29 ± 0.90 ng/mL at a Tmax of 1.79 ± 0.57 and 2.00 ± 0.82 days, respectively.","Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),[ng] / [ml],5.45,56788,DB00602,Ivermectin
,25728454,maximal concentrations,"Plasma and milk concentrations of eprinomectin increased to reach maximal concentrations of 5.45 ± 2.84 and 2.29 ± 0.90 ng/mL at a Tmax of 1.79 ± 0.57 and 2.00 ± 0.82 days, respectively.","Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),[ng] / [ml],2.29,56789,DB00602,Ivermectin
,25728454,Tmax,"Plasma and milk concentrations of eprinomectin increased to reach maximal concentrations of 5.45 ± 2.84 and 2.29 ± 0.90 ng/mL at a Tmax of 1.79 ± 0.57 and 2.00 ± 0.82 days, respectively.","Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),d,1.79,56790,DB00602,Ivermectin
,25728454,Tmax,"Plasma and milk concentrations of eprinomectin increased to reach maximal concentrations of 5.45 ± 2.84 and 2.29 ± 0.90 ng/mL at a Tmax of 1.79 ± 0.57 and 2.00 ± 0.82 days, respectively.","Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),d,2.00,56791,DB00602,Ivermectin
,25728454,mean residence times,"The mean residence times of eprinomectin in plasma and milk were 14.73 ± 6.22 and 9.37 ± 2.81 days, respectively.","Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),d,14.73,56792,DB00602,Ivermectin
,25728454,mean residence times,"The mean residence times of eprinomectin in plasma and milk were 14.73 ± 6.22 and 9.37 ± 2.81 days, respectively.","Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),d,9.37,56793,DB00602,Ivermectin
,25728454,AUC,The AUC value in plasma (55.89 ± 18.16 ng day/mL) was threefold greater than that in milk (18.02 ± 6.48 ng day/mL).,"Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),[d·ng] / [ml],55.89,56794,DB00602,Ivermectin
,25728454,AUC,The AUC value in plasma (55.89 ± 18.16 ng day/mL) was threefold greater than that in milk (18.02 ± 6.48 ng day/mL).,"Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),[d·ng] / [ml],18.02,56795,DB00602,Ivermectin
,25728454,AUC milk/plasma ratio,The AUC milk/plasma ratio was 0.33 ± 0.08.,"Plasma kinetics, excretion in milk of eprinomectin, and its efficacy against Hypoderma spp. following topical administration in yaks. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728454/),,0.33,56796,DB00602,Ivermectin
,25421461,Cmax,"The Cmax and Area Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml, and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ± standard deviation).",The relative plasma availabilities of ivermectin in reindeer (Rangifer tarandus tarandus) following subcutaneous and two different oral formulation applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421461/),[ng] / [ml],30.2,63246,DB00602,Ivermectin
,25421461,Cmax,"The Cmax and Area Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml, and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ± standard deviation).",The relative plasma availabilities of ivermectin in reindeer (Rangifer tarandus tarandus) following subcutaneous and two different oral formulation applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421461/),[ng] / [ml],14.9,63247,DB00602,Ivermectin
,25421461,Cmax,"The Cmax and Area Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml, and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ± standard deviation).",The relative plasma availabilities of ivermectin in reindeer (Rangifer tarandus tarandus) following subcutaneous and two different oral formulation applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421461/),[ng] / [ml],63.1,63248,DB00602,Ivermectin
,25421461,AUC∞,"The Cmax and Area Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml, and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ± standard deviation).",The relative plasma availabilities of ivermectin in reindeer (Rangifer tarandus tarandus) following subcutaneous and two different oral formulation applications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421461/),[h·ng] / [ml],2881,63249,DB00602,Ivermectin
,25421461,AUC∞,"The Cmax and Area Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml, and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ± standard deviation).",The relative plasma availabilities of ivermectin in reindeer (Rangifer tarandus tarandus) following subcutaneous and two different oral formulation applications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421461/),[h·ng] / [ml],1299,63250,DB00602,Ivermectin
,25421461,AUC∞,"The Cmax and Area Under Curve (AUC) differed significantly between the groups: Cmax was 30.2 ± 3.9, 14.9 ± 5.7 and 63.1 ± 13.1 ng/ml, and AUC∞ was 2881 ± 462, 1299 ± 342 and 6718 ± 1620 ng*h/ml for groups 1, 2 and 3, respectively (mean ± standard deviation).",The relative plasma availabilities of ivermectin in reindeer (Rangifer tarandus tarandus) following subcutaneous and two different oral formulation applications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421461/),[h·ng] / [ml],6718,63251,DB00602,Ivermectin
,30736951,efficacies,"The observed MXD efficacies were 85% (MXDSC0.2), 94% (MXDSC1.0), 84% (MXDIR0.2) and 99% (MXDIR1.0), at day +27.",Pharmacokinetic profile and anthelmintic efficacy of moxidectin administered by different doses and routes to feedlot calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30736951/),%,85,66329,DB00602,Ivermectin
,30736951,efficacies,"The observed MXD efficacies were 85% (MXDSC0.2), 94% (MXDSC1.0), 84% (MXDIR0.2) and 99% (MXDIR1.0), at day +27.",Pharmacokinetic profile and anthelmintic efficacy of moxidectin administered by different doses and routes to feedlot calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30736951/),%,94,66330,DB00602,Ivermectin
,30736951,efficacies,"The observed MXD efficacies were 85% (MXDSC0.2), 94% (MXDSC1.0), 84% (MXDIR0.2) and 99% (MXDIR1.0), at day +27.",Pharmacokinetic profile and anthelmintic efficacy of moxidectin administered by different doses and routes to feedlot calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30736951/),%,84,66331,DB00602,Ivermectin
,30736951,efficacies,"The observed MXD efficacies were 85% (MXDSC0.2), 94% (MXDSC1.0), 84% (MXDIR0.2) and 99% (MXDIR1.0), at day +27.",Pharmacokinetic profile and anthelmintic efficacy of moxidectin administered by different doses and routes to feedlot calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30736951/),%,99,66332,DB00602,Ivermectin
,27120064,Cmax,"The oral administration of the HPBCD-solution accounted for significantly higher (P < 0.05) Cmax and AUC (23.1 ± 4.4 μg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral CMC-suspension (AUC = 3.5 ± 1.0 μg h/mL) and injectable Tween 80-based formulation (AUC: 7.5 ± 1.7 μg h/mL).",Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120064/),[h·μg] / [ml],23.1,67133,DB00602,Ivermectin
,27120064,AUC,"The oral administration of the HPBCD-solution accounted for significantly higher (P < 0.05) Cmax and AUC (23.1 ± 4.4 μg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral CMC-suspension (AUC = 3.5 ± 1.0 μg h/mL) and injectable Tween 80-based formulation (AUC: 7.5 ± 1.7 μg h/mL).",Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120064/),[h·μg] / [ml],3.5,67134,DB00602,Ivermectin
,27120064,AUC,"The oral administration of the HPBCD-solution accounted for significantly higher (P < 0.05) Cmax and AUC (23.1 ± 4.4 μg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral CMC-suspension (AUC = 3.5 ± 1.0 μg h/mL) and injectable Tween 80-based formulation (AUC: 7.5 ± 1.7 μg h/mL).",Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120064/),[h·μg] / [ml],7.5,67135,DB00602,Ivermectin
,19732267,plasma distribution half-life (t(1/2)alpha),"The plasma distribution half-life (t(1/2)alpha) was estimated as 2.5 h, the elimination half-life (t(1/2)beta) as 216 h, the total body clearance (Cl(T)) as 0.0059 L kg(-1) h(-1) and mean residence time (MRT) as 385 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,2.5,75103,DB00602,Ivermectin
,19732267,elimination half-life (t(1/2)beta),"The plasma distribution half-life (t(1/2)alpha) was estimated as 2.5 h, the elimination half-life (t(1/2)beta) as 216 h, the total body clearance (Cl(T)) as 0.0059 L kg(-1) h(-1) and mean residence time (MRT) as 385 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,216,75104,DB00602,Ivermectin
,19732267,total body clearance (Cl(T)),"The plasma distribution half-life (t(1/2)alpha) was estimated as 2.5 h, the elimination half-life (t(1/2)beta) as 216 h, the total body clearance (Cl(T)) as 0.0059 L kg(-1) h(-1) and mean residence time (MRT) as 385 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),[l] / [h·kg],0.0059,75105,DB00602,Ivermectin
,19732267,mean residence time (MRT),"The plasma distribution half-life (t(1/2)alpha) was estimated as 2.5 h, the elimination half-life (t(1/2)beta) as 216 h, the total body clearance (Cl(T)) as 0.0059 L kg(-1) h(-1) and mean residence time (MRT) as 385 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,385,75106,DB00602,Ivermectin
,19732267,"volume of distribution at steady state, V(d(ss))","The volume of distribution at steady state, V(d(ss)), was calculated to be 1.839 L kg(-1).","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),[l] / [kg],1.839,75107,DB00602,Ivermectin
,19732267,peak plasma concentration (C(max)),"Following p.o. administration the peak plasma concentration (C(max)) was 15 ng mL(-1), the time to peak plasma concentration (T(max)) was 89 h and t(1/2)beta was 180 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),[ng] / [ml],15,75108,DB00602,Ivermectin
,19732267,time to peak plasma concentration (T(max)),"Following p.o. administration the peak plasma concentration (C(max)) was 15 ng mL(-1), the time to peak plasma concentration (T(max)) was 89 h and t(1/2)beta was 180 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,89,75109,DB00602,Ivermectin
,19732267,t(1/2)beta,"Following p.o. administration the peak plasma concentration (C(max)) was 15 ng mL(-1), the time to peak plasma concentration (T(max)) was 89 h and t(1/2)beta was 180 h.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,180,75110,DB00602,Ivermectin
,19732267,t(1/2)beta,The highest concentration in muscle (21 ng g(-1)) was measured after 7 days and t(1/2)beta was calculated to be 247 h.,"A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,247,75111,DB00602,Ivermectin
,19732267,peak concentration,"For skin, a peak concentration of 28 ng g(-1) at 3 days was observed and a t(1/2)beta of 235 h was determined.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),[ng] / [g],28,75112,DB00602,Ivermectin
,19732267,t(1/2)beta,"For skin, a peak concentration of 28 ng g(-1) at 3 days was observed and a t(1/2)beta of 235 h was determined.","A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),h,235,75113,DB00602,Ivermectin
,19732267,bioavailability,The bioavailability following p.o. administration was calculated to be 38%.,"A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732267/),%,38,75114,DB00602,Ivermectin
,33527105,run time,"An Xselect CSH™ C18 HPLC column was utilized as a stationary phase, with a mobile phase consisting of 0.1% v/v trifluoracetic acid in water and acetonitrile with a run time of 20 min.",New and sensitive HPLC-UV method for concomitant quantification of a combination of antifilariasis drugs in rat plasma and organs after simultaneous oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527105/),min,20,76307,DB00602,Ivermectin
,20128898,SO,SO obtained after TCBZ administration (653.9 +/- 140.6 microgxh/ml) was similar to that obtained after TCBZ co-administered with IVM and MTZ (650.7 +/- 122.8 microgxh/ml).,Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20128898/),[h·μg] / [ml],653.9,76722,DB00602,Ivermectin
,20128898,SO,SO obtained after TCBZ administration (653.9 +/- 140.6 microgxh/ml) was similar to that obtained after TCBZ co-administered with IVM and MTZ (650.7 +/- 122.8 microgxh/ml).,Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20128898/),[h·μg] / [ml],650.7,76723,DB00602,Ivermectin
,20128898,Efficacy,"Efficacy values of 56 and 38% were observed for TCBZ alone and for the combined treatment, respectively.",Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20128898/),%,56,76724,DB00602,Ivermectin
,20128898,Efficacy,"Efficacy values of 56 and 38% were observed for TCBZ alone and for the combined treatment, respectively.",Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20128898/),%,38,76725,DB00602,Ivermectin
,11355678,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) was 2 times lower for 0.5 mg kg(-1) (8.24 +/- 3.50 ng day(-1) ml(-1)) than for 1.0 mg kg(-1) (15.68 +/- 8.84 ng day(-1) ml(-1)), suggesting that the pharmacokinetics of eprinomectin in goats is dose independent.",Eprinomectin in dairy goats: dose influence on plasma levels and excretion in milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11355678/),[ng] / [day·ml],8.24,77035,DB00602,Ivermectin
,11355678,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) was 2 times lower for 0.5 mg kg(-1) (8.24 +/- 3.50 ng day(-1) ml(-1)) than for 1.0 mg kg(-1) (15.68 +/- 8.84 ng day(-1) ml(-1)), suggesting that the pharmacokinetics of eprinomectin in goats is dose independent.",Eprinomectin in dairy goats: dose influence on plasma levels and excretion in milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11355678/),[ng] / [day·ml],15.68,77036,DB00602,Ivermectin
,11355678,maximum acceptable level,"In all cases, the maximum level of residue in milk remained below the maximum acceptable level of 30 ng ml(-1) permitted in lactating cattle.",Eprinomectin in dairy goats: dose influence on plasma levels and excretion in milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11355678/),[ng] / [ml],30,77037,DB00602,Ivermectin
,33730100,lag phase,The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0-19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1-5.9 pg/h).,The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33730100/),h,18.5,77232,DB00602,Ivermectin
,33730100,zero-order elimination rate,The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0-19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1-5.9 pg/h).,The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33730100/),[pg] / [h],5.5,77233,DB00602,Ivermectin
,20418265,C( max),"The acquired C( max), T(max), and AUC were 9.89 ± 0.34 ng/mL, 11.33 ± 2.63 h, and 883.87 ng h/mL for IVM tablets based on compressed zein microspheres and 9.64 ± 1.05 ng/mL, 7.26 ± 2.09 h, and 666.30 ng h/mL for Yilijia(®), respectively.","Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),[ng] / [ml],9.89,77940,DB00602,Ivermectin
,20418265,T(max),"The acquired C( max), T(max), and AUC were 9.89 ± 0.34 ng/mL, 11.33 ± 2.63 h, and 883.87 ng h/mL for IVM tablets based on compressed zein microspheres and 9.64 ± 1.05 ng/mL, 7.26 ± 2.09 h, and 666.30 ng h/mL for Yilijia(®), respectively.","Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),h,11.33,77941,DB00602,Ivermectin
,20418265,T(max),"The acquired C( max), T(max), and AUC were 9.89 ± 0.34 ng/mL, 11.33 ± 2.63 h, and 883.87 ng h/mL for IVM tablets based on compressed zein microspheres and 9.64 ± 1.05 ng/mL, 7.26 ± 2.09 h, and 666.30 ng h/mL for Yilijia(®), respectively.","Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),[ng] / [ml],9.64,77942,DB00602,Ivermectin
,20418265,T(max),"The acquired C( max), T(max), and AUC were 9.89 ± 0.34 ng/mL, 11.33 ± 2.63 h, and 883.87 ng h/mL for IVM tablets based on compressed zein microspheres and 9.64 ± 1.05 ng/mL, 7.26 ± 2.09 h, and 666.30 ng h/mL for Yilijia(®), respectively.","Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),h,7.26,77943,DB00602,Ivermectin
,20418265,AUC,"The acquired C( max), T(max), and AUC were 9.89 ± 0.34 ng/mL, 11.33 ± 2.63 h, and 883.87 ng h/mL for IVM tablets based on compressed zein microspheres and 9.64 ± 1.05 ng/mL, 7.26 ± 2.09 h, and 666.30 ng h/mL for Yilijia(®), respectively.","Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),[h·ng] / [ml],883.87,77944,DB00602,Ivermectin
,20418265,AUC,"The acquired C( max), T(max), and AUC were 9.89 ± 0.34 ng/mL, 11.33 ± 2.63 h, and 883.87 ng h/mL for IVM tablets based on compressed zein microspheres and 9.64 ± 1.05 ng/mL, 7.26 ± 2.09 h, and 666.30 ng h/mL for Yilijia(®), respectively.","Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),[h·ng] / [ml],666.30,77945,DB00602,Ivermectin
,20418265,bioavailability,The bioavailability of the tablets based on compressed zein microspheres was 132.65% that of Yilijia( ®).,"Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418265/),%,132.65,77946,DB00602,Ivermectin
,32304335,elimination rate constant (Kel),"After oral administration of ivermectin microspheres at a single dose, the elimination rate constant (Kel), the half-life (t1/2 ), the peak time (Tmax ), the mean residence time (MRT), and the peak concentration (Cmax ) were 0.012 ± 0.0031/hr, 59.94 ± 20.18 hr, 9.50 ± 0.93 hr, 55.96 ± 11.40 hr, and 37.75 ± 3.45 ng/ml, respectively.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),1/[h],0.012,78638,DB00602,Ivermectin
,32304335,half-life (t1/2 ),"After oral administration of ivermectin microspheres at a single dose, the elimination rate constant (Kel), the half-life (t1/2 ), the peak time (Tmax ), the mean residence time (MRT), and the peak concentration (Cmax ) were 0.012 ± 0.0031/hr, 59.94 ± 20.18 hr, 9.50 ± 0.93 hr, 55.96 ± 11.40 hr, and 37.75 ± 3.45 ng/ml, respectively.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),h,59.94,78639,DB00602,Ivermectin
,32304335,mean residence time (MRT),"After oral administration of ivermectin microspheres at a single dose, the elimination rate constant (Kel), the half-life (t1/2 ), the peak time (Tmax ), the mean residence time (MRT), and the peak concentration (Cmax ) were 0.012 ± 0.0031/hr, 59.94 ± 20.18 hr, 9.50 ± 0.93 hr, 55.96 ± 11.40 hr, and 37.75 ± 3.45 ng/ml, respectively.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),h,59.94,78640,DB00602,Ivermectin
,32304335,peak concentration (Cmax ),"After oral administration of ivermectin microspheres at a single dose, the elimination rate constant (Kel), the half-life (t1/2 ), the peak time (Tmax ), the mean residence time (MRT), and the peak concentration (Cmax ) were 0.012 ± 0.0031/hr, 59.94 ± 20.18 hr, 9.50 ± 0.93 hr, 55.96 ± 11.40 hr, and 37.75 ± 3.45 ng/ml, respectively.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),[ng] / [ml],37.75,78641,DB00602,Ivermectin
,32304335,Cmax,The Cmax of microspheres was not statistically different (p > .05) compared with that of premix groups (39.81 ± 5.83 ng/ml).,Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),[ng] / [ml],39.81,78642,DB00602,Ivermectin
,32304335,AUC,"Moreover, the AUC of the microcapsule groups was increased from 1,129.76 ± 245.62 to 1,607.33 ± 343.35 hr ng/ml compared with the premix groups, and the relative bioavailability increased by an average of 17.53% after oral administration with ivermectin microspheres.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),[h·ng] / [ml],"1,129.76",78643,DB00602,Ivermectin
,32304335,AUC,"Moreover, the AUC of the microcapsule groups was increased from 1,129.76 ± 245.62 to 1,607.33 ± 343.35 hr ng/ml compared with the premix groups, and the relative bioavailability increased by an average of 17.53% after oral administration with ivermectin microspheres.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),[h·ng] / [ml],"1,607.33",78644,DB00602,Ivermectin
,32304335,relative bioavailability,"Moreover, the AUC of the microcapsule groups was increased from 1,129.76 ± 245.62 to 1,607.33 ± 343.35 hr ng/ml compared with the premix groups, and the relative bioavailability increased by an average of 17.53% after oral administration with ivermectin microspheres.",Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304335/),%,17.53,78645,DB00602,Ivermectin
,25841863,plasma,"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],41.9,84798,DB00602,Ivermectin
,25841863,plasma,"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],221,84799,DB00602,Ivermectin
,25841863,area under the concentration-time curve (AUC0-LOQ),"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],41.9,84800,DB00602,Ivermectin
,25841863,area under the concentration-time curve (AUC0-LOQ),"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],221,84801,DB00602,Ivermectin
,25841863,area under the concentration-time curve (AUC0-LOQ),"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],287,84802,DB00602,Ivermectin
,25841863,area under the concentration-time curve (AUC0-LOQ),"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],20.8,84803,DB00602,Ivermectin
,25841863,area under the concentration-time curve (AUC0-LOQ),"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],121,84804,DB00602,Ivermectin
,25841863,area under the concentration-time curve (AUC0-LOQ),"After the SC treatment, the IVM plasma area under the concentration-time curve (AUC0-LOQ) increased from 41.9 (IVM SCx1) up to 221 (IVM SCx5) and 287 (IVM SCx10)ng.day/mL and after the IR treatment from 20.8 (IVM IRx1) up to 121 (IVM IRx5) and 323 (IVM IRx10)ng.day/mL.","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),[d·ng] / [ml],323,84805,DB00602,Ivermectin
,25841863,efficacies,"The efficacies against resistant H. contortus after the SC treatment were 42% (IVM SC1), 75% (IVM SCx5) and 75% (IVM SCx10).","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),%,42,84806,DB00602,Ivermectin
,25841863,efficacies,"The efficacies against resistant H. contortus after the SC treatment were 42% (IVM SC1), 75% (IVM SCx5) and 75% (IVM SCx10).","Integrated assessment of ivermectin pharmacokinetics, efficacy against resistant Haemonchus contortus and P-glycoprotein expression in lambs treated at three different dosage levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841863/),%,75,84807,DB00602,Ivermectin
,18297309,half-life time of elimination,"In addition, there is an increase in the value of the area under the concentration curve (AUC) by 15.48% while the value of elimination rate constant was decreased by 38.2% and significantly increased the half-life time of elimination from 2.04 days for IVM alone to 3.3 days when given in combination with rafoxanide.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),d,2.04,86347,DB00602,Ivermectin
,18297309,half-life time of elimination,"In addition, there is an increase in the value of the area under the concentration curve (AUC) by 15.48% while the value of elimination rate constant was decreased by 38.2% and significantly increased the half-life time of elimination from 2.04 days for IVM alone to 3.3 days when given in combination with rafoxanide.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),d,3.3,86348,DB00602,Ivermectin
,18297309,t1/2ab,"In calves serum, the mean t1/2ab for IVM/rafoxanide was 0.131 days and for the control formulation 0.16 days, and t1/2el was 5.78 and 4.95, respectively.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),d,0.131,86349,DB00602,Ivermectin
,18297309,t1/2ab,"In calves serum, the mean t1/2ab for IVM/rafoxanide was 0.131 days and for the control formulation 0.16 days, and t1/2el was 5.78 and 4.95, respectively.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),d,0.16,86350,DB00602,Ivermectin
,18297309,t1/2el,"In calves serum, the mean t1/2ab for IVM/rafoxanide was 0.131 days and for the control formulation 0.16 days, and t1/2el was 5.78 and 4.95, respectively.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),,5.78,86351,DB00602,Ivermectin
,18297309,t1/2el,"In calves serum, the mean t1/2ab for IVM/rafoxanide was 0.131 days and for the control formulation 0.16 days, and t1/2el was 5.78 and 4.95, respectively.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),,4.95,86352,DB00602,Ivermectin
,18297309,Cmax,IVM Cmax for IVM/rafoxanide was 22.4 ng/ml and for the control formulation 19.1 ng/ml.,Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),[ng] / [ml],22.4,86353,DB00602,Ivermectin
,18297309,Cmax,IVM Cmax for IVM/rafoxanide was 22.4 ng/ml and for the control formulation 19.1 ng/ml.,Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),[ng] / [ml],19.1,86354,DB00602,Ivermectin
,18297309,T (max),"T (max) values were 0.99 and 1.12 days, and the mean AUC values were 188.9 and 165.4 ng/ml/day.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),d,0.99,86355,DB00602,Ivermectin
,18297309,T (max),"T (max) values were 0.99 and 1.12 days, and the mean AUC values were 188.9 and 165.4 ng/ml/day.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),d,1.12,86356,DB00602,Ivermectin
,18297309,AUC,"T (max) values were 0.99 and 1.12 days, and the mean AUC values were 188.9 and 165.4 ng/ml/day.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),[ng] / [d·ml],188.9,86357,DB00602,Ivermectin
,18297309,AUC,"T (max) values were 0.99 and 1.12 days, and the mean AUC values were 188.9 and 165.4 ng/ml/day.",Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18297309/),[ng] / [d·ml],165.4,86358,DB00602,Ivermectin
,17469275,peak plasma concentration,"The mean peak plasma concentration was 162.5 +/- 42.3 ng/ml, area under the curve was 2,856 ng day/ml, mean residence time was 12.2 days, and disappearance half-life was 1.87 days.",Plasma pharmacokinetics of selamectin after a single topical administration in the American bullfrog (Rana catesbeiana). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469275/),[ng] / [ml],162.5,87122,DB00602,Ivermectin
,17469275,area under the curve,"The mean peak plasma concentration was 162.5 +/- 42.3 ng/ml, area under the curve was 2,856 ng day/ml, mean residence time was 12.2 days, and disappearance half-life was 1.87 days.",Plasma pharmacokinetics of selamectin after a single topical administration in the American bullfrog (Rana catesbeiana). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469275/),[d·ng] / [ml],"2,856",87123,DB00602,Ivermectin
,17469275,mean residence time,"The mean peak plasma concentration was 162.5 +/- 42.3 ng/ml, area under the curve was 2,856 ng day/ml, mean residence time was 12.2 days, and disappearance half-life was 1.87 days.",Plasma pharmacokinetics of selamectin after a single topical administration in the American bullfrog (Rana catesbeiana). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469275/),d,12.2,87124,DB00602,Ivermectin
,17469275,disappearance half-life,"The mean peak plasma concentration was 162.5 +/- 42.3 ng/ml, area under the curve was 2,856 ng day/ml, mean residence time was 12.2 days, and disappearance half-life was 1.87 days.",Plasma pharmacokinetics of selamectin after a single topical administration in the American bullfrog (Rana catesbeiana). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469275/),d,1.87,87125,DB00602,Ivermectin
,33284799,area under the concentration-time curve,The median simulated area under the concentration-time curve was 976 μg∙h/L.,Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33284799/),[μg∙h] / [l],976,87949,DB00602,Ivermectin
,10088713,steady-state concentration,"Ivermectin plasma concentrations increased gradually to achieve the steady-state concentration (20 ng ml(-1)) at approximately four days post-treatment, which was maintained for 120 days.",Persistence of ivermectin in plasma and faeces following administration of a sustained-release bolus to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10088713/),[ng] / [ml],20,88042,DB00602,Ivermectin
,10088713,peak plasma concentration,The ivermectin peak plasma concentration (28.5 ng ml(-1)) was attained at 15 days post-administration of the bolus.,Persistence of ivermectin in plasma and faeces following administration of a sustained-release bolus to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10088713/),[ng] / [ml],28.5,88043,DB00602,Ivermectin
,10088713,maximal concentration,"The faecal ivermectin concentration rose to a maximal concentration of 4.1 microg g(-1) at four days post-treatment, dropping to a steady-state concentration of around 1.18 microg g(-1) which was maintained up to 120 days post-treatment.",Persistence of ivermectin in plasma and faeces following administration of a sustained-release bolus to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10088713/),[μg] / [g],4.1,88044,DB00602,Ivermectin
,10088713,steady-state concentration,"The faecal ivermectin concentration rose to a maximal concentration of 4.1 microg g(-1) at four days post-treatment, dropping to a steady-state concentration of around 1.18 microg g(-1) which was maintained up to 120 days post-treatment.",Persistence of ivermectin in plasma and faeces following administration of a sustained-release bolus to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10088713/),[μg] / [g],1.18,88045,DB00602,Ivermectin
,21466921,Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)),"Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)) was 15 and 28 μg day/L for group IVM and IVM+VER, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[d·μg] / [l],15,88828,DB00602,Ivermectin
,21466921,Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)),"Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)) was 15 and 28 μg day/L for group IVM and IVM+VER, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[d·μg] / [l],28,88829,DB00602,Ivermectin
,21466921,apparent plasma clearance (Cl/F),"With co-administration of VER, apparent plasma clearance (Cl/F) and mean residence time (MRT) of IVM decreased from 135 to 116 L/day and from 5.8 to 3.8 days, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[l] / [d],135,88830,DB00602,Ivermectin
,21466921,mean residence time (MRT),"With co-administration of VER, apparent plasma clearance (Cl/F) and mean residence time (MRT) of IVM decreased from 135 to 116 L/day and from 5.8 to 3.8 days, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),d,5.8 to 3.8,88831,DB00602,Ivermectin
,21466921,AUC(,Similar trends were observed for DOR (AUC(2) 48 vs.,Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),,48,88832,DB00602,Ivermectin
,21466921,Cl/F,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[l] / [d],61,88833,DB00602,Ivermectin
,21466921,Cl/F,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[l] / [d],46,88834,DB00602,Ivermectin
,21466921,MRT,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),d,5.6,88835,DB00602,Ivermectin
,21466921,MRT,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),d,4.4,88836,DB00602,Ivermectin
,20828822,maximum concentrations (C(max)),"Fecal maximum concentrations (C(max)) of DRM were 1.37 ± 0.19 μg/g (parasitized group) and 0.86 ± 0.15 μg/g (non-parasitized group) observed at the time of the maximum concentration (T(max)) of 2.1 ± 0.4 and 3.1 ± 0.3d, respectively.","The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828822/),[μg] / [g],1.37,89714,DB00602,Ivermectin
,20828822,maximum concentrations (C(max)),"Fecal maximum concentrations (C(max)) of DRM were 1.37 ± 0.19 μg/g (parasitized group) and 0.86 ± 0.15 μg/g (non-parasitized group) observed at the time of the maximum concentration (T(max)) of 2.1 ± 0.4 and 3.1 ± 0.3d, respectively.","The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828822/),[μg] / [g],0.86,89715,DB00602,Ivermectin
,20828822,time of the maximum concentration (T(max)),"Fecal maximum concentrations (C(max)) of DRM were 1.37 ± 0.19 μg/g (parasitized group) and 0.86 ± 0.15 μg/g (non-parasitized group) observed at the time of the maximum concentration (T(max)) of 2.1 ± 0.4 and 3.1 ± 0.3d, respectively.","The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828822/),d,2.1,89716,DB00602,Ivermectin
,20828822,time of the maximum concentration (T(max)),"Fecal maximum concentrations (C(max)) of DRM were 1.37 ± 0.19 μg/g (parasitized group) and 0.86 ± 0.15 μg/g (non-parasitized group) observed at the time of the maximum concentration (T(max)) of 2.1 ± 0.4 and 3.1 ± 0.3d, respectively.","The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828822/),d,3.1,89717,DB00602,Ivermectin
,20828822,accumulated elimination,"The accumulated elimination of DRM in feces, expressed as the percentage of DRM total dose, was 67.1% in the parasitized group, whereas in the non-parasitized group it was 56.5%.","The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828822/),%,67.1,89718,DB00602,Ivermectin
,20828822,accumulated elimination,"The accumulated elimination of DRM in feces, expressed as the percentage of DRM total dose, was 67.1% in the parasitized group, whereas in the non-parasitized group it was 56.5%.","The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828822/),%,56.5,89719,DB00602,Ivermectin
,32378737,IC50,"Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in the lungs after single oral administration of the approved dose (predicted lung: 0.0873 µM) or at doses 10× higher that the approved dose administered orally (predicted lung: 0.820 µM).",The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378737/),μM,0.0873,90094,DB00602,Ivermectin
,32378737,IC50,"Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in the lungs after single oral administration of the approved dose (predicted lung: 0.0873 µM) or at doses 10× higher that the approved dose administered orally (predicted lung: 0.820 µM).",The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378737/),,0.820,90095,DB00602,Ivermectin
,3841626,Biological half-life t1/2,Biological half-life t1/2 increases in the order: swine (0.5 day) less than dogs (1.8 day) less than cattle approximately equal to sheep (2.8 day).,Pharmacokinetic studies of ivermectin: effects of formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841626/),d,0.5,90152,DB00602,Ivermectin
,3841626,Biological half-life t1/2,Biological half-life t1/2 increases in the order: swine (0.5 day) less than dogs (1.8 day) less than cattle approximately equal to sheep (2.8 day).,Pharmacokinetic studies of ivermectin: effects of formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841626/),d,1.8,90153,DB00602,Ivermectin
,3841626,Biological half-life t1/2,Biological half-life t1/2 increases in the order: swine (0.5 day) less than dogs (1.8 day) less than cattle approximately equal to sheep (2.8 day).,Pharmacokinetic studies of ivermectin: effects of formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841626/),d,2.8,90154,DB00602,Ivermectin
,3841626,t1/2,The longer apparent biological half-life from this latter vehicle (t1/2 = 8.3 days) confirms that a slow absorption process dominates the pharmacokinetics in the nonaqueous injectable product to produce an effective controlled-release formulation.,Pharmacokinetic studies of ivermectin: effects of formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841626/),d,8.3,90155,DB00602,Ivermectin
,16031188,peak plasma level,"The fitted common curve had a peak plasma level of 15.8 (0.08) microg/l at 20 hours after injection, which had dropped to 7.9 (1.1) microg/l seven days after injection.",Efficacy and pharmacokinetics of febantel and ivermectin in red deer (Cervus elaphus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031188/),[μg] / [l],15.8,91777,DB00602,Ivermectin
,16031188,peak plasma level,"The fitted common curve had a peak plasma level of 15.8 (0.08) microg/l at 20 hours after injection, which had dropped to 7.9 (1.1) microg/l seven days after injection.",Efficacy and pharmacokinetics of febantel and ivermectin in red deer (Cervus elaphus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16031188/),[μg] / [l],7.9,91778,DB00602,Ivermectin
,8982789,plasma concentrations,"Group 2 (Pour-on) cows showed a rapid rise in plasma concentrations to 32.9 +/- 15.7 micrograms l-1 2 days after treatment, followed by a gradual decline to 1.3 +/- 0.07 micrograms l-1 at 28 days.","Persistence of ivermectin in plasma and faeces following treatment of cows with ivermectin sustained-release, pour-on or injectable formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8982789/),[μg] / [l],32.9,93253,DB00602,Ivermectin
,8982789,plasma concentrations,"Group 2 (Pour-on) cows showed a rapid rise in plasma concentrations to 32.9 +/- 15.7 micrograms l-1 2 days after treatment, followed by a gradual decline to 1.3 +/- 0.07 micrograms l-1 at 28 days.","Persistence of ivermectin in plasma and faeces following treatment of cows with ivermectin sustained-release, pour-on or injectable formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8982789/),μ,1,93254,DB00602,Ivermectin
,8982789,early plasma peak,"Group 3 (Injection) cows also showed a rapid rise to an early plasma peak of 46.1 +/- 22.7 micrograms l-1 3 days after treatment, followed by a gradual decline to 1.3 micrograms l-1 at 35 days.","Persistence of ivermectin in plasma and faeces following treatment of cows with ivermectin sustained-release, pour-on or injectable formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8982789/),[μg] / [l],46.1,93255,DB00602,Ivermectin
,8982789,early plasma peak,"Group 3 (Injection) cows also showed a rapid rise to an early plasma peak of 46.1 +/- 22.7 micrograms l-1 3 days after treatment, followed by a gradual decline to 1.3 micrograms l-1 at 35 days.","Persistence of ivermectin in plasma and faeces following treatment of cows with ivermectin sustained-release, pour-on or injectable formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8982789/),[μg] / [l],1.3,93256,DB00602,Ivermectin
,32481576,serum concentration (Cmax),"The maximum IVM serum concentration (Cmax) was 42.31 ± 10.20 ng/mL and was achieved at 16.80 ± 9.96 hours post-treatment (Tmax), area under the curve (AUC) was 135.56 ± 43.71 ng × day/mL.",Anthelmintic Efficacy and Pharmacokinetics of Ivermectin Paste after Oral Administration in Mules Infected by Cyathostomins. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481576/),[ng] / [ml],42.31,93520,DB00602,Ivermectin
,32481576,Tmax,"The maximum IVM serum concentration (Cmax) was 42.31 ± 10.20 ng/mL and was achieved at 16.80 ± 9.96 hours post-treatment (Tmax), area under the curve (AUC) was 135.56 ± 43.71 ng × day/mL.",Anthelmintic Efficacy and Pharmacokinetics of Ivermectin Paste after Oral Administration in Mules Infected by Cyathostomins. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481576/),h,16.80,93521,DB00602,Ivermectin
,32481576,area under the curve (AUC),"The maximum IVM serum concentration (Cmax) was 42.31 ± 10.20 ng/mL and was achieved at 16.80 ± 9.96 hours post-treatment (Tmax), area under the curve (AUC) was 135.56 ± 43.71 ng × day/mL.",Anthelmintic Efficacy and Pharmacokinetics of Ivermectin Paste after Oral Administration in Mules Infected by Cyathostomins. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481576/),[d·ng] / [ml],135.56,93522,DB00602,Ivermectin
,19342177,terminal half-life (t(1/2lambdaz)),"However the terminal half-life (t(1/2lambdaz)) and mean plasma residence time (MRT) in male goats (2.35 days and 4.78 days, respectively) were significantly longer compared with female animals (1.42 days and 3.55 days, respectively) and this suggesting that the excretion patterns of IVM in male and female animals are probably different each other.",Sex-related plasma disposition of ivermectin following pour-on administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342177/),d,2.35,95069,DB00602,Ivermectin
,19342177,terminal half-life (t(1/2lambdaz)),"However the terminal half-life (t(1/2lambdaz)) and mean plasma residence time (MRT) in male goats (2.35 days and 4.78 days, respectively) were significantly longer compared with female animals (1.42 days and 3.55 days, respectively) and this suggesting that the excretion patterns of IVM in male and female animals are probably different each other.",Sex-related plasma disposition of ivermectin following pour-on administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342177/),d,4.78,95070,DB00602,Ivermectin
,19342177,terminal half-life (t(1/2lambdaz)),"However the terminal half-life (t(1/2lambdaz)) and mean plasma residence time (MRT) in male goats (2.35 days and 4.78 days, respectively) were significantly longer compared with female animals (1.42 days and 3.55 days, respectively) and this suggesting that the excretion patterns of IVM in male and female animals are probably different each other.",Sex-related plasma disposition of ivermectin following pour-on administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342177/),d,1.42,95071,DB00602,Ivermectin
,19342177,terminal half-life (t(1/2lambdaz)),"However the terminal half-life (t(1/2lambdaz)) and mean plasma residence time (MRT) in male goats (2.35 days and 4.78 days, respectively) were significantly longer compared with female animals (1.42 days and 3.55 days, respectively) and this suggesting that the excretion patterns of IVM in male and female animals are probably different each other.",Sex-related plasma disposition of ivermectin following pour-on administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342177/),d,3.55,95072,DB00602,Ivermectin
,20444015,AUC(0-t),Drug diffusion from maternal to fetal circulation (AUC(0-t) = 232.6 +/- 72.5 ng.h/mL) was statistically not different (P = 0.09) compared with fetal to maternal diffusion (AUC(0-t) = 158.0 +/- 21.6 ng.h/mL).,Transplacental exchange of moxidectin after maternal or fetal intravenous administration in sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444015/),[h·ng] / [ml],232.6,96772,DB00602,Ivermectin
,20444015,AUC(0-t),Drug diffusion from maternal to fetal circulation (AUC(0-t) = 232.6 +/- 72.5 ng.h/mL) was statistically not different (P = 0.09) compared with fetal to maternal diffusion (AUC(0-t) = 158.0 +/- 21.6 ng.h/mL).,Transplacental exchange of moxidectin after maternal or fetal intravenous administration in sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444015/),[h·ng] / [ml],158.0,96773,DB00602,Ivermectin
,29887029,systemic availability,IVM systemic availability upon SC administration (421 ± 70.3 ng·d/mL) was higher (P < 0.05) compared to the oral treatment (132 ± 31.3 ng·d/mL).,Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),[d·ng] / [ml],421,99273,DB00602,Ivermectin
,29887029,systemic availability,IVM systemic availability upon SC administration (421 ± 70.3 ng·d/mL) was higher (P < 0.05) compared to the oral treatment (132 ± 31.3 ng·d/mL).,Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),[d·ng] / [ml],132,99274,DB00602,Ivermectin
,29887029,concentrations,"However, higher (P < 0.05) faecal IVM concentrations were observed following oral treatment (9896 ± 1931 ng·d/mL) compared to SC administration (4760 ± 924 ng·d/mL).",Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),[d·ng] / [ml],9896,99275,DB00602,Ivermectin
,29887029,concentrations,"However, higher (P < 0.05) faecal IVM concentrations were observed following oral treatment (9896 ± 1931 ng·d/mL) compared to SC administration (4760 ± 924 ng·d/mL).",Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),[d·ng] / [ml],4760,99276,DB00602,Ivermectin
,29887029,Efficacy,"Efficacy against resistant nematodes was slightly higher on Farms 3 and 4 after the oral (63 and 82%, respectively) compared to the SC (36 and 68%, respectively) treatment.",Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),%,63,99277,DB00602,Ivermectin
,29887029,Efficacy,"Efficacy against resistant nematodes was slightly higher on Farms 3 and 4 after the oral (63 and 82%, respectively) compared to the SC (36 and 68%, respectively) treatment.",Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),%,82,99278,DB00602,Ivermectin
,29887029,Efficacy,"Efficacy against resistant nematodes was slightly higher on Farms 3 and 4 after the oral (63 and 82%, respectively) compared to the SC (36 and 68%, respectively) treatment.",Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),%,36,99279,DB00602,Ivermectin
,29887029,Efficacy,"Efficacy against resistant nematodes was slightly higher on Farms 3 and 4 after the oral (63 and 82%, respectively) compared to the SC (36 and 68%, respectively) treatment.",Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29887029/),%,68,99280,DB00602,Ivermectin
,32030782,Cmax,"The results of pharmacokinetic study were Cmax of 47.15 ± 22.20 ng/ml, Tmax of 1.33 ± 0.492 days, T1/2 of 2.96 ± 1.212 days, AUC0-t of 228.08 ± 57.30 ng day ml-1 , and AUC0-∞ of 240.50 ± 58.44 ng day ml-1 .",Injectable eprinomectin for cattle: Tick efficacy and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030782/),[ng] / [ml],47.15,100658,DB00602,Ivermectin
,32030782,Tmax,"The results of pharmacokinetic study were Cmax of 47.15 ± 22.20 ng/ml, Tmax of 1.33 ± 0.492 days, T1/2 of 2.96 ± 1.212 days, AUC0-t of 228.08 ± 57.30 ng day ml-1 , and AUC0-∞ of 240.50 ± 58.44 ng day ml-1 .",Injectable eprinomectin for cattle: Tick efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030782/),d,1.33,100659,DB00602,Ivermectin
,32030782,T1/2,"The results of pharmacokinetic study were Cmax of 47.15 ± 22.20 ng/ml, Tmax of 1.33 ± 0.492 days, T1/2 of 2.96 ± 1.212 days, AUC0-t of 228.08 ± 57.30 ng day ml-1 , and AUC0-∞ of 240.50 ± 58.44 ng day ml-1 .",Injectable eprinomectin for cattle: Tick efficacy and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030782/),d,2.96,100660,DB00602,Ivermectin
,32030782,AUC0-t,"The results of pharmacokinetic study were Cmax of 47.15 ± 22.20 ng/ml, Tmax of 1.33 ± 0.492 days, T1/2 of 2.96 ± 1.212 days, AUC0-t of 228.08 ± 57.30 ng day ml-1 , and AUC0-∞ of 240.50 ± 58.44 ng day ml-1 .",Injectable eprinomectin for cattle: Tick efficacy and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030782/),[d·ng] / [ml],228.08,100661,DB00602,Ivermectin
,32030782,AUC0-∞,"The results of pharmacokinetic study were Cmax of 47.15 ± 22.20 ng/ml, Tmax of 1.33 ± 0.492 days, T1/2 of 2.96 ± 1.212 days, AUC0-t of 228.08 ± 57.30 ng day ml-1 , and AUC0-∞ of 240.50 ± 58.44 ng day ml-1 .",Injectable eprinomectin for cattle: Tick efficacy and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030782/),[d·ng] / [ml],240.50,100662,DB00602,Ivermectin
,23583861,plasma levels,"Maximum mean (±SD) plasma levels of ivermectin (67±49ngml(-1)) were reached within 2h in fasting patients, and had dropped to 26±20ngml(-1) after 30h.",The lack of influence of food and local alcoholic brew on the blood level of Mectizan(®) (ivermectin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23583861/),1/[ngml],67,100899,DB00602,Ivermectin
,23583861,plasma levels,"Maximum mean (±SD) plasma levels of ivermectin (67±49ngml(-1)) were reached within 2h in fasting patients, and had dropped to 26±20ngml(-1) after 30h.",The lack of influence of food and local alcoholic brew on the blood level of Mectizan(®) (ivermectin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23583861/),1/[ngml],26,100900,DB00602,Ivermectin
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],86.2,101172,DB00602,Ivermectin
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],26.2,101173,DB00602,Ivermectin
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],152,101174,DB00602,Ivermectin
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],51.8,101175,DB00602,Ivermectin
,16054893,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of IVM (23.6 ngml(-1)) and DRM (33.9 ngml(-1)) were obtained at (t(max)) 19.2 and 24h, respectively.","Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),1/[ngml],23.6,101655,DB00602,Ivermectin
,16054893,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of IVM (23.6 ngml(-1)) and DRM (33.9 ngml(-1)) were obtained at (t(max)) 19.2 and 24h, respectively.","Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),1/[ngml],33.9,101656,DB00602,Ivermectin
,16054893,t(max),"Maximum plasma concentrations (C(max)) of IVM (23.6 ngml(-1)) and DRM (33.9 ngml(-1)) were obtained at (t(max)) 19.2 and 24h, respectively.","Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),h,19.2,101657,DB00602,Ivermectin
,16054893,t(max),"Maximum plasma concentrations (C(max)) of IVM (23.6 ngml(-1)) and DRM (33.9 ngml(-1)) were obtained at (t(max)) 19.2 and 24h, respectively.","Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),h,24,101658,DB00602,Ivermectin
,16054893,area under the concentration curve (AUC),The area under the concentration curve (AUC) of DRM (228.9 ngdayml(-1)) was significantly larger than that of IVM (119.3 ngdayml(-1)) and mean residence time (MRT) was 6.5 days for IVM and 9.1days for DRM.,"Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),1/[ngdayml],228.9,101659,DB00602,Ivermectin
,16054893,area under the concentration curve (AUC),The area under the concentration curve (AUC) of DRM (228.9 ngdayml(-1)) was significantly larger than that of IVM (119.3 ngdayml(-1)) and mean residence time (MRT) was 6.5 days for IVM and 9.1days for DRM.,"Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),1/[ngdayml],119.3,101660,DB00602,Ivermectin
,16054893,mean residence time (MRT),The area under the concentration curve (AUC) of DRM (228.9 ngdayml(-1)) was significantly larger than that of IVM (119.3 ngdayml(-1)) and mean residence time (MRT) was 6.5 days for IVM and 9.1days for DRM.,"Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),d,6.5,101661,DB00602,Ivermectin
,16054893,mean residence time (MRT),The area under the concentration curve (AUC) of DRM (228.9 ngdayml(-1)) was significantly larger than that of IVM (119.3 ngdayml(-1)) and mean residence time (MRT) was 6.5 days for IVM and 9.1days for DRM.,"Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16054893/),d,9.1,101662,DB00602,Ivermectin
,16253529,AUC,The AUC values of the parasitised group (143.0 +/- 18 ng d/mL) were significantly lower (P<0.05) than those observed in the parasitically naïve animals (229.6 +/- 21.7 ng d/mL).,Gastrointestinal parasitism reduces the plasma availability of doramectin in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253529/),[d·ng] / [ml],143.0,102834,DB00602,Ivermectin
,16253529,AUC,The AUC values of the parasitised group (143.0 +/- 18 ng d/mL) were significantly lower (P<0.05) than those observed in the parasitically naïve animals (229.6 +/- 21.7 ng d/mL).,Gastrointestinal parasitism reduces the plasma availability of doramectin in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253529/),[d·ng] / [ml],229.6,102835,DB00602,Ivermectin
,16253529,mean residence time (MRT),The mean residence time (MRT) in the parasitised group (3.4 +/- 0.3 days) was significantly shorter (P<0.05) than in the healthy group (6.6 +/- 0.6 days).,Gastrointestinal parasitism reduces the plasma availability of doramectin in lambs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253529/),d,3.4,102836,DB00602,Ivermectin
,16253529,mean residence time (MRT),The mean residence time (MRT) in the parasitised group (3.4 +/- 0.3 days) was significantly shorter (P<0.05) than in the healthy group (6.6 +/- 0.6 days).,Gastrointestinal parasitism reduces the plasma availability of doramectin in lambs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253529/),d,6.6,102837,DB00602,Ivermectin
,32065572,half-life (t1/2),"The dissipation of these acaricides followed the first order kinetics model with half-life (t1/2) values 1.00, 3.50 and 1.50 days for abamectin, chlorfenapyr and pyridaben, respectively.","Residues and dissipation kinetic of abamectin, chlorfenapyr and pyridaben acaricides in green beans (Phaseolus vulgaris L.) under field conditions using QuEChERS method and HPLC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32065572/),d,1.00,103234,DB00602,Ivermectin
,32065572,half-life (t1/2),"The dissipation of these acaricides followed the first order kinetics model with half-life (t1/2) values 1.00, 3.50 and 1.50 days for abamectin, chlorfenapyr and pyridaben, respectively.","Residues and dissipation kinetic of abamectin, chlorfenapyr and pyridaben acaricides in green beans (Phaseolus vulgaris L.) under field conditions using QuEChERS method and HPLC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32065572/),d,3.50,103235,DB00602,Ivermectin
,32065572,half-life (t1/2),"The dissipation of these acaricides followed the first order kinetics model with half-life (t1/2) values 1.00, 3.50 and 1.50 days for abamectin, chlorfenapyr and pyridaben, respectively.","Residues and dissipation kinetic of abamectin, chlorfenapyr and pyridaben acaricides in green beans (Phaseolus vulgaris L.) under field conditions using QuEChERS method and HPLC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32065572/),d,1.50,103236,DB00602,Ivermectin
,18207642,Tmax,"In hair, ivermectin was detected later than in plasma and skin, with the Tmax ranging between 4 days (Holstein group) and 6 days (BB group).",Breed differences in the pharmacokinetics of ivermectin administered subcutaneously to Holstein and Belgian Blue calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207642/),d,4,105583,DB00602,Ivermectin
,18207642,Tmax,"In hair, ivermectin was detected later than in plasma and skin, with the Tmax ranging between 4 days (Holstein group) and 6 days (BB group).",Breed differences in the pharmacokinetics of ivermectin administered subcutaneously to Holstein and Belgian Blue calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207642/),d,6,105584,DB00602,Ivermectin
,30238696,m/,The multiple reaction monitoring precursor ion → product ion transitions for MOX and abamectin (IS) were m/z 638.40 → 236.30 and m/z 871.50 → 565.35 respectively.,Bioanalytical method development and validation of moxidectin in plasma by LC-MS/MS: Application to in vitro metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238696/),,638.40,106902,DB00602,Ivermectin
,15491592,Plasma clearances,"Plasma clearances were 185+/-43, 347+/-77 and 636+/-130ml/kg/day, faecal clearances representing 75+/-26, 28+/-13, and 39+/-30% of the plasma clearance for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),[ml] / [d·kg],185,107705,DB00602,Ivermectin
,15491592,Plasma clearances,"Plasma clearances were 185+/-43, 347+/-77 and 636+/-130ml/kg/day, faecal clearances representing 75+/-26, 28+/-13, and 39+/-30% of the plasma clearance for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),[ml] / [d·kg],347,107706,DB00602,Ivermectin
,15491592,Plasma clearances,"Plasma clearances were 185+/-43, 347+/-77 and 636+/-130ml/kg/day, faecal clearances representing 75+/-26, 28+/-13, and 39+/-30% of the plasma clearance for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),[ml] / [d·kg],636,107707,DB00602,Ivermectin
,15491592,faecal clearances,"Plasma clearances were 185+/-43, 347+/-77 and 636+/-130ml/kg/day, faecal clearances representing 75+/-26, 28+/-13, and 39+/-30% of the plasma clearance for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),%,75,107708,DB00602,Ivermectin
,15491592,faecal clearances,"Plasma clearances were 185+/-43, 347+/-77 and 636+/-130ml/kg/day, faecal clearances representing 75+/-26, 28+/-13, and 39+/-30% of the plasma clearance for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),%,28,107709,DB00602,Ivermectin
,15491592,faecal clearances,"Plasma clearances were 185+/-43, 347+/-77 and 636+/-130ml/kg/day, faecal clearances representing 75+/-26, 28+/-13, and 39+/-30% of the plasma clearance for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),%,39,107710,DB00602,Ivermectin
,15491592,Oral bioavailability,"Oral bioavailability after drug ingestion due to allo-licking was 13.5+/-9.4, 17.5+/-3.5 and 26.1+/-11.1% for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),%,13.5,107711,DB00602,Ivermectin
,15491592,Oral bioavailability,"Oral bioavailability after drug ingestion due to allo-licking was 13.5+/-9.4, 17.5+/-3.5 and 26.1+/-11.1% for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),%,17.5,107712,DB00602,Ivermectin
,15491592,Oral bioavailability,"Oral bioavailability after drug ingestion due to allo-licking was 13.5+/-9.4, 17.5+/-3.5 and 26.1+/-11.1% for doramectin, ivermectin and moxidectin, respectively.","Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491592/),%,26.1,107713,DB00602,Ivermectin
,10669102,Tmax,Delayed Tmax values for DRM (4 days post-administration) compared to those for IVM (1 day) were observed in the different tissues and fluids.,Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669102/),d,4,109897,DB00602,Ivermectin
,10669102,Tmax,Delayed Tmax values for DRM (4 days post-administration) compared to those for IVM (1 day) were observed in the different tissues and fluids.,Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669102/),d,1,109898,DB00602,Ivermectin
,10669102,availabilities,Enhanced availabilities of both IVM (between 45 and 244%) and DRM (20-147%) were obtained in tissues compared to plasma.,Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669102/),%,45 and 244,109899,DB00602,Ivermectin
,10669102,availabilities,Enhanced availabilities of both IVM (between 45 and 244%) and DRM (20-147%) were obtained in tissues compared to plasma.,Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669102/),%,20-147,109900,DB00602,Ivermectin
,8583542,AUC0-infinity,Animals treated by the sc route showed a mean AUC0-infinity of 457 +/- 66 ng.,Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583542/),ng,457,110342,DB00602,Ivermectin
,8583542,Cmax,day/mL (+/- SD) and a mean Cmax of 27.8 +/- 7.9 ng/mL.,Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583542/),[ng] / [ml],27.8,110343,DB00602,Ivermectin
,8583542,AUC0-infinity,Results from the i.m. treatment group showed a mean AUC0-infinity of 475 +/- 82 ng.,Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583542/),ng,475,110344,DB00602,Ivermectin
,8583542,Cmax,day/mL and a mean Cmax of 33.1 +/- 9.0 ng/mL.,Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583542/),[ng] / [ml],33.1,110345,DB00602,Ivermectin
,8583542,Absorption constants (ka),Absorption constants (ka) determined by modelling were 0.542 +/- 0.336 day-1 after sc administration and 0.710 +/- 0.357 day-1 after i.m. administration.,Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583542/),1/[d],0.542,110346,DB00602,Ivermectin
,8583542,Absorption constants (ka),Absorption constants (ka) determined by modelling were 0.542 +/- 0.336 day-1 after sc administration and 0.710 +/- 0.357 day-1 after i.m. administration.,Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583542/),1/[d],0.710,110347,DB00602,Ivermectin
,33812451,Cmax,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),[ng] / [ml],130,110808,DB00602,Ivermectin
,33812451,Tmax,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),d,7.1,110809,DB00602,Ivermectin
,33812451,Tmax,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),d,21.7,110810,DB00602,Ivermectin
,33812451,T1/2,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),d,7.1,110811,DB00602,Ivermectin
,33812451,T1/2,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),d,21.7,110812,DB00602,Ivermectin
,33812451,topic,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),d,7.1,110813,DB00602,Ivermectin
,33812451,topic,"The mean Cmax, Tmax, T1/2, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties.","Pharmacokinetics of a novel endectoparasiticide topical formulation for cats, combining esafoxolaner, eprinomectin and praziquantel. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33812451/),d,21.7,110814,DB00602,Ivermectin
,27084471,mean residence time (MRT),"However, after adminstration of Tivm+pzq, mean residence time (MRT) and plasma elimination half-life (t1/2z) were 20.36h and 11.65h, which were 2.61 and 3.22 times longer than those of Rpzq (7.81h and 3.62h).",Pharmacokinetics of a new ivermectin/praziquantel suspension after intramuscular administration in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27084471/),h,20.36,113081,DB00602,Ivermectin
,27084471,mean residence time (MRT),"However, after adminstration of Tivm+pzq, mean residence time (MRT) and plasma elimination half-life (t1/2z) were 20.36h and 11.65h, which were 2.61 and 3.22 times longer than those of Rpzq (7.81h and 3.62h).",Pharmacokinetics of a new ivermectin/praziquantel suspension after intramuscular administration in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27084471/),h,7.81,113082,DB00602,Ivermectin
,27084471,plasma elimination half-life (t1/2z),"However, after adminstration of Tivm+pzq, mean residence time (MRT) and plasma elimination half-life (t1/2z) were 20.36h and 11.65h, which were 2.61 and 3.22 times longer than those of Rpzq (7.81h and 3.62h).",Pharmacokinetics of a new ivermectin/praziquantel suspension after intramuscular administration in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27084471/),h,11.65,113083,DB00602,Ivermectin
,27084471,plasma elimination half-life (t1/2z),"However, after adminstration of Tivm+pzq, mean residence time (MRT) and plasma elimination half-life (t1/2z) were 20.36h and 11.65h, which were 2.61 and 3.22 times longer than those of Rpzq (7.81h and 3.62h).",Pharmacokinetics of a new ivermectin/praziquantel suspension after intramuscular administration in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27084471/),h,3.62,113084,DB00602,Ivermectin
,9463543,Dermal absorption,Dermal absorption of [3H]emamectin benzoate was calculated as 1.6%.,"Dermal penetration of 4""-(epi-methylamino)-4""-deoxyavermectin B1a benzoate in the rhesus monkey. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463543/),%,1.6,113541,DB00602,Ivermectin
,29889311,elimination half-life,"In healthy sheep, the values of the pharmacokinetic parameters were as follows: elimination half-life (2.85 days), mean residence time (MRT) (2.27 days), area under the plasma concentration curve over time (AUC, 117.4 ng day-1 ml-1 ), volume of distribution (875.6 ml/kg), and clearance (187.1 ml/day).",Pharmacokinetics of ivermectin in sheep following pretreatment with Escherichia coli endotoxin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29889311/),d,2.85,116168,DB00602,Ivermectin
,29889311,mean residence time (MRT),"In healthy sheep, the values of the pharmacokinetic parameters were as follows: elimination half-life (2.85 days), mean residence time (MRT) (2.27 days), area under the plasma concentration curve over time (AUC, 117.4 ng day-1 ml-1 ), volume of distribution (875.6 ml/kg), and clearance (187.1 ml/day).",Pharmacokinetics of ivermectin in sheep following pretreatment with Escherichia coli endotoxin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29889311/),d,2.27,116169,DB00602,Ivermectin
,29889311,area under the plasma concentration curve over time (AUC,"In healthy sheep, the values of the pharmacokinetic parameters were as follows: elimination half-life (2.85 days), mean residence time (MRT) (2.27 days), area under the plasma concentration curve over time (AUC, 117.4 ng day-1 ml-1 ), volume of distribution (875.6 ml/kg), and clearance (187.1 ml/day).",Pharmacokinetics of ivermectin in sheep following pretreatment with Escherichia coli endotoxin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29889311/),[ng] / [d·ml],117.4,116170,DB00602,Ivermectin
,29889311,volume of distribution,"In healthy sheep, the values of the pharmacokinetic parameters were as follows: elimination half-life (2.85 days), mean residence time (MRT) (2.27 days), area under the plasma concentration curve over time (AUC, 117.4 ng day-1 ml-1 ), volume of distribution (875.6 ml/kg), and clearance (187.1 ml/day).",Pharmacokinetics of ivermectin in sheep following pretreatment with Escherichia coli endotoxin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29889311/),[ml] / [kg],875.6,116171,DB00602,Ivermectin
,29889311,clearance,"In healthy sheep, the values of the pharmacokinetic parameters were as follows: elimination half-life (2.85 days), mean residence time (MRT) (2.27 days), area under the plasma concentration curve over time (AUC, 117.4 ng day-1 ml-1 ), volume of distribution (875.6 ml/kg), and clearance (187.1 ml/day).",Pharmacokinetics of ivermectin in sheep following pretreatment with Escherichia coli endotoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29889311/),[ml] / [d],187.1,116172,DB00602,Ivermectin
,18478051,bioavailability,"The mixture model had two additional fixed parameters and identified two populations, A (55% of subjects), where there was no change in bioavailability, and B (45% of subjects), where ivermectin bioavailability was increased 37%.",The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478051/),%,37,116652,DB00602,Ivermectin
,10447828,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of 70.3+/-10.7 ng/mL (mean +/- SD) were obtained for MXD and 44.0+/-23.1 ng/mL for IVM.,Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447828/),[ng] / [ml],70.3,116709,DB00602,Ivermectin
,10447828,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of 70.3+/-10.7 ng/mL (mean +/- SD) were obtained for MXD and 44.0+/-23.1 ng/mL for IVM.,Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447828/),[ng] / [ml],44.0,116710,DB00602,Ivermectin
,10447828,area under concentration-time curve (AUC),"Moreover, the values for area under concentration-time curve (AUC) were 363.6+/-66.0 ng x d/mL for the MXD treated group, and 132.7+/-47.3 ng x d/mL for the IVM treated group.",Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447828/),[d·ng] / [ml],363.6,116711,DB00602,Ivermectin
,10447828,area under concentration-time curve (AUC),"Moreover, the values for area under concentration-time curve (AUC) were 363.6+/-66.0 ng x d/mL for the MXD treated group, and 132.7+/-47.3 ng x d/mL for the IVM treated group.",Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447828/),[d·ng] / [ml],132.7,116712,DB00602,Ivermectin
,10447828,plasma residence times (MRT),"The mean plasma residence times (MRT) were 18.4+/-4.4 and 4.8+/-0.6 days for MXD and IVM treated groups, respectively.",Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447828/),d,18.4,116713,DB00602,Ivermectin
,10447828,plasma residence times (MRT),"The mean plasma residence times (MRT) were 18.4+/-4.4 and 4.8+/-0.6 days for MXD and IVM treated groups, respectively.",Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447828/),d,4.8,116714,DB00602,Ivermectin
,10392970,time (Tmax) to reach Cmax,The time (Tmax) to reach Cmax was significantly faster for MXD (1.0 day) than that for IVM (12.33 days).,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),d,1.0,118405,DB00602,Ivermectin
,10392970,time (Tmax) to reach Cmax,The time (Tmax) to reach Cmax was significantly faster for MXD (1.0 day) than that for IVM (12.33 days).,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),d,12.33,118406,DB00602,Ivermectin
,10392970,Cmax,The Cmax and the AUC were significantly higher for MXD (Cmax = 8.33 ng ml(-1); AUC = 70.63 ng day ml(-1)) than for IVM (Cmax = 1.79 ng ml(-1); AUC = 30.12 ng day ml(-1)) respectively.,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),[ng] / [ml],8.33,118407,DB00602,Ivermectin
,10392970,AUC,The Cmax and the AUC were significantly higher for MXD (Cmax = 8.33 ng ml(-1); AUC = 70.63 ng day ml(-1)) than for IVM (Cmax = 1.79 ng ml(-1); AUC = 30.12 ng day ml(-1)) respectively.,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),[d·ng] / [ml],70.63,118408,DB00602,Ivermectin
,10392970,Cmax,The Cmax and the AUC were significantly higher for MXD (Cmax = 8.33 ng ml(-1); AUC = 70.63 ng day ml(-1)) than for IVM (Cmax = 1.79 ng ml(-1); AUC = 30.12 ng day ml(-1)) respectively.,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),[ng] / [ml],1.79,118409,DB00602,Ivermectin
,10392970,AUC,The Cmax and the AUC were significantly higher for MXD (Cmax = 8.33 ng ml(-1); AUC = 70.63 ng day ml(-1)) than for IVM (Cmax = 1.79 ng ml(-1); AUC = 30.12 ng day ml(-1)) respectively.,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),[d·ng] / [ml],30.12,118410,DB00602,Ivermectin
,10392970,Tmax,Drug appearance in milk was also more rapid for MXD (Tmax = 3.66 days) compared to IVM (Tmax = 17.33 days).,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),d,3.66,118411,DB00602,Ivermectin
,10392970,Tmax,Drug appearance in milk was also more rapid for MXD (Tmax = 3.66 days) compared to IVM (Tmax = 17.33 days).,A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),d,17.33,118412,DB00602,Ivermectin
,10392970,AUCmilk/AUCplasma ratio,"The extent of drug exchange from blood to milk, expressed by the AUCmilk/AUCplasma ratio, was more than three-fold greater for MXD (4.10) compared to that of IVM (1.26), which is consistent with the more lipophilic characteristic of MXD.",A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),,4.10,118413,DB00602,Ivermectin
,10392970,AUCmilk/AUCplasma ratio,"The extent of drug exchange from blood to milk, expressed by the AUCmilk/AUCplasma ratio, was more than three-fold greater for MXD (4.10) compared to that of IVM (1.26), which is consistent with the more lipophilic characteristic of MXD.",A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392970/),,1.26,118414,DB00602,Ivermectin
,28579029,maximal plasma concentrations (Cmax),The maximal plasma concentrations (Cmax) were 20.68±12.85 vs 39.79±17.25μg/L and the plasma bioavailabilities (AUC) 83.45±34.75 vs 169.37±43.44μg*d/L for 0.2 vs 0.4mg/kg respectively.,Pharmacokinetics and anthelmintic efficacy of injectable eprinomectin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579029/),[μg] / [l],20.68,119255,DB00602,Ivermectin
,28579029,maximal plasma concentrations (Cmax),The maximal plasma concentrations (Cmax) were 20.68±12.85 vs 39.79±17.25μg/L and the plasma bioavailabilities (AUC) 83.45±34.75 vs 169.37±43.44μg*d/L for 0.2 vs 0.4mg/kg respectively.,Pharmacokinetics and anthelmintic efficacy of injectable eprinomectin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579029/),[μg] / [l],39.79,119256,DB00602,Ivermectin
,28579029,plasma bioavailabilities (AUC),The maximal plasma concentrations (Cmax) were 20.68±12.85 vs 39.79±17.25μg/L and the plasma bioavailabilities (AUC) 83.45±34.75 vs 169.37±43.44μg*d/L for 0.2 vs 0.4mg/kg respectively.,Pharmacokinetics and anthelmintic efficacy of injectable eprinomectin in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579029/),[d·μg] / [l],83.45,119257,DB00602,Ivermectin
,28579029,plasma bioavailabilities (AUC),The maximal plasma concentrations (Cmax) were 20.68±12.85 vs 39.79±17.25μg/L and the plasma bioavailabilities (AUC) 83.45±34.75 vs 169.37±43.44μg*d/L for 0.2 vs 0.4mg/kg respectively.,Pharmacokinetics and anthelmintic efficacy of injectable eprinomectin in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579029/),[d·μg] / [l],169.37,119258,DB00602,Ivermectin
,25106840,AUCinfinity,"Basic pharmacokinetic parameters for eprinomectin B1a were AUCinfinity, 37.1 ± 15.2 day ng/mL; T½, 5.11 ± 2.83 days; and Cmax, 5.93 ± 1.87 ng/mL; individual maximal concentrations were observed 1 or 2 days after treatment.",Pharmacokinetics and anthelmintic efficacy of topical eprinomectin in goats prevented from grooming. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106840/),[d·ng] / [ml],37.1,121926,DB00602,Ivermectin
,25106840,T½,"Basic pharmacokinetic parameters for eprinomectin B1a were AUCinfinity, 37.1 ± 15.2 day ng/mL; T½, 5.11 ± 2.83 days; and Cmax, 5.93 ± 1.87 ng/mL; individual maximal concentrations were observed 1 or 2 days after treatment.",Pharmacokinetics and anthelmintic efficacy of topical eprinomectin in goats prevented from grooming. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106840/),d,5.11,121927,DB00602,Ivermectin
,25106840,Cmax,"Basic pharmacokinetic parameters for eprinomectin B1a were AUCinfinity, 37.1 ± 15.2 day ng/mL; T½, 5.11 ± 2.83 days; and Cmax, 5.93 ± 1.87 ng/mL; individual maximal concentrations were observed 1 or 2 days after treatment.",Pharmacokinetics and anthelmintic efficacy of topical eprinomectin in goats prevented from grooming. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106840/),[ng] / [ml],5.93,121928,DB00602,Ivermectin
,21198680,peak plasma concentration,Abamectin absorption in fallow deer was rapid with a peak plasma concentration of 120.7 ± 33.2 ng/mL observed at 19.1 ± 7.7 h (mean ± SD).,Plasma pharmacokinetics of abamectin in fallow deer (Cervus dama dama) following subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21198680/),[ng] / [ml],120.7,123593,DB00602,Ivermectin
,21198680,Half-lives of the distribution,"Half-lives of the distribution and terminal phase were 17.2 and 119.3 h, respectively.",Plasma pharmacokinetics of abamectin in fallow deer (Cervus dama dama) following subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21198680/),h,17.2,123594,DB00602,Ivermectin
,21198680,Half-lives of the distribution,"Half-lives of the distribution and terminal phase were 17.2 and 119.3 h, respectively.",Plasma pharmacokinetics of abamectin in fallow deer (Cervus dama dama) following subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21198680/),h,119.3,123595,DB00602,Ivermectin
,21198680,terminal phase,"Half-lives of the distribution and terminal phase were 17.2 and 119.3 h, respectively.",Plasma pharmacokinetics of abamectin in fallow deer (Cervus dama dama) following subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21198680/),h,17.2,123596,DB00602,Ivermectin
,21198680,terminal phase,"Half-lives of the distribution and terminal phase were 17.2 and 119.3 h, respectively.",Plasma pharmacokinetics of abamectin in fallow deer (Cervus dama dama) following subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21198680/),h,119.3,123597,DB00602,Ivermectin
,21198680,apparent clearance of the bioavailable fraction (CL/F),Typical apparent clearance of the bioavailable fraction (CL/F) was 0.795 L/h and was independent of animal weight.,Plasma pharmacokinetics of abamectin in fallow deer (Cervus dama dama) following subcutaneous administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21198680/),[l] / [h],0.795,123598,DB00602,Ivermectin
,10211714,peak plasma concentration (C(max)),Early detection of IVM (12 h) with a peak plasma concentration (C(max)) between 33 and 39 ng/mL was observed in pigs.,Bioequivalence of ivermectin formulations in pigs and cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211714/),[ng] / [ml],33 and 39,123739,DB00602,Ivermectin
,10211714,elimination half-lives,"The drug was detected in plasma up to 20 days post-administration of either formulation, resulting in elimination half-lives between 3.47 and 3.80 days.",Bioequivalence of ivermectin formulations in pigs and cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211714/),d,3.47 and 3.80,123740,DB00602,Ivermectin
,10211714,C(max),C(max) values (between 40.5 and 46.4 ng/mL) were achieved at 2 days post-administration of both formulations.,Bioequivalence of ivermectin formulations in pigs and cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211714/),[ng] / [ml],40.5 and 46.4,123741,DB00602,Ivermectin
,12188637,maximal concentration,"Ivermectin reached the maximal concentration in plasma (28.5 +/- 1.7 ng mL(-)(1)) and milk (23.6 +/- 2.6 ng mL(-)(1)) after 2.4 +/- 0.32 and 2.8 +/- 0.44 days, respectively.","Residue study of ivermectin in plasma, milk, and mozzarella cheese following subcutaneous administration to buffalo (Bubalus bubalis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12188637/),ml(-)(1)·ng,28.5,124917,DB00602,Ivermectin
,12188637,maximal concentration,"Ivermectin reached the maximal concentration in plasma (28.5 +/- 1.7 ng mL(-)(1)) and milk (23.6 +/- 2.6 ng mL(-)(1)) after 2.4 +/- 0.32 and 2.8 +/- 0.44 days, respectively.","Residue study of ivermectin in plasma, milk, and mozzarella cheese following subcutaneous administration to buffalo (Bubalus bubalis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12188637/),ml(-)(1)·ng,23.6,124918,DB00602,Ivermectin
,27016093,AUCmilk/plasma,"Surprisingly, EPM displayed a much higher disposition rate into milk (AUCmilk/plasma : 0.48) than IVM (AUCmilk/plasma : 0.19).","Comparative plasma and milk dispositions, faecal excretion and efficacy of per os ivermectin and pour-on eprinomectin in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016093/),,0.48,125476,DB00602,Ivermectin
,27016093,AUCmilk/plasma,"Surprisingly, EPM displayed a much higher disposition rate into milk (AUCmilk/plasma : 0.48) than IVM (AUCmilk/plasma : 0.19).","Comparative plasma and milk dispositions, faecal excretion and efficacy of per os ivermectin and pour-on eprinomectin in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016093/),,0.19,125477,DB00602,Ivermectin
,27016093,AUCfaeces,IVM exhibited significantly higher faecal excretion (AUCfaeces : 7148.54 ng·d/g) but shorter faecal persistence (MRTfaeces : 1.17 days) compared with EPM (AUCfaeces : 42.43 ng·d/g and MRTfaeces : 3.29 days).,"Comparative plasma and milk dispositions, faecal excretion and efficacy of per os ivermectin and pour-on eprinomectin in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016093/),[d·ng] / [g],7148.54,125478,DB00602,Ivermectin
,27016093,MRTfaeces,IVM exhibited significantly higher faecal excretion (AUCfaeces : 7148.54 ng·d/g) but shorter faecal persistence (MRTfaeces : 1.17 days) compared with EPM (AUCfaeces : 42.43 ng·d/g and MRTfaeces : 3.29 days).,"Comparative plasma and milk dispositions, faecal excretion and efficacy of per os ivermectin and pour-on eprinomectin in horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016093/),d,1.17,125479,DB00602,Ivermectin
,27016093,AUCfaeces,IVM exhibited significantly higher faecal excretion (AUCfaeces : 7148.54 ng·d/g) but shorter faecal persistence (MRTfaeces : 1.17 days) compared with EPM (AUCfaeces : 42.43 ng·d/g and MRTfaeces : 3.29 days).,"Comparative plasma and milk dispositions, faecal excretion and efficacy of per os ivermectin and pour-on eprinomectin in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016093/),[d·ng] / [g],42.43,125480,DB00602,Ivermectin
,27016093,MRTfaeces,IVM exhibited significantly higher faecal excretion (AUCfaeces : 7148.54 ng·d/g) but shorter faecal persistence (MRTfaeces : 1.17 days) compared with EPM (AUCfaeces : 42.43 ng·d/g and MRTfaeces : 3.29 days).,"Comparative plasma and milk dispositions, faecal excretion and efficacy of per os ivermectin and pour-on eprinomectin in horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016093/),d,3.29,125481,DB00602,Ivermectin
above,10511102,plasma concentrations,"IVM plasma concentrations were above 0.5 ng/ml for 20.6 (CONTROL) and 27.5 days (IVM-TEST SC), respectively (p < 0.05).",Ivermectin disposition kinetics after subcutaneous and intramuscular administration of an oil-based formulation to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511102/),[ng] / [ml],0.5,126940,DB00602,Ivermectin
,15839552,maximum plasma concentrations,"The maximum plasma concentrations of 12.24 ng ml(-1) occurred 2 d after administration, and eprinomectin remained detectable in plasma 29 d after administration (0.10 ng ml(-1)).",Pour-on formulation of eprinomectin for cattle: fecal elimination profile and effects on the development of the dung-inhabiting Diptera Neomyia cornicina (L.) (Muscidae). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15839552/),[ng] / [ml],12.24,127317,DB00602,Ivermectin
,15839552,maximum plasma concentrations,"The maximum plasma concentrations of 12.24 ng ml(-1) occurred 2 d after administration, and eprinomectin remained detectable in plasma 29 d after administration (0.10 ng ml(-1)).",Pour-on formulation of eprinomectin for cattle: fecal elimination profile and effects on the development of the dung-inhabiting Diptera Neomyia cornicina (L.) (Muscidae). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15839552/),[ng] / [ml],0.10,127318,DB00602,Ivermectin
,15839552,maximum dung concentration,The maximum dung concentration of 350 ng g(-1) was observed 3 d after administration and thereafter for at least 29 d (4 ng g(-1)).,Pour-on formulation of eprinomectin for cattle: fecal elimination profile and effects on the development of the dung-inhabiting Diptera Neomyia cornicina (L.) (Muscidae). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15839552/),[ng] / [g],350,127319,DB00602,Ivermectin
,15839552,maximum dung concentration,The maximum dung concentration of 350 ng g(-1) was observed 3 d after administration and thereafter for at least 29 d (4 ng g(-1)).,Pour-on formulation of eprinomectin for cattle: fecal elimination profile and effects on the development of the dung-inhabiting Diptera Neomyia cornicina (L.) (Muscidae). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15839552/),[ng] / [g],4,127320,DB00602,Ivermectin
,15839552,no-observed-effect concentration,The no-observed-effect concentration for N. cornicina was estimated to be close to 7+/-5 ng g(-1).,Pour-on formulation of eprinomectin for cattle: fecal elimination profile and effects on the development of the dung-inhabiting Diptera Neomyia cornicina (L.) (Muscidae). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15839552/),[ng] / [g],7,127321,DB00602,Ivermectin
,20069313,half-life of absorption,"Compared to the non-licking group, self-licking behavior contributed to an extremely significant shorter half-life of absorption (14.85+/-2.79 h in licking group vs.29.44+/-7.81 h in non-licking group, p<0.01) and an extremely significant higher C(max) value for eprinomectin (21.95+/-5.36 h in licking group vs. 6.98+/-0.72 ng ml(-1) in non-licking group, p<0.01) in plasma disposition.",The effect of self-licking behavior on pharmacokinetics of eprinomectin and clinical efficacy against Psoroptes cuniculi in topically administered rabbits. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20069313/),h,14.85,129286,DB00602,Ivermectin
,20069313,half-life of absorption,"Compared to the non-licking group, self-licking behavior contributed to an extremely significant shorter half-life of absorption (14.85+/-2.79 h in licking group vs.29.44+/-7.81 h in non-licking group, p<0.01) and an extremely significant higher C(max) value for eprinomectin (21.95+/-5.36 h in licking group vs. 6.98+/-0.72 ng ml(-1) in non-licking group, p<0.01) in plasma disposition.",The effect of self-licking behavior on pharmacokinetics of eprinomectin and clinical efficacy against Psoroptes cuniculi in topically administered rabbits. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20069313/),h,29.44,129287,DB00602,Ivermectin
,20069313,C(max),"Compared to the non-licking group, self-licking behavior contributed to an extremely significant shorter half-life of absorption (14.85+/-2.79 h in licking group vs.29.44+/-7.81 h in non-licking group, p<0.01) and an extremely significant higher C(max) value for eprinomectin (21.95+/-5.36 h in licking group vs. 6.98+/-0.72 ng ml(-1) in non-licking group, p<0.01) in plasma disposition.",The effect of self-licking behavior on pharmacokinetics of eprinomectin and clinical efficacy against Psoroptes cuniculi in topically administered rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20069313/),h,21.95,129288,DB00602,Ivermectin
,20069313,C(max),"Compared to the non-licking group, self-licking behavior contributed to an extremely significant shorter half-life of absorption (14.85+/-2.79 h in licking group vs.29.44+/-7.81 h in non-licking group, p<0.01) and an extremely significant higher C(max) value for eprinomectin (21.95+/-5.36 h in licking group vs. 6.98+/-0.72 ng ml(-1) in non-licking group, p<0.01) in plasma disposition.",The effect of self-licking behavior on pharmacokinetics of eprinomectin and clinical efficacy against Psoroptes cuniculi in topically administered rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20069313/),[ng] / [ml],6.98,129289,DB00602,Ivermectin
,20069313,mean residence time,An extremely significantly shorter mean residence time (50.72+/-3.45 h) in self-licking group was also determined compared with the value obtained in non-licking group (106.66+/-7.39 h; p<0.01).,The effect of self-licking behavior on pharmacokinetics of eprinomectin and clinical efficacy against Psoroptes cuniculi in topically administered rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20069313/),h,50.72,129290,DB00602,Ivermectin
,20069313,mean residence time,An extremely significantly shorter mean residence time (50.72+/-3.45 h) in self-licking group was also determined compared with the value obtained in non-licking group (106.66+/-7.39 h; p<0.01).,The effect of self-licking behavior on pharmacokinetics of eprinomectin and clinical efficacy against Psoroptes cuniculi in topically administered rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20069313/),h,106.66,129291,DB00602,Ivermectin
,20197212,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of 51.6+/-22.2 and 33.3+/-10.5 ng/mL were obtained after oral administration and IM route, respectively.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),[ng] / [ml],51.6,130935,DB00602,Ivermectin
,20197212,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of 51.6+/-22.2 and 33.3+/-10.5 ng/mL were obtained after oral administration and IM route, respectively.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),[ng] / [ml],33.3,130936,DB00602,Ivermectin
,20197212,area under the concentration-time curve (AUC),"The value for the area under the concentration-time curve (AUC) was 178.6+/-53.7 and 393.6+/-66.6 ng day/mL for Group 1 and Group 2, respectively.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),[d·ng] / [ml],178.6,130937,DB00602,Ivermectin
,20197212,area under the concentration-time curve (AUC),"The value for the area under the concentration-time curve (AUC) was 178.6+/-53.7 and 393.6+/-66.6 ng day/mL for Group 1 and Group 2, respectively.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),[d·ng] / [ml],393.6,130938,DB00602,Ivermectin
,20197212,mean residence time (MRT),"The averages for mean residence time (MRT) values were 7.7+/-0.9 and 13.2+/-4.5 days for oral and IM treated groups, respectively.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),d,7.7,130939,DB00602,Ivermectin
,20197212,mean residence time (MRT),"The averages for mean residence time (MRT) values were 7.7+/-0.9 and 13.2+/-4.5 days for oral and IM treated groups, respectively.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),d,13.2,130940,DB00602,Ivermectin
,20197212,peak fecal concentration (F C max),"In horses treated using the oral route, the peak fecal concentration (F C max) was 2295+/-593 ng/g observed at 1.9+/-0.5 days after oral treatment.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),[ng] / [g],2295,130941,DB00602,Ivermectin
,20197212,F C max,"Whereas, for those treated by IM route, the F C max was lower (162+/-26 ng/g) (P<0.0079) and it was observed at 5.6+/-2.9 days.",Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197212/),[ng] / [g],162,130942,DB00602,Ivermectin
,25744609,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) values were 17.62 ± 9.68 ng day/ml and 6.56 ± 4.00 ng day/ml for plasma and milk respectively after the administration of 0.5mg/kg BW and 45.32 ± 13.90 ng day/ml and 13.88 ± 1.77 ng day/ml for plasma and milk, respectively after the administration of 1mg/kg BW.",Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),[d·ng] / [ml],17.62,131916,DB00602,Ivermectin
,25744609,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) values were 17.62 ± 9.68 ng day/ml and 6.56 ± 4.00 ng day/ml for plasma and milk respectively after the administration of 0.5mg/kg BW and 45.32 ± 13.90 ng day/ml and 13.88 ± 1.77 ng day/ml for plasma and milk, respectively after the administration of 1mg/kg BW.",Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),[d·ng] / [ml],6.56,131917,DB00602,Ivermectin
,25744609,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) values were 17.62 ± 9.68 ng day/ml and 6.56 ± 4.00 ng day/ml for plasma and milk respectively after the administration of 0.5mg/kg BW and 45.32 ± 13.90 ng day/ml and 13.88 ± 1.77 ng day/ml for plasma and milk, respectively after the administration of 1mg/kg BW.",Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),[d·ng] / [ml],45.32,131918,DB00602,Ivermectin
,25744609,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) values were 17.62 ± 9.68 ng day/ml and 6.56 ± 4.00 ng day/ml for plasma and milk respectively after the administration of 0.5mg/kg BW and 45.32 ± 13.90 ng day/ml and 13.88 ± 1.77 ng day/ml for plasma and milk, respectively after the administration of 1mg/kg BW.",Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),[d·ng] / [ml],13.88,131919,DB00602,Ivermectin
,25744609,milk-to-plasma ratio,The milk-to-plasma ratio ranged from 0.33 to 0.36 and the amount of drug recovered in the milk was 0.4% of the total administered dose.,Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),,0.33 to 0.36,131920,DB00602,Ivermectin
<,25744609,maximum concentrations,The maximum concentrations of eprinomectin residues determined in milk after oral treatment were < 20 μg/kg (Maximum Residue Limit in goat milk).,Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),[μg] / [kg],20,131921,DB00602,Ivermectin
<,25744609,Maximum Residue Limit,The maximum concentrations of eprinomectin residues determined in milk after oral treatment were < 20 μg/kg (Maximum Residue Limit in goat milk).,Kinetics and anthelmintic efficacy of topical eprinomectin when given orally to goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25744609/),[μg] / [kg],20,131922,DB00602,Ivermectin
,16411909,area under the curve,The area under the curve values of the parasitized group (75.2 +/- 15.5 ng x d/ml) were significantly lower that those observed in the parasite-free group (134.3 +/- 15.7 ng x d/ml).,Effect of parasitism on the pharmacokinetic disposition of ivermectin in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411909/),[d·ng] / [ml],75.2,132522,DB00602,Ivermectin
,16411909,area under the curve,The area under the curve values of the parasitized group (75.2 +/- 15.5 ng x d/ml) were significantly lower that those observed in the parasite-free group (134.3 +/- 15.7 ng x d/ml).,Effect of parasitism on the pharmacokinetic disposition of ivermectin in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411909/),[d·ng] / [ml],134.3,132523,DB00602,Ivermectin
,16411909,mean residence time (MRT),The mean residence time (MRT) of the parasitized group (2.93 +/- 0.16 days) was significantly lower than the MRT of healthy group (3.93 +/- 0.29 days).,Effect of parasitism on the pharmacokinetic disposition of ivermectin in lambs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411909/),d,2.93,132524,DB00602,Ivermectin
,16411909,MRT,The mean residence time (MRT) of the parasitized group (2.93 +/- 0.16 days) was significantly lower than the MRT of healthy group (3.93 +/- 0.29 days).,Effect of parasitism on the pharmacokinetic disposition of ivermectin in lambs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411909/),d,3.93,132525,DB00602,Ivermectin
,29914951,Plasma mean residence times (MRT),"Plasma mean residence times (MRT) were 7.1 ± 2.4 and 1.1 ± 0.2 days for AFX and IVM, respectively.",Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914951/),d,7.1,133032,DB00602,Ivermectin
,29914951,Plasma mean residence times (MRT),"Plasma mean residence times (MRT) were 7.1 ± 2.4 and 1.1 ± 0.2 days for AFX and IVM, respectively.",Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914951/),d,1.1,133033,DB00602,Ivermectin
,29914951,Skin MRT,"Skin MRT values were 16.2 ± 16.9 and 2.7 ± 0.5 days for AFX and IVM, respectively.",Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914951/),d,16.2,133034,DB00602,Ivermectin
,29914951,Skin MRT,"Skin MRT values were 16.2 ± 16.9 and 2.7 ± 0.5 days for AFX and IVM, respectively.",Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914951/),d,2.7,133035,DB00602,Ivermectin
,20851527,peak values (C(max)),"For topical administration, the concentrations of eprinomectin in plasma reached peak values (C(max)) of 16.16 ± 6.02 ng ml(-1) at 3.20 ± 1.30 days (T(max)).",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[ng] / [ml],16.16,135010,DB00602,Ivermectin
,20851527,T(max),"For topical administration, the concentrations of eprinomectin in plasma reached peak values (C(max)) of 16.16 ± 6.02 ng ml(-1) at 3.20 ± 1.30 days (T(max)).",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),d,3,135011,DB00602,Ivermectin
,20851527,C(max),"In milk, the C(max) values of 2.28 ± 0.85 ng ml(-1) were obtained at 3.48 ± 0.65 days.",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[ng] / [ml],2.28,135012,DB00602,Ivermectin
,20851527,MRT,The MRT values were 5.00 ± 0.96 days for plasma and 4.65 ± 0.60 days for milk.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),d,5.00,135013,DB00602,Ivermectin
,20851527,MRT,The MRT values were 5.00 ± 0.96 days for plasma and 4.65 ± 0.60 days for milk.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),d,4.65,135014,DB00602,Ivermectin
,20851527,AUC,The AUC values were 91.00 ± 25.32 ng d ml(-1) for plasma and 10.53 ± 1.55 ng d ml(-1) for milk.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[d·ng] / [ml],91.00,135015,DB00602,Ivermectin
,20851527,AUC,The AUC values were 91.00 ± 25.32 ng d ml(-1) for plasma and 10.53 ± 1.55 ng d ml(-1) for milk.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[d·ng] / [ml],10.53,135016,DB00602,Ivermectin
,20851527,ratio of AUC milk,The ratio of AUC milk/plasma was 0.124 ± 0.041.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),,0.124,135017,DB00602,Ivermectin
,20851527,peak values,"For oral administration, the concentrations of eprinomectin reach peak values of 30.02 ± 5.73 ng ml(-1) at 1.60 ± 0.55 days in plasma and 3.14 ± 0.88 ng ml(-1) at 1.40 ± 0.27 days in milk.",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[ng] / [ml],30.02,135018,DB00602,Ivermectin
,20851527,peak values,"For oral administration, the concentrations of eprinomectin reach peak values of 30.02 ± 5.73 ng ml(-1) at 1.60 ± 0.55 days in plasma and 3.14 ± 0.88 ng ml(-1) at 1.40 ± 0.27 days in milk.",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[ng] / [ml],3.14,135019,DB00602,Ivermectin
,20851527,MRT,"The MRT values for plasma and milk were 3.00 ± 0.46 and 3.18 ± 0.55 days, respectively.",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),d,3.00,135020,DB00602,Ivermectin
,20851527,MRT,"The MRT values for plasma and milk were 3.00 ± 0.46 and 3.18 ± 0.55 days, respectively.",Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),d,3.18,135021,DB00602,Ivermectin
,20851527,AUC,The AUC values were 98.46 ± 24.75 ng d ml(-1) for plasma and 10.42 ± 4.22 ng d ml(-1) for milk.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[d·ng] / [ml],98.46,135022,DB00602,Ivermectin
,20851527,AUC,The AUC values were 98.46 ± 24.75 ng d ml(-1) for plasma and 10.42 ± 4.22 ng d ml(-1) for milk.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),[d·ng] / [ml],10.42,135023,DB00602,Ivermectin
,20851527,ratio of AUC,The ratio of AUC milk/plasma was 0.104 ± 0.022.,Plasma and milk kinetics of eprinomectin following topical or oral administration to lactating Chinese Holstein cows. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20851527/),,0.104,135024,DB00602,Ivermectin
,19368248,Peak plasma concentration,"Peak plasma concentration, area under the curve, and half-life for plasma ranged between 5.41-8.49 ng/ml, 17.1-20.3 ng x day/ml, and 3.12-4.47 day, respectively.",The pharmacokinetics of orally administered ivermectin in African elephants (Loxodonta africana): implications for parasite elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19368248/),[ng] / [ml],5.41-8.49,135202,DB00602,Ivermectin
,19368248,area under the curve,"Peak plasma concentration, area under the curve, and half-life for plasma ranged between 5.41-8.49 ng/ml, 17.1-20.3 ng x day/ml, and 3.12-4.47 day, respectively.",The pharmacokinetics of orally administered ivermectin in African elephants (Loxodonta africana): implications for parasite elimination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19368248/),[d·ng] / [ml],17.1-20.3,135203,DB00602,Ivermectin
,19368248,half-life,"Peak plasma concentration, area under the curve, and half-life for plasma ranged between 5.41-8.49 ng/ml, 17.1-20.3 ng x day/ml, and 3.12-4.47 day, respectively.",The pharmacokinetics of orally administered ivermectin in African elephants (Loxodonta africana): implications for parasite elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19368248/),d,3.12-4.47,135204,DB00602,Ivermectin
more,29626533,time above the LC50,Dosing optimization demonstrating a twice-daily dose for 3- or 5-day regimens would provide a time above the LC50 of more than 7 days for adult and pediatric subjects.,The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626533/),d,7,136038,DB00602,Ivermectin
,29626533,time above LC50,"Furthermore, to address the occurrence of CYP450 induction that is often encountered with antiretroviral agents, simulated drug-drug interaction studies with efavirenz highlighted that a 1-mg/kg once-daily dose for 5 days would counteract the increased ivermectin hepatic clearance and enable a time above LC50 of 138.8 h in adults and 141.2 h in pediatric subjects.",The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626533/),h,138.8,136039,DB00602,Ivermectin
,29626533,time above LC50,"Furthermore, to address the occurrence of CYP450 induction that is often encountered with antiretroviral agents, simulated drug-drug interaction studies with efavirenz highlighted that a 1-mg/kg once-daily dose for 5 days would counteract the increased ivermectin hepatic clearance and enable a time above LC50 of 138.8 h in adults and 141.2 h in pediatric subjects.",The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626533/),h,141.2,136040,DB00602,Ivermectin
,12203677,trueness,"The trueness at 2 and 25 ng ml(-1) (n = 6) was +4.2 and -17.1%, respectively.",Determination of ivermectin B(1a) in animal plasma by liquid chromatography combined with electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12203677/),%,4,136540,DB00602,Ivermectin
,12203677,signal-to-noise ratio,"Using a signal-to-noise ratio of 3 : 1, the limit of detection was calculated to be 0.2 ng ml(-1).",Determination of ivermectin B(1a) in animal plasma by liquid chromatography combined with electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12203677/),,3 : 1,136541,DB00602,Ivermectin
,12203677,limit of detection,"Using a signal-to-noise ratio of 3 : 1, the limit of detection was calculated to be 0.2 ng ml(-1).",Determination of ivermectin B(1a) in animal plasma by liquid chromatography combined with electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12203677/),[ng] / [ml],0.2,136542,DB00602,Ivermectin
,16280198,maximum plasma concentration (C(max),"The results indicated that IVM produced a significantly higher maximum plasma concentration (C(max): 116.80+/-10.79 ng/ml) with slower absorption (t(max): 0.23+/-0.09 day) and larger area under the concentration versus time curve (AUC: 236.79+/-41.45 ng day/ml) as compared with DRM (C(max): 86.47+/-19.80 ng/ml, t(max): 0.12+/-0.05 day, AUC: 183.48+/-13.17 ng day/ml) following oral administration of both drugs; whereas no significant differences were observed on the pharmacokinetic parameters between IVM and DRM after subcutaneous administrations.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[ng] / [ml],116.80,136743,DB00602,Ivermectin
,16280198,area under the concentration versus time curve (AUC,"The results indicated that IVM produced a significantly higher maximum plasma concentration (C(max): 116.80+/-10.79 ng/ml) with slower absorption (t(max): 0.23+/-0.09 day) and larger area under the concentration versus time curve (AUC: 236.79+/-41.45 ng day/ml) as compared with DRM (C(max): 86.47+/-19.80 ng/ml, t(max): 0.12+/-0.05 day, AUC: 183.48+/-13.17 ng day/ml) following oral administration of both drugs; whereas no significant differences were observed on the pharmacokinetic parameters between IVM and DRM after subcutaneous administrations.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[d·ng] / [ml],236.79,136744,DB00602,Ivermectin
,16280198,C(max),"The results indicated that IVM produced a significantly higher maximum plasma concentration (C(max): 116.80+/-10.79 ng/ml) with slower absorption (t(max): 0.23+/-0.09 day) and larger area under the concentration versus time curve (AUC: 236.79+/-41.45 ng day/ml) as compared with DRM (C(max): 86.47+/-19.80 ng/ml, t(max): 0.12+/-0.05 day, AUC: 183.48+/-13.17 ng day/ml) following oral administration of both drugs; whereas no significant differences were observed on the pharmacokinetic parameters between IVM and DRM after subcutaneous administrations.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[ng] / [ml],86.47,136745,DB00602,Ivermectin
,16280198,t(max),"The results indicated that IVM produced a significantly higher maximum plasma concentration (C(max): 116.80+/-10.79 ng/ml) with slower absorption (t(max): 0.23+/-0.09 day) and larger area under the concentration versus time curve (AUC: 236.79+/-41.45 ng day/ml) as compared with DRM (C(max): 86.47+/-19.80 ng/ml, t(max): 0.12+/-0.05 day, AUC: 183.48+/-13.17 ng day/ml) following oral administration of both drugs; whereas no significant differences were observed on the pharmacokinetic parameters between IVM and DRM after subcutaneous administrations.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),d,0.12,136746,DB00602,Ivermectin
,16280198,AUC,"The results indicated that IVM produced a significantly higher maximum plasma concentration (C(max): 116.80+/-10.79 ng/ml) with slower absorption (t(max): 0.23+/-0.09 day) and larger area under the concentration versus time curve (AUC: 236.79+/-41.45 ng day/ml) as compared with DRM (C(max): 86.47+/-19.80 ng/ml, t(max): 0.12+/-0.05 day, AUC: 183.48+/-13.17 ng day/ml) following oral administration of both drugs; whereas no significant differences were observed on the pharmacokinetic parameters between IVM and DRM after subcutaneous administrations.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[d·ng] / [ml],183.48,136747,DB00602,Ivermectin
,16280198,maximum plasma concentration (C(max),"In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[ng] / [ml],66.80,136748,DB00602,Ivermectin
,16280198,maximum plasma concentration (C(max),"In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[ng] / [ml],54.78,136749,DB00602,Ivermectin
,16280198,t(max),"In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),d,1.40,136750,DB00602,Ivermectin
,16280198,t(max),"In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),d,1.70,136751,DB00602,Ivermectin
,16280198,area under the concentration versus time curve (AUC,"In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[d·ng] / [ml],349.18,136752,DB00602,Ivermectin
,16280198,area under the concentration versus time curve (AUC,"In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.",Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280198/),[d·ng] / [ml],292.10,136753,DB00602,Ivermectin
,27692320,Cmax,The samples collected during the efficacy test was analyzed by this validated method and prove Cmax of 350ng/mL at 4h (tmax) and AUC of 8411ng/h/mL.,Evaluation of pharmacokinetics and efficacy of ivermectin following oral administration in dogs against experimental infection of Ctenocephalides felis felis and Rhipicephalus sanguineus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692320/),[ng] / [ml],350,137050,DB00602,Ivermectin
,27692320,tmax,The samples collected during the efficacy test was analyzed by this validated method and prove Cmax of 350ng/mL at 4h (tmax) and AUC of 8411ng/h/mL.,Evaluation of pharmacokinetics and efficacy of ivermectin following oral administration in dogs against experimental infection of Ctenocephalides felis felis and Rhipicephalus sanguineus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692320/),h,4,137051,DB00602,Ivermectin
,27692320,AUC,The samples collected during the efficacy test was analyzed by this validated method and prove Cmax of 350ng/mL at 4h (tmax) and AUC of 8411ng/h/mL.,Evaluation of pharmacokinetics and efficacy of ivermectin following oral administration in dogs against experimental infection of Ctenocephalides felis felis and Rhipicephalus sanguineus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27692320/),[ng] / [h·ml],8411,137052,DB00602,Ivermectin
,19959569,area under the concentration-time curves,"There was no significant difference in C(max) values among the three molecules, whereas the area under the concentration-time curves of DRM (258.40 ng.d/mL) and IVM (191.62 ng.d/mL) was significantly higher than that of MXD (83.17 ng.d/mL).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),[d·ng] / [ml],258.40,138853,DB00602,Ivermectin
,19959569,area under the concentration-time curves,"There was no significant difference in C(max) values among the three molecules, whereas the area under the concentration-time curves of DRM (258.40 ng.d/mL) and IVM (191.62 ng.d/mL) was significantly higher than that of MXD (83.17 ng.d/mL).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),[d·ng] / [ml],191.62,138854,DB00602,Ivermectin
,19959569,area under the concentration-time curves,"There was no significant difference in C(max) values among the three molecules, whereas the area under the concentration-time curves of DRM (258.40 ng.d/mL) and IVM (191.62 ng.d/mL) was significantly higher than that of MXD (83.17 ng.d/mL).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),[d·ng] / [ml],83.17,138855,DB00602,Ivermectin
,19959569,plasma residence time,"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,7.52,138856,DB00602,Ivermectin
,19959569,plasma residence time,"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,8.97,138857,DB00602,Ivermectin
,19959569,plasma residence time,"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,4.73,138858,DB00602,Ivermectin
,19959569,terminal half-life (t(1/2lambdaz)),"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,4.48,138859,DB00602,Ivermectin
,19959569,terminal half-life (t(1/2lambdaz)),"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,8.16,138860,DB00602,Ivermectin
,19959569,terminal half-life (t(1/2lambdaz)),"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,4.73,138861,DB00602,Ivermectin
,19959569,terminal half-life (t(1/2lambdaz)),"The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively).","Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959569/),d,2.75,138862,DB00602,Ivermectin
,21321059,IC(50),"In addition, spinosad was a strong inhibitor of the P-gp transport of digoxin, calcein acetoxymethyl ester (IC(50) = 3.2 μM), and ivermectin (IC(50) = 2.3 μM).",Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321059/),μM,3.2,143281,DB00602,Ivermectin
,21321059,IC(50),"In addition, spinosad was a strong inhibitor of the P-gp transport of digoxin, calcein acetoxymethyl ester (IC(50) = 3.2 μM), and ivermectin (IC(50) = 2.3 μM).",Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321059/),μM,2.3,143282,DB00602,Ivermectin
> or =,9024866,milk to plasma ratios,"Compounds that were saturated at the C-22,23 bond had milk to plasma ratios > or = 1.0, whereas those unsaturated at this bond were generally < or = 1.0.",Efficacy in sheep and pharmacokinetics in cattle that led to the selection of eprinomectin as a topical endectocide for cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024866/),,1.0,144525,DB00602,Ivermectin
<,9024866,milk to plasma ratios,"Compounds that were saturated at the C-22,23 bond had milk to plasma ratios > or = 1.0, whereas those unsaturated at this bond were generally < or = 1.0.",Efficacy in sheep and pharmacokinetics in cattle that led to the selection of eprinomectin as a topical endectocide for cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024866/),,1.0,144526,DB00602,Ivermectin
<,9024866,milk to plasma ratio,The milk to plasma ratio of eprinomectin was < or = 0.2.,Efficacy in sheep and pharmacokinetics in cattle that led to the selection of eprinomectin as a topical endectocide for cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024866/),,0.2,144527,DB00602,Ivermectin
,26708436,t1/2λz,"Pharmacokinetic results indicate that the effective blood concentration of the gel could be maintained up to 110-120 days, t1/2λz of the gels was (24.37 ± 1.71) days and MRT was (32.86 ± 0.91) days.",Study of an injectable in situ forming gel for sustained-release of Ivermectin in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26708436/),d,24.37,148912,DB00602,Ivermectin
,26708436,MRT,"Pharmacokinetic results indicate that the effective blood concentration of the gel could be maintained up to 110-120 days, t1/2λz of the gels was (24.37 ± 1.71) days and MRT was (32.86 ± 0.91) days.",Study of an injectable in situ forming gel for sustained-release of Ivermectin in vitro and in vivo. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26708436/),d,32.86,148913,DB00602,Ivermectin
,11676618,total fraction of the dose recovered,"Doramectin could be detected in the milk for 21.0+/-2.9 days after subcutaneous treatment, and the total fraction of the dose recovered from the milk was estimated to be 2.9+/-0.88 per cent.",Milk kinetics of moxidectin and doramectin in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11676618/),%,2.9,151193,DB00602,Ivermectin
,11676618,total fractions,"Moxidectin, after either oral or subcutaneous administration, could be detected in the milk up to day 40 and the total fractions of the dose recovered from the milk were estimated to be 5.7+/-1.04 per cent and 22.53+/-1.09 per cent, respectively.",Milk kinetics of moxidectin and doramectin in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11676618/),%,5.7,151194,DB00602,Ivermectin
,11676618,total fractions,"Moxidectin, after either oral or subcutaneous administration, could be detected in the milk up to day 40 and the total fractions of the dose recovered from the milk were estimated to be 5.7+/-1.04 per cent and 22.53+/-1.09 per cent, respectively.",Milk kinetics of moxidectin and doramectin in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11676618/),%,22.53,151195,DB00602,Ivermectin
,10598075,maximum plasma concentration,The maximum plasma concentration of 5.60+/-1.01 ng/ml occurred 2.55 days after administration.,Some pharmacokinetic parameters of eprinomectin in goats following pour-on administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598075/),[ng] / [ml],5.60,152039,DB00602,Ivermectin
,10598075,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) was 72.31+/-1.15 ng day/ml and the mean residence time (MRT) was 9.42+/-0.43 days.,Some pharmacokinetic parameters of eprinomectin in goats following pour-on administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598075/),[d·ng] / [ml],72.31,152040,DB00602,Ivermectin
,10598075,mean residence time (MRT),The area under the concentration-time curve (AUC) was 72.31+/-1.15 ng day/ml and the mean residence time (MRT) was 9.42+/-0.43 days.,Some pharmacokinetic parameters of eprinomectin in goats following pour-on administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598075/),d,9.42,152041,DB00602,Ivermectin
above,32438446,Cmax /EC90 ratio,Only 14 of the 56 analyzed drugs achieved a Cmax /EC90 ratio above 1.,Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438446/),,1,152820,DB00602,Ivermectin
,12213114,terminal phase half-lives (t(1/2)),"Plasma concentrations after intravenous administration declined polyexponentially in cats and biphasically in dogs, with mean terminal phase half-lives (t(1/2)) of approximately 69 h in cats and 14 h in dogs.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),h,69,153390,DB00602,Ivermectin
,12213114,terminal phase half-lives (t(1/2)),"Plasma concentrations after intravenous administration declined polyexponentially in cats and biphasically in dogs, with mean terminal phase half-lives (t(1/2)) of approximately 69 h in cats and 14 h in dogs.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),h,14,153391,DB00602,Ivermectin
,12213114,overall Clb,"In cats, overall Clb was 0.470 +/- 0.039 mL/min/kg (+/-SD) and overall Vd(ss) was 2.19 +/- 0.05 L/kg, compared with values of 1.18 +/- 0.31 mL/min/kg and 1.24 +/- 0.26 L/kg, respectively, in dogs.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[ml] / [kg·min],0.470,153392,DB00602,Ivermectin
,12213114,overall Vd(ss),"In cats, overall Clb was 0.470 +/- 0.039 mL/min/kg (+/-SD) and overall Vd(ss) was 2.19 +/- 0.05 L/kg, compared with values of 1.18 +/- 0.31 mL/min/kg and 1.24 +/- 0.26 L/kg, respectively, in dogs.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[l] / [kg],2.19,153393,DB00602,Ivermectin
,12213114,overall Vd(ss),"In cats, overall Clb was 0.470 +/- 0.039 mL/min/kg (+/-SD) and overall Vd(ss) was 2.19 +/- 0.05 L/kg, compared with values of 1.18 +/- 0.31 mL/min/kg and 1.24 +/- 0.26 L/kg, respectively, in dogs.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[ml] / [kg·min],1.18,153394,DB00602,Ivermectin
,12213114,overall Vd(ss),"In cats, overall Clb was 0.470 +/- 0.039 mL/min/kg (+/-SD) and overall Vd(ss) was 2.19 +/- 0.05 L/kg, compared with values of 1.18 +/- 0.31 mL/min/kg and 1.24 +/- 0.26 L/kg, respectively, in dogs.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[l] / [kg],1.24,153395,DB00602,Ivermectin
,12213114,C(max),"After topical administration, the mean C(max) in cats was 5513 +/- 2173 ng/mL reached at a time (T(max)) of 15 +/- 12 h postadministration; in dogs, C(max) was 86.5 +/- 34.0 ng/mL at T(max) of 72 +/- 48 h.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[ng] / [ml],5513,153396,DB00602,Ivermectin
,12213114,time (T(max)),"After topical administration, the mean C(max) in cats was 5513 +/- 2173 ng/mL reached at a time (T(max)) of 15 +/- 12 h postadministration; in dogs, C(max) was 86.5 +/- 34.0 ng/mL at T(max) of 72 +/- 48 h.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),h,15,153397,DB00602,Ivermectin
,12213114,C(max),"After topical administration, the mean C(max) in cats was 5513 +/- 2173 ng/mL reached at a time (T(max)) of 15 +/- 12 h postadministration; in dogs, C(max) was 86.5 +/- 34.0 ng/mL at T(max) of 72 +/- 48 h.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[ng] / [ml],86.5,153398,DB00602,Ivermectin
,12213114,T(max),"After topical administration, the mean C(max) in cats was 5513 +/- 2173 ng/mL reached at a time (T(max)) of 15 +/- 12 h postadministration; in dogs, C(max) was 86.5 +/- 34.0 ng/mL at T(max) of 72 +/- 48 h.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),h,72,153399,DB00602,Ivermectin
,12213114,Bioavailability,Bioavailability was 74% in cats and 4.4% in dogs.,"Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),%,74,153400,DB00602,Ivermectin
,12213114,Bioavailability,Bioavailability was 74% in cats and 4.4% in dogs.,"Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),%,4.4,153401,DB00602,Ivermectin
,12213114,C(max),"Following oral administration to cats, mean C(max) was 11,929 +/- 5922 ng/mL at T(max) of 7 +/- 6 h and bioavailability was 109%.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[ng] / [ml],"11,929",153402,DB00602,Ivermectin
,12213114,T(max),"Following oral administration to cats, mean C(max) was 11,929 +/- 5922 ng/mL at T(max) of 7 +/- 6 h and bioavailability was 109%.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),h,7,153403,DB00602,Ivermectin
,12213114,bioavailability,"Following oral administration to cats, mean C(max) was 11,929 +/- 5922 ng/mL at T(max) of 7 +/- 6 h and bioavailability was 109%.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),%,109,153404,DB00602,Ivermectin
,12213114,C(max),"In dogs, mean C(max) was 7630 +/- 3140 ng/mL at T(max) of 8 +/- 5 h and bioavailability was 62%.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),[ng] / [ml],7630,153405,DB00602,Ivermectin
,12213114,T(max),"In dogs, mean C(max) was 7630 +/- 3140 ng/mL at T(max) of 8 +/- 5 h and bioavailability was 62%.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),h,8,153406,DB00602,Ivermectin
,12213114,bioavailability,"In dogs, mean C(max) was 7630 +/- 3140 ng/mL at T(max) of 8 +/- 5 h and bioavailability was 62%.","Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213114/),%,62,153407,DB00602,Ivermectin
,31660626,Cmax,"The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days).",Pharmacokinetics of subcutaneously administered doramectin in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660626/),[ng] / [ml],6.05,154821,DB00602,Ivermectin
,31660626,Tmax,"The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days).",Pharmacokinetics of subcutaneously administered doramectin in alpacas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660626/),d,3.83,154822,DB00602,Ivermectin
,31660626,AUC,"The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days).",Pharmacokinetics of subcutaneously administered doramectin in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660626/),[ng] / [d·ml],62.12,154823,DB00602,Ivermectin
,31660626,terminal half-life,"The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days).",Pharmacokinetics of subcutaneously administered doramectin in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660626/),d,6.2,154824,DB00602,Ivermectin
,31660626,MRT,"The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days).",Pharmacokinetics of subcutaneously administered doramectin in alpacas. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660626/),d,11.56,154825,DB00602,Ivermectin
,17937481,elimination half-lives,"ABM elimination half-lives and mean residence times were 1.7 and 3.7 days for blood plasma and 1.9 and 3.8 days for milk, respectively.",Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),d,1.7,160018,DB00602,Ivermectin
,17937481,elimination half-lives,"ABM elimination half-lives and mean residence times were 1.7 and 3.7 days for blood plasma and 1.9 and 3.8 days for milk, respectively.",Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),d,1.9,160019,DB00602,Ivermectin
,17937481,mean residence times,"ABM elimination half-lives and mean residence times were 1.7 and 3.7 days for blood plasma and 1.9 and 3.8 days for milk, respectively.",Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),d,3.7,160020,DB00602,Ivermectin
,17937481,mean residence times,"ABM elimination half-lives and mean residence times were 1.7 and 3.7 days for blood plasma and 1.9 and 3.8 days for milk, respectively.",Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),d,3.8,160021,DB00602,Ivermectin
,17937481,milk to plasma concentration ratio,The ABM milk to plasma concentration ratio (0.89) primarily depends on milk fat content.,Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),,0.89,160022,DB00602,Ivermectin
,17937481,maximal concentration,"Mean maximal concentration in lambs was 1.6 microg L(-1) at 3.3 days, and elimination half-life was 2.7 days.",Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),[μg] / [l],1.6,160023,DB00602,Ivermectin
,17937481,elimination half-life,"Mean maximal concentration in lambs was 1.6 microg L(-1) at 3.3 days, and elimination half-life was 2.7 days.",Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17937481/),d,2.7,160024,DB00602,Ivermectin
,14597289,observed peak plasma concentration (Cmax),The observed peak plasma concentration (Cmax) was 48.93 ng ml(-1) and the time to reach Cmax (Tmax) was 0.73 day.,Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),[ng] / [ml],48.93,163895,DB00602,Ivermectin
,14597289,time to reach Cmax (Tmax),The observed peak plasma concentration (Cmax) was 48.93 ng ml(-1) and the time to reach Cmax (Tmax) was 0.73 day.,Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),d,0.73,163896,DB00602,Ivermectin
,14597289,absorption half-life (t(1/2a)),"The values for the absorption half-life (t(1/2a)), the distribution half-life (t(1/2alpha)) and the terminal half-life (t(1/2beta)) were 0.31, 0.74 and 4.82 days, respectively.",Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),d,0.31,163897,DB00602,Ivermectin
,14597289,distribution half-life (t(1/2alpha)),"The values for the absorption half-life (t(1/2a)), the distribution half-life (t(1/2alpha)) and the terminal half-life (t(1/2beta)) were 0.31, 0.74 and 4.82 days, respectively.",Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),d,0.74,163898,DB00602,Ivermectin
,14597289,terminal half-life (t(1/2beta)),"The values for the absorption half-life (t(1/2a)), the distribution half-life (t(1/2alpha)) and the terminal half-life (t(1/2beta)) were 0.31, 0.74 and 4.82 days, respectively.",Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),d,4.82,163899,DB00602,Ivermectin
,14597289,area under the concentration-time curve (AUC),The calculated area under the concentration-time curve (AUC) was 146.2 ng day ml(-1) and the mean residence time (MRT) was 3.57 days.,Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),[d·ng] / [ml],146.2,163900,DB00602,Ivermectin
,14597289,mean residence time (MRT),The calculated area under the concentration-time curve (AUC) was 146.2 ng day ml(-1) and the mean residence time (MRT) was 3.57 days.,Pharmacokinetics of ivermectin in the yak (Bos grunniens). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14597289/),d,3.57,163901,DB00602,Ivermectin
,25725422,peak value,"After topical administration, plasma eprinomectin reached a peak value of 15.31 ± 3.71 ng/ml (Cmax) at 3.01 ± 1.22 days (Tmax).","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[ng] / [ml],15.31,165292,DB00602,Ivermectin
,25725422,Cmax,"After topical administration, plasma eprinomectin reached a peak value of 15.31 ± 3.71 ng/ml (Cmax) at 3.01 ± 1.22 days (Tmax).","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[ng] / [ml],15.31,165293,DB00602,Ivermectin
,25725422,Tmax,"After topical administration, plasma eprinomectin reached a peak value of 15.31 ± 3.71 ng/ml (Cmax) at 3.01 ± 1.22 days (Tmax).","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),d,3.01,165294,DB00602,Ivermectin
,25725422,Cmax,"In milk, the Cmax was 3.74 ± 1.05 ng/ml at 3.00 ± 0.88 days.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[ng] / [ml],3.74,165295,DB00602,Ivermectin
,25725422,AUC0-t,The AUC0-t for plasma was 193.84 ± 26.34 ng d/ml and for milk AUC(0-t) was 46.24 ± 10.37 ng d/ml.,"Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[d·ng] / [ml],193.84,165296,DB00602,Ivermectin
,25725422,AUC(0-t),The AUC0-t for plasma was 193.84 ± 26.34 ng d/ml and for milk AUC(0-t) was 46.24 ± 10.37 ng d/ml.,"Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[d·ng] / [ml],46.24,165297,DB00602,Ivermectin
,25725422,mean residence time (MRT),"The mean residence time (MRT) was 10.74 ± 1.44 days and 10.90 ± 3.87 days in plasma and milk, respectively.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),d,10.74,165298,DB00602,Ivermectin
,25725422,mean residence time (MRT),"The mean residence time (MRT) was 10.74 ± 1.44 days and 10.90 ± 3.87 days in plasma and milk, respectively.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),d,10.90,165299,DB00602,Ivermectin
,25725422,Cmax,"After subcutaneous administration, the Cmax was 35.78 ± 10.53 ng/ml at 0.91 ± 0.39 days in plasma and 9.10 ± 3.61 ng/ml at 1.61 ± 1.05 days in milk.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[ng] / [ml],35.78,165300,DB00602,Ivermectin
,25725422,Cmax,"After subcutaneous administration, the Cmax was 35.78 ± 10.53 ng/ml at 0.91 ± 0.39 days in plasma and 9.10 ± 3.61 ng/ml at 1.61 ± 1.05 days in milk.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[ng] / [ml],9.10,165301,DB00602,Ivermectin
,25725422,MRTs,"The MRTs in plasma and milk were 3.07 ± 1.50 and 3.64 ± 1.15 days, respectively.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),d,3.07,165302,DB00602,Ivermectin
,25725422,MRTs,"The MRTs in plasma and milk were 3.07 ± 1.50 and 3.64 ± 1.15 days, respectively.","Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),d,3.64,165303,DB00602,Ivermectin
,25725422,AUC(0-t),The AUC(0-t) was 133.71 ± 32.51 ng d/ml for plasma and 43.85 ± 14.16 ng d/ml for milk.,"Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[d·ng] / [ml],133.71,165304,DB00602,Ivermectin
,25725422,AUC(0-t),The AUC(0-t) was 133.71 ± 32.51 ng d/ml for plasma and 43.85 ± 14.16 ng d/ml for milk.,"Anthelmintic efficacy, plasma and milk kinetics of eprinomectin following topical and subcutaneous administration to yaks (Bos grumniens). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725422/),[d·ng] / [ml],43.85,165305,DB00602,Ivermectin
,29442007,peak plasma concentrations (Cmax),"Oral administration of 100 mg/kg fenbendazole, 5 mg/kg praziquantel and 0.2 mg/kg ivermectin using a non-compartmental model defined peak plasma concentrations (Cmax) of 495, 826, 73 ng/mL, and 218 ng/mL for the metabolite oxfendazole, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[ng] / [ml],495,167152,DB00602,Ivermectin
,29442007,peak plasma concentrations (Cmax),"Oral administration of 100 mg/kg fenbendazole, 5 mg/kg praziquantel and 0.2 mg/kg ivermectin using a non-compartmental model defined peak plasma concentrations (Cmax) of 495, 826, 73 ng/mL, and 218 ng/mL for the metabolite oxfendazole, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[ng] / [ml],826,167153,DB00602,Ivermectin
,29442007,peak plasma concentrations (Cmax),"Oral administration of 100 mg/kg fenbendazole, 5 mg/kg praziquantel and 0.2 mg/kg ivermectin using a non-compartmental model defined peak plasma concentrations (Cmax) of 495, 826, 73 ng/mL, and 218 ng/mL for the metabolite oxfendazole, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[ng] / [ml],73,167154,DB00602,Ivermectin
,29442007,peak plasma concentrations (Cmax),"Oral administration of 100 mg/kg fenbendazole, 5 mg/kg praziquantel and 0.2 mg/kg ivermectin using a non-compartmental model defined peak plasma concentrations (Cmax) of 495, 826, 73 ng/mL, and 218 ng/mL for the metabolite oxfendazole, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[ng] / [ml],218,167155,DB00602,Ivermectin
,29442007,area under the curve (AUClast),"The area under the curve (AUClast) values for these drugs were 4653, 1045, 1971 and 5525 h×ng/mL, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[h·ng] / [ml],4653,167156,DB00602,Ivermectin
,29442007,area under the curve (AUClast),"The area under the curve (AUClast) values for these drugs were 4653, 1045, 1971 and 5525 h×ng/mL, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[h·ng] / [ml],1045,167157,DB00602,Ivermectin
,29442007,area under the curve (AUClast),"The area under the curve (AUClast) values for these drugs were 4653, 1045, 1971 and 5525 h×ng/mL, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[h·ng] / [ml],1971,167158,DB00602,Ivermectin
,29442007,area under the curve (AUClast),"The area under the curve (AUClast) values for these drugs were 4653, 1045, 1971 and 5525 h×ng/mL, respectively.",Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29442007/),[h·ng] / [ml],5525,167159,DB00602,Ivermectin
,8260963,maximum plasma concentration,The maximum plasma concentration of 6.12 ng/ml occurred at 2.85 d; the half-life of 4.03 d was similar to the value in sheep (3.68 d).,Ivermectin in goat plasma and milk after subcutaneous injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260963/),[ng] / [ml],6.12,169868,DB00602,Ivermectin
,8260963,half-life,The maximum plasma concentration of 6.12 ng/ml occurred at 2.85 d; the half-life of 4.03 d was similar to the value in sheep (3.68 d).,Ivermectin in goat plasma and milk after subcutaneous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260963/),d,4.03,169869,DB00602,Ivermectin
,8260963,half-life,The maximum plasma concentration of 6.12 ng/ml occurred at 2.85 d; the half-life of 4.03 d was similar to the value in sheep (3.68 d).,Ivermectin in goat plasma and milk after subcutaneous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260963/),d,3.68,169870,DB00602,Ivermectin
,8260963,milk-plasma concentration ratio,Comparison of the milk and plasma data shows the parallel disposition of the drug in milk and plasma with a milk-plasma concentration ratio of 1.08 +/- 0.23.,Ivermectin in goat plasma and milk after subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260963/),,1.08,169871,DB00602,Ivermectin
,27856406,time above the lethal concentration 50% (LC50,"Modeling showed that a 3-day regimen of 600 mcg/kg/day achieved similar median (5 to 95 percentiles) maximum drug concentrations (Cmax) of ivermectin to a single of dose of 800 mcg/kg, while increasing the median time above the lethal concentration 50% (LC50, 16 ng/mL) from 1.9 days (1.0 to 5.7) to 6.8 (3.8 to 13.4) days.","Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27856406/),[ng] / [ml],16,170314,DB00602,Ivermectin
,27856406,time above the lethal concentration 50% (LC50,"Modeling showed that a 3-day regimen of 600 mcg/kg/day achieved similar median (5 to 95 percentiles) maximum drug concentrations (Cmax) of ivermectin to a single of dose of 800 mcg/kg, while increasing the median time above the lethal concentration 50% (LC50, 16 ng/mL) from 1.9 days (1.0 to 5.7) to 6.8 (3.8 to 13.4) days.","Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27856406/),d,1.9,170315,DB00602,Ivermectin
,27856406,time above the lethal concentration 50% (LC50,"Modeling showed that a 3-day regimen of 600 mcg/kg/day achieved similar median (5 to 95 percentiles) maximum drug concentrations (Cmax) of ivermectin to a single of dose of 800 mcg/kg, while increasing the median time above the lethal concentration 50% (LC50, 16 ng/mL) from 1.9 days (1.0 to 5.7) to 6.8 (3.8 to 13.4) days.","Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27856406/),d,6.8,170316,DB00602,Ivermectin
,8236738,plasma half-life,The plasma pharmacokinetic characteristics of doramectin in cattle following intravenous administration revealed a plasma half-life of approximately 89 h.,Doramectin--a potent novel endectocide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236738/),h,89,170475,DB00602,Ivermectin
,15236438,limit of detection,"The limit of detection was 0.3 ng mL(-1), while the quantitative limit was 1 ng mL(-1), using a 0.5 mL sample size.",Validated capillary electrophoretic method for the analysis of ivermectin in plasma after intragastric administration in pigs and horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236438/),[ng] / [ml],0.3,172404,DB00602,Ivermectin
,15236438,quantitative limit,"The limit of detection was 0.3 ng mL(-1), while the quantitative limit was 1 ng mL(-1), using a 0.5 mL sample size.",Validated capillary electrophoretic method for the analysis of ivermectin in plasma after intragastric administration in pigs and horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236438/),[ng] / [ml],1,172405,DB00602,Ivermectin
,10607502,maximum plasma concentration,"The maximum plasma concentration of 43.76 ng ml(-1)occurred 2.02 days post administration, and the mean residence time was 4.16 days.",Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10607502/),[ng] / [ml],43.76,172542,DB00602,Ivermectin
,10607502,mean residence time,"The maximum plasma concentration of 43.76 ng ml(-1)occurred 2.02 days post administration, and the mean residence time was 4.16 days.",Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10607502/),d,4.16,172543,DB00602,Ivermectin
,10607502,milk / plasma concentration ratio,Comparison of the milk and plasma data demonstrated the parallel disposition of the drug in the milk and plasma with a milk / plasma concentration ratio of 0. 102+/-0.048.,Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10607502/),,0,172544,DB00602,Ivermectin
,10607502,amount of drug recovered,The amount of drug recovered in the milk during this period was 0.109% +/- 0.038 of the total administered dose.,Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10607502/),%,0.109,172545,DB00602,Ivermectin
,10607502,maximum level,"This supports the permitted use in lactating cattle, as the maximum level of residue in milk did not exceed the maximum acceptable limit of 30 ng ml(-1).",Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10607502/),[ng] / [ml],30,172546,DB00602,Ivermectin
,24712181,plasma terminal half-life,"Mean plasma terminal half-life and maximum plasma concentrations of selamectin were 5.8 days and 16.1 ng/ml, respectively, with maximum plasma levels reached at 3 days.",Pharmacokinetics of selamectin in helmeted guineafowl (Numida meleagris) after topical administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712181/),d,5.8,172621,DB00602,Ivermectin
,24712181,maximum plasma concentrations,"Mean plasma terminal half-life and maximum plasma concentrations of selamectin were 5.8 days and 16.1 ng/ml, respectively, with maximum plasma levels reached at 3 days.",Pharmacokinetics of selamectin in helmeted guineafowl (Numida meleagris) after topical administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24712181/),[ng] / [ml],16.1,172622,DB00602,Ivermectin
,22882122,AUC0-last,"Analysis of data by the Classic Method yielded confidence intervals of 80.59-114.47 (for AUC0-last ), 90.38-119.68 (for Cmax ) and 84.70-111.96 (for Css ).",Pharmacokinetics and bioequivalence in the pig of two ivermectin feed formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882122/),,80.59-114.47,175674,DB00602,Ivermectin
,22882122,Cmax,"Analysis of data by the Classic Method yielded confidence intervals of 80.59-114.47 (for AUC0-last ), 90.38-119.68 (for Cmax ) and 84.70-111.96 (for Css ).",Pharmacokinetics and bioequivalence in the pig of two ivermectin feed formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882122/),,90.38-119.68,175675,DB00602,Ivermectin
,22882122,Css,"Analysis of data by the Classic Method yielded confidence intervals of 80.59-114.47 (for AUC0-last ), 90.38-119.68 (for Cmax ) and 84.70-111.96 (for Css ).",Pharmacokinetics and bioequivalence in the pig of two ivermectin feed formulations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882122/),,84.70-111.96,175676,DB00602,Ivermectin
,9131534,absorption half-life (t1/2ab),The absorption of MXD from the site of injection was significantly faster (absorption half-life (t1/2ab) = 1.32 h) than those of IVM (t1/2ab = 39.2 h) and DRM (t1/2ab = 56.4 h).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),h,1.32,177372,DB00602,Ivermectin
,9131534,t1/2ab,The absorption of MXD from the site of injection was significantly faster (absorption half-life (t1/2ab) = 1.32 h) than those of IVM (t1/2ab = 39.2 h) and DRM (t1/2ab = 56.4 h).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),h,39.2,177373,DB00602,Ivermectin
,9131534,t1/2ab,The absorption of MXD from the site of injection was significantly faster (absorption half-life (t1/2ab) = 1.32 h) than those of IVM (t1/2ab = 39.2 h) and DRM (t1/2ab = 56.4 h).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),h,56.4,177374,DB00602,Ivermectin
,9131534,area under the concentration-time curve (AUC),There were no differences on Cmax values: the area under the concentration-time curve (AUC) was higher for IVM (459 ng.d/mL) and DRM (627 ng.d/mL) compared to that of MXD (217 ng.d/mL).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),[d·ng] / [ml],459,177375,DB00602,Ivermectin
,9131534,area under the concentration-time curve (AUC),There were no differences on Cmax values: the area under the concentration-time curve (AUC) was higher for IVM (459 ng.d/mL) and DRM (627 ng.d/mL) compared to that of MXD (217 ng.d/mL).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),[d·ng] / [ml],627,177376,DB00602,Ivermectin
,9131534,area under the concentration-time curve (AUC),There were no differences on Cmax values: the area under the concentration-time curve (AUC) was higher for IVM (459 ng.d/mL) and DRM (627 ng.d/mL) compared to that of MXD (217 ng.d/mL).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),[d·ng] / [ml],217,177377,DB00602,Ivermectin
,9131534,plasma residence time,The mean plasma residence time was longer for MXD (14.6 d) compared to IVM (7.35 d) and DRM (9.09 d).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),d,14.6,177378,DB00602,Ivermectin
,9131534,plasma residence time,The mean plasma residence time was longer for MXD (14.6 d) compared to IVM (7.35 d) and DRM (9.09 d).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),d,7.35,177379,DB00602,Ivermectin
,9131534,plasma residence time,The mean plasma residence time was longer for MXD (14.6 d) compared to IVM (7.35 d) and DRM (9.09 d).,"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131534/),d,9.09,177380,DB00602,Ivermectin
,16416124,maximum plasma concentration,The maximum plasma concentration of 8.83+/-2.15 ng ml(-1) occurred 1.30 days post-administration.,Eprinomectin in dairy zebu Gobra cattle (Bos indicus): plasma kinetics and excretion in milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416124/),[ng] / [ml],8.83,177735,DB00602,Ivermectin
,16416124,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was 30.63+/-5.56 ng day(-1) ml(-1) and the mean residence time was 3.38+/-0.60 days.,Eprinomectin in dairy zebu Gobra cattle (Bos indicus): plasma kinetics and excretion in milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416124/),[ng] / [day·ml],30.63,177736,DB00602,Ivermectin
,16416124,mean residence time,The area under the plasma concentration-time curve was 30.63+/-5.56 ng day(-1) ml(-1) and the mean residence time was 3.38+/-0.60 days.,Eprinomectin in dairy zebu Gobra cattle (Bos indicus): plasma kinetics and excretion in milk. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416124/),d,3.38,177737,DB00602,Ivermectin
,15233455,efficacy,"In ewes naturally infected with the nasal bot fly, the efficacy of the drug against O. ovis was 97.7 per cent.",Efficacy of eprinomectin pour-on against gastrointestinal nematodes and the nasal bot fly (Oestrus ovis) in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15233455/),-1,97.7,177814,DB00602,Ivermectin
,15233455,systemic area under the curve (AUC),"The mean (se) systemic area under the curve (AUC) was 56.0 (26.2) ng/day/ml and the mean residence time was 5.3 (1.0) days, but there were wide variations between individual sheep.",Efficacy of eprinomectin pour-on against gastrointestinal nematodes and the nasal bot fly (Oestrus ovis) in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15233455/),[ng] / [d·ml],56.0,177815,DB00602,Ivermectin
,15233455,mean residence time,"The mean (se) systemic area under the curve (AUC) was 56.0 (26.2) ng/day/ml and the mean residence time was 5.3 (1.0) days, but there were wide variations between individual sheep.",Efficacy of eprinomectin pour-on against gastrointestinal nematodes and the nasal bot fly (Oestrus ovis) in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15233455/),d,5.3,177816,DB00602,Ivermectin
,18774650,maximal concentrations (C(max)),"Following administration of moxidectin, plasma and milk concentrations of moxidectin increased to reach maximal concentrations (C(max)) of 5.46+/-3.50 and 23.76+/-16.63ngml(-1) at T(max) of 1.20+/-0.33 and 1.87+/-0.77 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngml],5.46,177923,DB00602,Ivermectin
,18774650,maximal concentrations (C(max)),"Following administration of moxidectin, plasma and milk concentrations of moxidectin increased to reach maximal concentrations (C(max)) of 5.46+/-3.50 and 23.76+/-16.63ngml(-1) at T(max) of 1.20+/-0.33 and 1.87+/-0.77 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngml],23.76,177924,DB00602,Ivermectin
,18774650,T(max),"Following administration of moxidectin, plasma and milk concentrations of moxidectin increased to reach maximal concentrations (C(max)) of 5.46+/-3.50 and 23.76+/-16.63ngml(-1) at T(max) of 1.20+/-0.33 and 1.87+/-0.77 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,1.20,177925,DB00602,Ivermectin
,18774650,T(max),"Following administration of moxidectin, plasma and milk concentrations of moxidectin increased to reach maximal concentrations (C(max)) of 5.46+/-3.50 and 23.76+/-16.63ngml(-1) at T(max) of 1.20+/-0.33 and 1.87+/-0.77 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,1.87,177926,DB00602,Ivermectin
,18774650,mean residence time (MRT),"The mean residence time (MRT) were similar for plasma and milk (5.27+/-0.45 and 5.87+/-0.80 days, respectively).",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,5.27,177927,DB00602,Ivermectin
,18774650,mean residence time (MRT),"The mean residence time (MRT) were similar for plasma and milk (5.27+/-0.45 and 5.87+/-0.80 days, respectively).",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,5.87,177928,DB00602,Ivermectin
,18774650,AUC,The AUC value was 5-fold higher in milk (109.68+/-65.01ngdayml(-1)) than in plasma (23.66+/-12.26ngdayml(-1)).,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngdayml],109.68,177929,DB00602,Ivermectin
,18774650,AUC,The AUC value was 5-fold higher in milk (109.68+/-65.01ngdayml(-1)) than in plasma (23.66+/-12.26ngdayml(-1)).,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngdayml],23.66,177930,DB00602,Ivermectin
,18774650,ratio of AUC milk/plasma,The ratio of AUC milk/plasma for moxidectin was 5.04+/-2.13.,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),,5.04,177931,DB00602,Ivermectin
,18774650,Maximal Residue Level value (MRL),"Nevertheless, due to its high excretion in milk and its high detected maximum concentration in milk which is equivalent or higher to the Maximal Residue Level value (MRL) (40ngml(-1)), its use should be prohibited in lactating buffaloes.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngml],40,177932,DB00602,Ivermectin
,18774650,C(max),"Concerning eprinomectin, the C(max) were of 2.74+/-0.89 and 3.40+/-1.68ngml(-1) at T(max) of 1.44+/-0.20 and 1.33+/-0.0.41 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngml],2.74,177933,DB00602,Ivermectin
,18774650,C(max),"Concerning eprinomectin, the C(max) were of 2.74+/-0.89 and 3.40+/-1.68ngml(-1) at T(max) of 1.44+/-0.20 and 1.33+/-0.0.41 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngml],3.40,177934,DB00602,Ivermectin
,18774650,T(max),"Concerning eprinomectin, the C(max) were of 2.74+/-0.89 and 3.40+/-1.68ngml(-1) at T(max) of 1.44+/-0.20 and 1.33+/-0.0.41 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,1.44,177935,DB00602,Ivermectin
,18774650,T(max),"Concerning eprinomectin, the C(max) were of 2.74+/-0.89 and 3.40+/-1.68ngml(-1) at T(max) of 1.44+/-0.20 and 1.33+/-0.0.41 days in plasma and milk, respectively.",Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,1.33,177936,DB00602,Ivermectin
,18774650,MRT,The MRT and the AUC were similar for plasma (3.17+/-0.41 days and 11.43+/-4.01ngdayml(-1)) and milk (2.70+/-0.44 days and 8.49+/-3.33ngdayml(-1)).,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,3.17,177937,DB00602,Ivermectin
,18774650,MRT,The MRT and the AUC were similar for plasma (3.17+/-0.41 days and 11.43+/-4.01ngdayml(-1)) and milk (2.70+/-0.44 days and 8.49+/-3.33ngdayml(-1)).,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),d,2.70,177938,DB00602,Ivermectin
,18774650,AUC,The MRT and the AUC were similar for plasma (3.17+/-0.41 days and 11.43+/-4.01ngdayml(-1)) and milk (2.70+/-0.44 days and 8.49+/-3.33ngdayml(-1)).,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngdayml],11.43,177939,DB00602,Ivermectin
,18774650,AUC,The MRT and the AUC were similar for plasma (3.17+/-0.41 days and 11.43+/-4.01ngdayml(-1)) and milk (2.70+/-0.44 days and 8.49+/-3.33ngdayml(-1)).,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngdayml],8.49,177940,DB00602,Ivermectin
,18774650,ratio of AUC milk/plasma,The ratio of AUC milk/plasma for eprinomectin was 0.76+/-0.16.,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),,0.76,177941,DB00602,Ivermectin
,18774650,MRL,The very low extent of mammary excretion and the milk levels reported lower than the MRL (20ngml(-1)) supports the permitted use of eprinomectin in lactating water buffaloes.,Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774650/),1/[ngml],20,177942,DB00602,Ivermectin
,11730797,plasma (total) clearance,Ivermectin plasma (total) clearance (270+/-57.4 ml/kg/day) was very homogeneous among the 12 cattle.,Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730797/),[ml] / [d·kg],270,178313,DB00602,Ivermectin
,11730797,terminal plasma half-life,Prevention of licking resulted in an extended terminal plasma half-life (363+/-16.2 vs. 154+/-7.4 h in lickers) and in a lower and less variable systemic availability of ivermectin (19+/-4.9 vs. 33+/-18.5% in lickers).,Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730797/),h,363,178314,DB00602,Ivermectin
,11730797,terminal plasma half-life,Prevention of licking resulted in an extended terminal plasma half-life (363+/-16.2 vs. 154+/-7.4 h in lickers) and in a lower and less variable systemic availability of ivermectin (19+/-4.9 vs. 33+/-18.5% in lickers).,Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730797/),h,154,178315,DB00602,Ivermectin
,11730797,systemic availability,Prevention of licking resulted in an extended terminal plasma half-life (363+/-16.2 vs. 154+/-7.4 h in lickers) and in a lower and less variable systemic availability of ivermectin (19+/-4.9 vs. 33+/-18.5% in lickers).,Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730797/),%,19,178316,DB00602,Ivermectin
,11730797,systemic availability,Prevention of licking resulted in an extended terminal plasma half-life (363+/-16.2 vs. 154+/-7.4 h in lickers) and in a lower and less variable systemic availability of ivermectin (19+/-4.9 vs. 33+/-18.5% in lickers).,Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730797/),%,33,178317,DB00602,Ivermectin
,15720000,concentrations,"The level of avermectin B1 concentrations in the fish muscles was 7.75+/-0.88 and 38.29+/-1.65 ng x g(-1) for the low and high concentrations, respectively, on day 22.",Bioconcentration and elimination of avermectin B1 in sturgeon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720000/),[ng] / [g],7.75,178512,DB00602,Ivermectin
,15720000,concentrations,"The level of avermectin B1 concentrations in the fish muscles was 7.75+/-0.88 and 38.29+/-1.65 ng x g(-1) for the low and high concentrations, respectively, on day 22.",Bioconcentration and elimination of avermectin B1 in sturgeon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720000/),[ng] / [g],38.29,178513,DB00602,Ivermectin
,15720000,half-life (t1/2),"The half-life (t1/2) of the concentrations for the two treated groups was 4.95 and 4.33 d for the low and high concentrations, respectively.",Bioconcentration and elimination of avermectin B1 in sturgeon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720000/),d,4.95,178514,DB00602,Ivermectin
,15720000,half-life (t1/2),"The half-life (t1/2) of the concentrations for the two treated groups was 4.95 and 4.33 d for the low and high concentrations, respectively.",Bioconcentration and elimination of avermectin B1 in sturgeon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720000/),d,4.33,178515,DB00602,Ivermectin
,15720000,bioconcentration factor,"The estimated values of the bioconcentration factor were 42 L/kg for the low-concentration group and 41 L/kg for high-concentration group, and these values were not significantly different (alpha = 0.05).",Bioconcentration and elimination of avermectin B1 in sturgeon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720000/),[l] / [kg],42,178516,DB00602,Ivermectin
,15720000,bioconcentration factor,"The estimated values of the bioconcentration factor were 42 L/kg for the low-concentration group and 41 L/kg for high-concentration group, and these values were not significantly different (alpha = 0.05).",Bioconcentration and elimination of avermectin B1 in sturgeon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720000/),[l] / [kg],41,178517,DB00602,Ivermectin
,7856833,concentrations,"The overall mean +/- SD ivermectin concentrations one and two days after a single oral dose (150 micrograms/kg) were 16.4 +/- 6.4 and 6.6 +/- 3.1 ng/ml, respectively.",Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7856833/),,16.4,180561,DB00602,Ivermectin
,7856833,concentrations,"The overall mean +/- SD ivermectin concentrations one and two days after a single oral dose (150 micrograms/kg) were 16.4 +/- 6.4 and 6.6 +/- 3.1 ng/ml, respectively.",Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7856833/),,6.6,180562,DB00602,Ivermectin
,7856833,half-life,The overall mean +/- SD half-life was estimated to be 19.9 +/- 8.6 hr.,Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7856833/),h,19.9,180563,DB00602,Ivermectin
,24975211,retention time,The retention time was approximately 4.8min.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),min,4.8,180933,DB00602,Ivermectin
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,84.2,180934,DB00602,Ivermectin
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,90.1,180935,DB00602,Ivermectin
,12362927,t(max),"Following single doses of 30 to 120 mg, AUC and Cmax were generally dose proportional, with t(max) approximately 4 hours and t1/2 approximately 18 hours.","Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362927/),h,4,181516,DB00602,Ivermectin
,12362927,t1/2,"Following single doses of 30 to 120 mg, AUC and Cmax were generally dose proportional, with t(max) approximately 4 hours and t1/2 approximately 18 hours.","Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362927/),h,18,181517,DB00602,Ivermectin
,12362927,AUC ratios,"Geometric mean AUC ratios (day 7/day 1) were 1.24 and 1.40 for the 30 and 60 mg doses, respectively, indicating that the accumulation of ivermectin given every fourth day is minimal.","Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362927/),,1.24,181518,DB00602,Ivermectin
,12362927,AUC ratios,"Geometric mean AUC ratios (day 7/day 1) were 1.24 and 1.40 for the 30 and 60 mg doses, respectively, indicating that the accumulation of ivermectin given every fourth day is minimal.","Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362927/),,1.40,181519,DB00602,Ivermectin
,30566757,apparent population clearance,"The model estimates (inter-individual variability) for a 70 kg subject were: apparent population clearance 7.7 (25%) l h-1 , and central and peripheral volumes of distribution 89 (10%) l and 234 (20%) l, respectively.",Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30566757/),[l] / [h],7.7,181938,DB00602,Ivermectin
,30566757,central,"The model estimates (inter-individual variability) for a 70 kg subject were: apparent population clearance 7.7 (25%) l h-1 , and central and peripheral volumes of distribution 89 (10%) l and 234 (20%) l, respectively.",Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30566757/),,89,181939,DB00602,Ivermectin
,30566757,peripheral volumes of distribution,"The model estimates (inter-individual variability) for a 70 kg subject were: apparent population clearance 7.7 (25%) l h-1 , and central and peripheral volumes of distribution 89 (10%) l and 234 (20%) l, respectively.",Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30566757/),,89,181940,DB00602,Ivermectin
,30566757,peripheral volumes of distribution,"The model estimates (inter-individual variability) for a 70 kg subject were: apparent population clearance 7.7 (25%) l h-1 , and central and peripheral volumes of distribution 89 (10%) l and 234 (20%) l, respectively.",Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30566757/),,234,181941,DB00602,Ivermectin
,26820168,maximum concentration of EPM in plasma (Cmax),"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [ml],59.70,183536,DB00602,Ivermectin
,26820168,maximum concentration of EPM in plasma (Cmax),"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [ml],20.73,183537,DB00602,Ivermectin
,26820168,time to reach Cmax,"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,1.30,183538,DB00602,Ivermectin
,26820168,time to reach Cmax,"The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,4.40,183539,DB00602,Ivermectin
,26820168,area under the curve; AUC,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],295.9,183540,DB00602,Ivermectin
,26820168,terminal half-life,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],295.9,183541,DB00602,Ivermectin
,26820168,terminal half-life,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,2.95,183542,DB00602,Ivermectin
,26820168,terminal half-life,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],168.2,183543,DB00602,Ivermectin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,2.95,183544,DB00602,Ivermectin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,4.69,183545,DB00602,Ivermectin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [ml],168.2,183546,DB00602,Ivermectin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,4.63,183547,DB00602,Ivermectin
,26820168,mean residence time,"In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),d,8.23,183548,DB00602,Ivermectin
,26820168,AUC,"Subcutaneous administration resulted in greater faecal excretion than topical administration, expressed as AUC adjusted for dose (1188.9 (SD 491.64) vs. 311.5 (SD 46.90) ng.day/g; p<0.05).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [g],1188.9,183549,DB00602,Ivermectin
,26820168,AUC,"Subcutaneous administration resulted in greater faecal excretion than topical administration, expressed as AUC adjusted for dose (1188.9 (SD 491.64) vs. 311.5 (SD 46.90) ng.day/g; p<0.05).",Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[d·ng] / [g],311.5,183550,DB00602,Ivermectin
,26820168,Maximum concentration,Maximum concentration in faeces was also higher following S/C than topical administration (223.0 (SD 63.96) vs. 99.47 (SD 43.24) ng/g; p<0.01).,Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [g],223.0,183551,DB00602,Ivermectin
,26820168,Maximum concentration,Maximum concentration in faeces was also higher following S/C than topical administration (223.0 (SD 63.96) vs. 99.47 (SD 43.24) ng/g; p<0.01).,Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26820168/),[ng] / [g],99.47,183552,DB00602,Ivermectin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],-,185697,DB00602,Ivermectin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.4,185698,DB00602,Ivermectin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],6.8,185699,DB00602,Ivermectin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.9,185700,DB00602,Ivermectin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],9.1,185701,DB00602,Ivermectin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],7.5,185702,DB00602,Ivermectin
,16454640,volume of distribution at a steady state,"Pharmacokinetics of ivermectin after IV administration were best described by a 2-compartment open model; values for main compartmental variables included volume of distribution at a steady state (9.94 L/kg), clearance (1.54 L/kg/d), and area under the plasma concentration-time curve (AUC; 143 [ng x d]/mL).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),[l] / [kg],9.94,190079,DB00602,Ivermectin
,16454640,clearance,"Pharmacokinetics of ivermectin after IV administration were best described by a 2-compartment open model; values for main compartmental variables included volume of distribution at a steady state (9.94 L/kg), clearance (1.54 L/kg/d), and area under the plasma concentration-time curve (AUC; 143 [ng x d]/mL).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),[l] / [d·kg],1.54,190080,DB00602,Ivermectin
,16454640,area under the plasma concentration-time curve (AUC;,"Pharmacokinetics of ivermectin after IV administration were best described by a 2-compartment open model; values for main compartmental variables included volume of distribution at a steady state (9.94 L/kg), clearance (1.54 L/kg/d), and area under the plasma concentration-time curve (AUC; 143 [ng x d]/mL).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),[d·ng] / [ml],143,190081,DB00602,Ivermectin
,16454640,mean residence time,"Values for the noncompartmental variables included mean residence time (7.37 days), AUC (153 [ng x d]/mL), and clearance (1.43 L/kg/d).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),d,7.37,190082,DB00602,Ivermectin
,16454640,AUC,"Values for the noncompartmental variables included mean residence time (7.37 days), AUC (153 [ng x d]/mL), and clearance (1.43 L/kg/d).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),[d·ng] / [ml],153,190083,DB00602,Ivermectin
,16454640,clearance,"Values for the noncompartmental variables included mean residence time (7.37 days), AUC (153 [ng x d]/mL), and clearance (1.43 L/kg/d).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),[l] / [d·kg],1.43,190084,DB00602,Ivermectin
,16454640,maximum plasma concentration (Cmax,"Values of the variables calculated by use of this method included maximum plasma concentration (Cmax; 21.8 ng/mL), time to reach Cmax (3 days), and bioavailability (F; 91.8%).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),[ng] / [ml],21.8,190085,DB00602,Ivermectin
,16454640,time to reach Cmax,"Values of the variables calculated by use of this method included maximum plasma concentration (Cmax; 21.8 ng/mL), time to reach Cmax (3 days), and bioavailability (F; 91.8%).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),d,3,190086,DB00602,Ivermectin
,16454640,bioavailability (F,"Values of the variables calculated by use of this method included maximum plasma concentration (Cmax; 21.8 ng/mL), time to reach Cmax (3 days), and bioavailability (F; 91.8%).",Pharmacokinetics of a novel formulation of ivermectin after administration to goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454640/),%,91.8,190087,DB00602,Ivermectin
,17217403,Cmax,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),[ng] / [ml],37.11,191840,DB00602,Ivermectin
,17217403,Tmax,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),d,16,191841,DB00602,Ivermectin
,17217403,T(1/2),"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),d,44.62,191842,DB00602,Ivermectin
,17217403,AUC,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),[d·ng] / [ml],928.2,191843,DB00602,Ivermectin
,17217403,MRT,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),d,36.73,191844,DB00602,Ivermectin
,17217403,Cmax,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),[ng] / [ml],28.70,191845,DB00602,Ivermectin
,17217403,Tmax,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),d,14,191846,DB00602,Ivermectin
,17217403,T(1/2),"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),d,15.40,191847,DB00602,Ivermectin
,17217403,AUC,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),[d·ng] / [ml],618.05,191848,DB00602,Ivermectin
,17217403,MRT,"The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.",Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217403/),d,20.79,191849,DB00602,Ivermectin
,10502489,MRT,MRT of doramectin (4.91 +/- 0.07 days) was also significantly shorter than that of moxidectin (12.43 +/- 1.28 days).,Pharmacokinetics of moxidectin and doramectin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),d,4.91,193737,DB00602,Ivermectin
,10502489,MRT,MRT of doramectin (4.91 +/- 0.07 days) was also significantly shorter than that of moxidectin (12.43 +/- 1.28 days).,Pharmacokinetics of moxidectin and doramectin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),d,12.43,193738,DB00602,Ivermectin
,10502489,apparent absorption rate,"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[ng] / [ml],24.27,193739,DB00602,Ivermectin
,10502489,apparent absorption rate,"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[d·ng] / [ml],136.72,193740,DB00602,Ivermectin
,10502489,apparent absorption rate,"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[ng] / [ml],15.53,193741,DB00602,Ivermectin
,10502489,apparent absorption rate,"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[d·ng] / [ml],36.72,193742,DB00602,Ivermectin
,10502489,peak concentration (C(max)),"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[ng] / [ml],24.27,193743,DB00602,Ivermectin
,10502489,peak concentration (C(max)),"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[ng] / [ml],15.53,193744,DB00602,Ivermectin
,10502489,area under the concentration-time curve (AUC),"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[d·ng] / [ml],136.72,193745,DB00602,Ivermectin
,10502489,area under the concentration-time curve (AUC),"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[ng] / [ml],15.53,193746,DB00602,Ivermectin
,10502489,area under the concentration-time curve (AUC),"The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24.27 +/- 1.99 ng ml(-1) and 136.72 +/- 7.35 ng d ml(-1) respectively) was significantly greater than that of the oral administration (15.53 +/- 1.27 ng ml(-1) and 36.72 +/- 4.05 ng d ml(-1) respectively).",Pharmacokinetics of moxidectin and doramectin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10502489/),[d·ng] / [ml],36.72,193747,DB00602,Ivermectin
lower,28282989,drug:carrier ratio,IVM was completely dispersed in HCO in an amorphous state at a drug:carrier ratio lower than 1:3.,Sustained release ivermectin-loaded solid lipid dispersion for subcutaneous delivery: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28282989/),,1,196024,DB00602,Ivermectin
,26790731,Peak plasma concentrations,"Peak plasma concentrations were within a range between 13.8 and 90ng/ml, which guarantee milk drug concentrations below the maximum residues level.",Eprinomectin accumulation in Rhipicephalus (Boophilus) microplus: Pharmacokinetic and efficacy assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26790731/),[ng] / [ml],13.8 and 90,202342,DB00602,Ivermectin
,28687086,LC50,The GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC50 = 16.3 ng/ml) > An. campestris (LC50 = 26.4 ng/ml) = An. sawadwongporni (LC50 = 26.9 ng/ml) > An. dirus (LC50 = 55.6 ng/ml).,Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28687086/),[ng] / [ml],16.3,202384,DB00602,Ivermectin
,28687086,LC50,The GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC50 = 16.3 ng/ml) > An. campestris (LC50 = 26.4 ng/ml) = An. sawadwongporni (LC50 = 26.9 ng/ml) > An. dirus (LC50 = 55.6 ng/ml).,Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28687086/),[ng] / [ml],26.4,202385,DB00602,Ivermectin
,28687086,LC50,The GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC50 = 16.3 ng/ml) > An. campestris (LC50 = 26.4 ng/ml) = An. sawadwongporni (LC50 = 26.9 ng/ml) > An. dirus (LC50 = 55.6 ng/ml).,Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28687086/),[ng] / [ml],26.9,202386,DB00602,Ivermectin
,28687086,LC50,The GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC50 = 16.3 ng/ml) > An. campestris (LC50 = 26.4 ng/ml) = An. sawadwongporni (LC50 = 26.9 ng/ml) > An. dirus (LC50 = 55.6 ng/ml).,Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28687086/),[ng] / [ml],55.6,202387,DB00602,Ivermectin
,23828187,peak plasma concentration,"To substantiate increase in MIF activity, pharmacokinetics study was designed on Wistar rats which revealed a greater peak plasma concentration (45.3 ± 1.79 ng/ml), area under the concentration curve (298 ± 38.7 ng d/ml) and extended mean residence time (23.4 ± 8.56 days)of IVM in chitosan-alginate nanoparticles.","Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23828187/),[ng] / [ml],45.3,202676,DB00602,Ivermectin
,23828187,area under the concentration curve,"To substantiate increase in MIF activity, pharmacokinetics study was designed on Wistar rats which revealed a greater peak plasma concentration (45.3 ± 1.79 ng/ml), area under the concentration curve (298 ± 38.7 ng d/ml) and extended mean residence time (23.4 ± 8.56 days)of IVM in chitosan-alginate nanoparticles.","Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23828187/),[d·ng] / [ml],298,202677,DB00602,Ivermectin
,23828187,mean residence time,"To substantiate increase in MIF activity, pharmacokinetics study was designed on Wistar rats which revealed a greater peak plasma concentration (45.3 ± 1.79 ng/ml), area under the concentration curve (298 ± 38.7 ng d/ml) and extended mean residence time (23.4 ± 8.56 days)of IVM in chitosan-alginate nanoparticles.","Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23828187/),d,23.4,202678,DB00602,Ivermectin
,11936884,peak serum concentration (Cmax),"In five llamas given 1 per cent ivermectin subcutaneously at 200 microg/kg, the median peak serum concentration (Cmax) was 3 ng/ml and the area under the serum concentration-time curve (AUC) was 13.5 ng x day/ml.",Pharmacokinetics of ivermectin in llamas (Lama glama). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936884/),[ng] / [ml],3,203318,DB00602,Ivermectin
,11936884,area under the serum concentration-time curve (AUC),"In five llamas given 1 per cent ivermectin subcutaneously at 200 microg/kg, the median peak serum concentration (Cmax) was 3 ng/ml and the area under the serum concentration-time curve (AUC) was 13.5 ng x day/ml.",Pharmacokinetics of ivermectin in llamas (Lama glama). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936884/),[d·ng] / [ml],13.5,203319,DB00602,Ivermectin
,11936884,Cmax,"In six llamas treated topically with 0.5 per cent ivermedin pour-on at 500 microg/kg, Cmax was 2.5 ng/ml or less and the AUC was 7.75 ng x day/ml or less.",Pharmacokinetics of ivermectin in llamas (Lama glama). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936884/),[ng] / [ml],2.5,203320,DB00602,Ivermectin
,11936884,AUC,"In six llamas treated topically with 0.5 per cent ivermedin pour-on at 500 microg/kg, Cmax was 2.5 ng/ml or less and the AUC was 7.75 ng x day/ml or less.",Pharmacokinetics of ivermectin in llamas (Lama glama). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936884/),[d·ng] / [ml],7.75,203321,DB00602,Ivermectin
,11936884,Cmax,"In five llamas treated subcutaneously with 25 per cent ivermectin sustained-release microspheres at 1500 microg/kg, the median Cmax was 5 ng/ml and the median AUC was 224 ng x day/ml.",Pharmacokinetics of ivermectin in llamas (Lama glama). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936884/),[ng] / [ml],5,203322,DB00602,Ivermectin
,11936884,AUC,"In five llamas treated subcutaneously with 25 per cent ivermectin sustained-release microspheres at 1500 microg/kg, the median Cmax was 5 ng/ml and the median AUC was 224 ng x day/ml.",Pharmacokinetics of ivermectin in llamas (Lama glama). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936884/),[d·ng] / [ml],224,203323,DB00602,Ivermectin
,18177322,mean residence time (MRT),The mean residence time (MRT) values for the pregnant group (8.8+/-1.4 days) were higher (P<0.05) than those observed in the control group (5.3+/-1.9 days).,Pharmacokinetics of ivermectin in pregnant and nonpregnant sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177322/),d,8.8,207040,DB00602,Ivermectin
,18177322,mean residence time (MRT),The mean residence time (MRT) values for the pregnant group (8.8+/-1.4 days) were higher (P<0.05) than those observed in the control group (5.3+/-1.9 days).,Pharmacokinetics of ivermectin in pregnant and nonpregnant sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177322/),d,5.3,207041,DB00602,Ivermectin
,12954187,intestinal clearance,"The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min, exhibiting a stereoselective intestinal elimination to (-)ABZSO form.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.106,208940,DB00602,Ivermectin
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.079,208941,DB00602,Ivermectin
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.069,208942,DB00602,Ivermectin
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.065,208943,DB00602,Ivermectin
,15379435,maximum plasma concentrations,The maximum plasma concentrations of 12.72 +/- 5.13 ng/ml for males and 22.65 +/- 11.95 ng/ml for females occurred around 5 days after administration.,Pharmacokinetics of selamectin in dogs after topical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379435/),[ng] / [ml],12.72,211073,DB00602,Ivermectin
,15379435,maximum plasma concentrations,The maximum plasma concentrations of 12.72 +/- 5.13 ng/ml for males and 22.65 +/- 11.95 ng/ml for females occurred around 5 days after administration.,Pharmacokinetics of selamectin in dogs after topical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379435/),[ng] / [ml],22.65,211074,DB00602,Ivermectin
,15379435,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) was 192.08 +/- 63.85 ng.,Pharmacokinetics of selamectin in dogs after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379435/),ng,192.08,211075,DB00602,Ivermectin
,15379435,mean residence time,The mean residence time was the same in males and females (12.55 days).,Pharmacokinetics of selamectin in dogs after topical application. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379435/),d,12.55,211076,DB00602,Ivermectin
,12585598,mean,Moxidectin had a mean (sd) residence time of 9.04 (2.12) days compared with 4.83 (1.14) days for ivermectin.,Efficacy of ivermectin and moxidectin against Otostrongylus circumlitus and Parafilaroides gymnurus in harbour seals (Phoca vitulina). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12585598/),d,9.04,211753,DB00602,Ivermectin
,8477558,half-life,"The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml.",Protein binding and ivermectin estimations in patients with onchocerciasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477558/),h,56.50,215965,DB00602,Ivermectin
,8477558,clearance,"The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml.",Protein binding and ivermectin estimations in patients with onchocerciasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477558/),[l] / [kg],142.5,215966,DB00602,Ivermectin
,8477558,volume of distribution,"The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml.",Protein binding and ivermectin estimations in patients with onchocerciasis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477558/),[l] / [kg],9.91,215967,DB00602,Ivermectin
,8477558,area under the plasma concentration-time curve,"The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml.",Protein binding and ivermectin estimations in patients with onchocerciasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477558/),[ng] / [h·ml],1545.3,215968,DB00602,Ivermectin
,8477558,time to reach maximum concentration,"The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml.",Protein binding and ivermectin estimations in patients with onchocerciasis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477558/),h,4.7,215969,DB00602,Ivermectin
,8477558,maximum concentration,"The mean (+/- SEM) plasma values for the nine subjects were as follows: weight, 66.3 +/- 2.8 kg; dose, 11.11 +/- 0.4 mg; half-life, 56.50 +/- 7.01 hours; clearance, 142.5 +/- 22.6 L/kg; volume of distribution, 9.91 +/- 2.67 L/kg; area under the plasma concentration-time curve, 1545.3 +/- 190.5 ng/ml.hr; time to reach maximum concentration, 4.7 +/- 0.5 hours; and maximum concentration, 38.2 +/- 5.8 ng/ml.",Protein binding and ivermectin estimations in patients with onchocerciasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477558/),[ng] / [ml],38.2,215970,DB00602,Ivermectin
,18679717,absorption half-life [t1/2ab],The results indicate that the absorption of moxidectin from the site of injection was significantly faster (absorption half-life [t1/2ab] = 0.7 day) than that of doramectin (t1/2ab = 3.1 days).,A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),d,0.7,217268,DB00602,Ivermectin
,18679717,t1/2ab,The results indicate that the absorption of moxidectin from the site of injection was significantly faster (absorption half-life [t1/2ab] = 0.7 day) than that of doramectin (t1/2ab = 3.1 days).,A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),d,3.1,217269,DB00602,Ivermectin
,18679717,tmax,Moxidectin peak plasma concentration (Cmax) was reached significantly earlier (tmax = 0.4 day) compared with that of doramectin (tmax = 5.3 days).,A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),d,0.4,217270,DB00602,Ivermectin
,18679717,tmax,Moxidectin peak plasma concentration (Cmax) was reached significantly earlier (tmax = 0.4 day) compared with that of doramectin (tmax = 5.3 days).,A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),d,5.3,217271,DB00602,Ivermectin
,18679717,area under the concentration-time curve,"No differences in Cmax values were observed; the area under the concentration-time curve was higher for doramectin (475 ng day ml(-1)) compared with moxidectin (198 ng day ml(-1)), while the mean residence time was longer for moxidectin (13.4 days) compared with doramectin (9.4 days).",A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),[d·ng] / [ml],475,217272,DB00602,Ivermectin
,18679717,area under the concentration-time curve,"No differences in Cmax values were observed; the area under the concentration-time curve was higher for doramectin (475 ng day ml(-1)) compared with moxidectin (198 ng day ml(-1)), while the mean residence time was longer for moxidectin (13.4 days) compared with doramectin (9.4 days).",A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),[d·ng] / [ml],198,217273,DB00602,Ivermectin
,18679717,mean residence time,"No differences in Cmax values were observed; the area under the concentration-time curve was higher for doramectin (475 ng day ml(-1)) compared with moxidectin (198 ng day ml(-1)), while the mean residence time was longer for moxidectin (13.4 days) compared with doramectin (9.4 days).",A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),d,13.4,217274,DB00602,Ivermectin
,18679717,mean residence time,"No differences in Cmax values were observed; the area under the concentration-time curve was higher for doramectin (475 ng day ml(-1)) compared with moxidectin (198 ng day ml(-1)), while the mean residence time was longer for moxidectin (13.4 days) compared with doramectin (9.4 days).",A comparative kinetic study of doramectin and moxidectin in zebu Gobra cattle (Bos indicus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679717/),d,9.4,217275,DB00602,Ivermectin
,30981310,concentrations,"Ivermectin concentrations in fat biopsies were 366 ng/g (51 days after the first treatment), 275 ng/g (51 days after the second treatment) and 15 ng/g (64 days after the second treatment).",Relationship between pharmacokinetics of ivermectin (3.15%) and its efficacy to control the infestation with the tick Rhipicephalus (Boophilus) microplus in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981310/),[ng] / [g],366,217296,DB00602,Ivermectin
,30981310,concentrations,"Ivermectin concentrations in fat biopsies were 366 ng/g (51 days after the first treatment), 275 ng/g (51 days after the second treatment) and 15 ng/g (64 days after the second treatment).",Relationship between pharmacokinetics of ivermectin (3.15%) and its efficacy to control the infestation with the tick Rhipicephalus (Boophilus) microplus in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981310/),[ng] / [g],275,217297,DB00602,Ivermectin
,30981310,concentrations,"Ivermectin concentrations in fat biopsies were 366 ng/g (51 days after the first treatment), 275 ng/g (51 days after the second treatment) and 15 ng/g (64 days after the second treatment).",Relationship between pharmacokinetics of ivermectin (3.15%) and its efficacy to control the infestation with the tick Rhipicephalus (Boophilus) microplus in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981310/),[ng] / [g],15,217298,DB00602,Ivermectin
,9950328,Cmax,The Cmax of doramectin (12.2+/-4.8 ng ml(-1)) and ivermectin (12.2+/-6.0 ng ml(-1)) and Tmax of doramectin (4.3+/-1.6 days) and ivermectin (3.4+/-0.8 days) were not significantly different (p > 0.05).,Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),[ng] / [ml],12.2,219919,DB00602,Ivermectin
,9950328,Cmax,The Cmax of doramectin (12.2+/-4.8 ng ml(-1)) and ivermectin (12.2+/-6.0 ng ml(-1)) and Tmax of doramectin (4.3+/-1.6 days) and ivermectin (3.4+/-0.8 days) were not significantly different (p > 0.05).,Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),[ng] / [ml],12.2,219920,DB00602,Ivermectin
,9950328,Tmax,The Cmax of doramectin (12.2+/-4.8 ng ml(-1)) and ivermectin (12.2+/-6.0 ng ml(-1)) and Tmax of doramectin (4.3+/-1.6 days) and ivermectin (3.4+/-0.8 days) were not significantly different (p > 0.05).,Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),d,4.3,219921,DB00602,Ivermectin
,9950328,Tmax,The Cmax of doramectin (12.2+/-4.8 ng ml(-1)) and ivermectin (12.2+/-6.0 ng ml(-1)) and Tmax of doramectin (4.3+/-1.6 days) and ivermectin (3.4+/-0.8 days) were not significantly different (p > 0.05).,Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),d,3.4,219922,DB00602,Ivermectin
,9950328,AUC,"In contrast, the AUC of doramectin (168.0+/-41.7 ng day ml(-1)) was significantly greater than that of ivermectin (115.5+/-43.0 ng day ml(-1)).",Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),[d·ng] / [ml],168.0,219923,DB00602,Ivermectin
,9950328,AUC,"In contrast, the AUC of doramectin (168.0+/-41.7 ng day ml(-1)) was significantly greater than that of ivermectin (115.5+/-43.0 ng day ml(-1)).",Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),[d·ng] / [ml],115.5,219924,DB00602,Ivermectin
,9950328,AUC,"Furthermore, the range of AUC values calculated for ivermectin was wider than that obtained for doramectin, extending from 51.3 to 182.3 ng day ml(-1) for ivermectin versus 104.3-228.7 ng day ml(-1) for doramectin.",Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),[d·ng] / [ml],51.3 to 182.3,219925,DB00602,Ivermectin
,9950328,AUC,"Furthermore, the range of AUC values calculated for ivermectin was wider than that obtained for doramectin, extending from 51.3 to 182.3 ng day ml(-1) for ivermectin versus 104.3-228.7 ng day ml(-1) for doramectin.",Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),[d·ng] / [ml],104.3-228.7,219926,DB00602,Ivermectin
,9950328,MRT,The MRT was significantly greater for doramectin (12.8+/-1.9 days) than for ivermectin (8.4+/-1.5 days).,Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),d,12.8,219927,DB00602,Ivermectin
,9950328,MRT,The MRT was significantly greater for doramectin (12.8+/-1.9 days) than for ivermectin (8.4+/-1.5 days).,Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9950328/),d,8.4,219928,DB00602,Ivermectin
,16242280,retention times,"The retention times of ivermectin and internal standard, moxidectin are approximately 24.5 and 12.5 min, respectively.",Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16242280/),min,24.5,222022,DB00602,Ivermectin
,16242280,retention times,"The retention times of ivermectin and internal standard, moxidectin are approximately 24.5 and 12.5 min, respectively.",Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16242280/),min,12.5,222023,DB00602,Ivermectin
greater,16242280,Recoveries,Recoveries of ivermectin are greater than 80% at all concentrations.,Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16242280/),%,80,222024,DB00602,Ivermectin
,12887622,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of 51.3 +/- 16.1 ng/ml (mean +/- SD) were obtained after oral administration and of 31.4 +/- 6.0 ng/ml for the IM route.,Plasma profiles of ivermectin in horses following oral or intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887622/),[ng] / [ml],51.3,222240,DB00602,Ivermectin
,12887622,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of 51.3 +/- 16.1 ng/ml (mean +/- SD) were obtained after oral administration and of 31.4 +/- 6.0 ng/ml for the IM route.,Plasma profiles of ivermectin in horses following oral or intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887622/),[ng] / [ml],31.4,222241,DB00602,Ivermectin
,12887622,area under concentration-time curve,"The values for area under concentration-time curve were 137.1 +/- 35.9 ng day/ml for the group treated orally, and 303.2 +/- 4.3 ng day/ml for the IM treated group.",Plasma profiles of ivermectin in horses following oral or intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887622/),[d·ng] / [ml],137.1,222242,DB00602,Ivermectin
,12887622,area under concentration-time curve,"The values for area under concentration-time curve were 137.1 +/- 35.9 ng day/ml for the group treated orally, and 303.2 +/- 4.3 ng day/ml for the IM treated group.",Plasma profiles of ivermectin in horses following oral or intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887622/),[d·ng] / [ml],303.2,222243,DB00602,Ivermectin
,12887622,plasma residence times,"The mean plasma residence times were 4.2 +/- 0.4 and 8.9 +/- 0.7 days for oral and IM-treated groups, respectively.",Plasma profiles of ivermectin in horses following oral or intramuscular administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887622/),d,4.2,222244,DB00602,Ivermectin
,12887622,plasma residence times,"The mean plasma residence times were 4.2 +/- 0.4 and 8.9 +/- 0.7 days for oral and IM-treated groups, respectively.",Plasma profiles of ivermectin in horses following oral or intramuscular administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887622/),d,8.9,222245,DB00602,Ivermectin
,24703069,maximum plasma concentration (Cmax),"For cats treated by topical application, the average eprinomectin (B1a component) maximum plasma concentration (Cmax) was 20 ng/mL.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),[ng] / [ml],20,223822,DB00602,Ivermectin
,24703069,terminal half-life,The average terminal half-life was 114 h due to slow absorption ('flip-flop' kinetics).,"Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),h,114,223823,DB00602,Ivermectin
,24703069,Cmax,"Following intravenous administration the average Cmax was 503 ng/mL at 5 min post-dose, and the mean elimination half-life was 23 h.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),[ng] / [ml],503,223824,DB00602,Ivermectin
,24703069,elimination half-life,"Following intravenous administration the average Cmax was 503 ng/mL at 5 min post-dose, and the mean elimination half-life was 23 h.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),h,23,223825,DB00602,Ivermectin
,24703069,volume of distribution,"Eprinomectin was widely distributed with a mean volume of distribution of 2,390 mL/kg, and the clearance rate was 81 mL/h/kg.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),[ml] / [kg],"2,390",223826,DB00602,Ivermectin
,24703069,clearance rate,"Eprinomectin was widely distributed with a mean volume of distribution of 2,390 mL/kg, and the clearance rate was 81 mL/h/kg.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),[ml] / [h·kg],81,223827,DB00602,Ivermectin
,24703069,areas under the plasma concentration versus time curves,"Mean areas under the plasma concentration versus time curves extrapolated to infinity were 2,100 ngh/mL and 5,160 ngh/mL for the topical and intravenous doses, respectively.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),[ngh] / [ml],"2,100",223828,DB00602,Ivermectin
,24703069,areas under the plasma concentration versus time curves,"Mean areas under the plasma concentration versus time curves extrapolated to infinity were 2,100 ngh/mL and 5,160 ngh/mL for the topical and intravenous doses, respectively.","Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),[ngh] / [ml],"5,160",223829,DB00602,Ivermectin
,24703069,absolute bioavailability,Topical eprinomectin was absorbed with an average absolute bioavailability of 31%.,"Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24703069/),%,31,223830,DB00602,Ivermectin
,8329009,elimination half-life,Plasma concentrations increased linearly with dose but elimination half-life (12.6/13.4 h) was independent of the administered dose.,Determination of ivermectin in human plasma by high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329009/),h,12.6,224545,DB00602,Ivermectin
,8329009,elimination half-life,Plasma concentrations increased linearly with dose but elimination half-life (12.6/13.4 h) was independent of the administered dose.,Determination of ivermectin in human plasma by high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329009/),h,13.4,224546,DB00602,Ivermectin
,17472650,terminal half-life,"After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL).",Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),h,3.4,226145,DB00602,Ivermectin
,17472650,maximal plasma concentration,"After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL).",Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),[ng] / [ml],132,226146,DB00602,Ivermectin
,17472650,time to reach maximal plasma concentration,The time to reach maximal plasma concentration was 0.7 h (0.5-0.8 h).,Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),h,0.7,226147,DB00602,Ivermectin
,28117946,reduction ratio,"Ivermectin reduction ratio was calculated at 29% and 39% for each dog, respectively.",Clearance of plasma ivermectin with single pass lipid dialysis in 2 dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28117946/),%,29,229052,DB00602,Ivermectin
,28117946,reduction ratio,"Ivermectin reduction ratio was calculated at 29% and 39% for each dog, respectively.",Clearance of plasma ivermectin with single pass lipid dialysis in 2 dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28117946/),%,39,229053,DB00602,Ivermectin
,28558828,Cmax,"The main pharmacokinetic parameters were: Cmax 6.20 ± 1.71 ng/mL, AUClast 48.8 ± 19.2 day*ng/mL, Tmax 3.13 ± 2.99 days and T1/2 6.40 ± 2.95 days.","Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28558828/),[ng] / [ml],6.20,233201,DB00602,Ivermectin
,28558828,AUClast,"The main pharmacokinetic parameters were: Cmax 6.20 ± 1.71 ng/mL, AUClast 48.8 ± 19.2 day*ng/mL, Tmax 3.13 ± 2.99 days and T1/2 6.40 ± 2.95 days.","Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28558828/),[d·ng] / [ml],48.8,233202,DB00602,Ivermectin
,28558828,Tmax,"The main pharmacokinetic parameters were: Cmax 6.20 ± 1.71 ng/mL, AUClast 48.8 ± 19.2 day*ng/mL, Tmax 3.13 ± 2.99 days and T1/2 6.40 ± 2.95 days.","Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28558828/),d,3.13,233203,DB00602,Ivermectin
,28558828,T1/2,"The main pharmacokinetic parameters were: Cmax 6.20 ± 1.71 ng/mL, AUClast 48.8 ± 19.2 day*ng/mL, Tmax 3.13 ± 2.99 days and T1/2 6.40 ± 2.95 days.","Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28558828/),d,6.40,233204,DB00602,Ivermectin
,9403971,peak plasma concentration,"Doramectin exhibited a similar peak plasma concentration to ivermectin (about 32 ng ml-1), but the time to Cmax was longer for doramectin (5.3 +/- 0.35 days) than for ivermectin (4.0 +/- 0.28 days).",Comparative pharmacokinetics of doramectin and ivermectin in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403971/),[ng] / [ml],32,233282,DB00602,Ivermectin
,9403971,time to Cmax,"Doramectin exhibited a similar peak plasma concentration to ivermectin (about 32 ng ml-1), but the time to Cmax was longer for doramectin (5.3 +/- 0.35 days) than for ivermectin (4.0 +/- 0.28 days).",Comparative pharmacokinetics of doramectin and ivermectin in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403971/),d,5.3,233283,DB00602,Ivermectin
,9403971,time to Cmax,"Doramectin exhibited a similar peak plasma concentration to ivermectin (about 32 ng ml-1), but the time to Cmax was longer for doramectin (5.3 +/- 0.35 days) than for ivermectin (4.0 +/- 0.28 days).",Comparative pharmacokinetics of doramectin and ivermectin in cattle. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403971/),d,4.0,233284,DB00602,Ivermectin
,9403971,area under the curve from time 0 to infinity,The area under the curve from time 0 to infinity post-injection was significantly higher (p < 0.001) for doramectin (511 +/- 16 ng day ml-1) than for ivermectin (361 +/- 17 ng day ml-1).,Comparative pharmacokinetics of doramectin and ivermectin in cattle. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403971/),[d·ng] / [ml],511,233285,DB00602,Ivermectin
,9403971,area under the curve from time 0 to infinity,The area under the curve from time 0 to infinity post-injection was significantly higher (p < 0.001) for doramectin (511 +/- 16 ng day ml-1) than for ivermectin (361 +/- 17 ng day ml-1).,Comparative pharmacokinetics of doramectin and ivermectin in cattle. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403971/),[d·ng] / [ml],361,233286,DB00602,Ivermectin
,22452505,terminal half-life,"Mean terminal half-life and maximum plasma concentrations of selamectin were 0.93 days and 91.7 ng/mL, respectively, for rabbits in the 10 mg/kg group and 0.97 days and 304.2 ng/mL, respectively, for rabbits in the 20 mg/kg group.","Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452505/),d,0.93,239542,DB00602,Ivermectin
,22452505,terminal half-life,"Mean terminal half-life and maximum plasma concentrations of selamectin were 0.93 days and 91.7 ng/mL, respectively, for rabbits in the 10 mg/kg group and 0.97 days and 304.2 ng/mL, respectively, for rabbits in the 20 mg/kg group.","Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452505/),d,0.97,239543,DB00602,Ivermectin
,22452505,maximum plasma concentrations,"Mean terminal half-life and maximum plasma concentrations of selamectin were 0.93 days and 91.7 ng/mL, respectively, for rabbits in the 10 mg/kg group and 0.97 days and 304.2 ng/mL, respectively, for rabbits in the 20 mg/kg group.","Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452505/),[ng] / [ml],91.7,239544,DB00602,Ivermectin
,22452505,maximum plasma concentrations,"Mean terminal half-life and maximum plasma concentrations of selamectin were 0.93 days and 91.7 ng/mL, respectively, for rabbits in the 10 mg/kg group and 0.97 days and 304.2 ng/mL, respectively, for rabbits in the 20 mg/kg group.","Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452505/),[ng] / [ml],304.2,239545,DB00602,Ivermectin
,11809336,overall concentration,The highest overall concentration was found in the same animal: 21.7 microg/l of H(2)B(1a) in plasma on the second day and 44.9 microg/kg of H(2)B(1a) in milk on the first day after the drug was administered.,Ivermectin pharmacokinetics in lactating sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[μg] / [l],21.7,244530,DB00602,Ivermectin
,11809336,overall concentration,The highest overall concentration was found in the same animal: 21.7 microg/l of H(2)B(1a) in plasma on the second day and 44.9 microg/kg of H(2)B(1a) in milk on the first day after the drug was administered.,Ivermectin pharmacokinetics in lactating sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[μg] / [kg],44.9,244531,DB00602,Ivermectin
,11809336,t(max),"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),d,1.70,244532,DB00602,Ivermectin
,11809336,c(max),"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[μg] / [l],11.88,244533,DB00602,Ivermectin
,11809336,t(1/2k(e)),"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[μg] / [l],11.88,244534,DB00602,Ivermectin
,11809336,AUC,"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[d·μg] / [l],63.99,244535,DB00602,Ivermectin
,11809336,AUC,"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),d,1.28,244536,DB00602,Ivermectin
,11809336,AUC,"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[μg] / [l],22.67,244537,DB00602,Ivermectin
,11809336,AUC,"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),d,3.56,244538,DB00602,Ivermectin
,11809336,AUC,"Mean t(max), c(max), t(1/2k(e)) and AUC values for plasma data were: 1.70+/-0.65 days, 11.88+/-6.96 microg/l, 2.85+/-1.97 days and 63.99+/-28.34 microg day/l, respectively, and for milk: 1.28+/-1.07 days, 22.67+/-18.27 microg/l, 3.56+/-2.01 days and 114.60+/-60.41 microg day/l, respectively.",Ivermectin pharmacokinetics in lactating sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),[d·μg] / [l],114.60,244539,DB00602,Ivermectin
,11809336,lamb to ewe,The mean lamb to ewe ratio of areas under the plasma concentration-time curve for the first 5 days was 0.02.,Ivermectin pharmacokinetics in lactating sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),,0.02,244540,DB00602,Ivermectin
,11809336,ratio of areas,The mean lamb to ewe ratio of areas under the plasma concentration-time curve for the first 5 days was 0.02.,Ivermectin pharmacokinetics in lactating sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11809336/),,0.02,244541,DB00602,Ivermectin
,11145833,f,"The ivermectin treatment groups' faecal concentrations remained above the detectable level for 40 days (0.6 +/- 0.3 ng/g), whereas the moxidectin treatment group remained above the detectable level for 75 days (4.3 +/- 2.8 ng/g).",Faecal excretion profile of moxidectin and ivermectin after oral administration in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145833/),ng,0,245991,DB00602,Ivermectin
,11145833,f,"The ivermectin treatment groups' faecal concentrations remained above the detectable level for 40 days (0.6 +/- 0.3 ng/g), whereas the moxidectin treatment group remained above the detectable level for 75 days (4.3 +/- 2.8 ng/g).",Faecal excretion profile of moxidectin and ivermectin after oral administration in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145833/),ng,4,245992,DB00602,Ivermectin
,11145833,area under the faecal concentration time curve,The values of the area under the faecal concentration time curve were slightly higher in the moxidectin treatment group (7104 +/- 2277 ng.day/g) but were not significantly different from those obtained in the ivermectin treatment group (5642 +/- 1122 ng.day/g).,Faecal excretion profile of moxidectin and ivermectin after oral administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145833/),[d·ng] / [g],7104,245993,DB00602,Ivermectin
,11145833,area under the faecal concentration time curve,The values of the area under the faecal concentration time curve were slightly higher in the moxidectin treatment group (7104 +/- 2277 ng.day/g) but were not significantly different from those obtained in the ivermectin treatment group (5642 +/- 1122 ng.day/g).,Faecal excretion profile of moxidectin and ivermectin after oral administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145833/),[d·ng] / [g],5642,245994,DB00602,Ivermectin
,9602386,limit of detection,The intra- and inter-assay coefficient of variation was < 10% in the range of 1.0-30 ng ml-1 and the limit of detection was 0.3 ng ml-1.,"A direct competitive ELISA for the simple, sensitive and accurate determination of diethylcarbamazine concentration in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602386/),[ng] / [ml],0.3,247310,DB00602,Ivermectin
<,9602386,cross reactivities,The cross reactivities of anti-diethylcarbamazine antibodies with diethylcarbamazine metabolites and ivermectin were < 0.09%.,"A direct competitive ELISA for the simple, sensitive and accurate determination of diethylcarbamazine concentration in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602386/),%,0.09,247311,DB00602,Ivermectin
,32891630,maximum concentration,"The simulated ivermectin lung exposures reached a maximum concentration of 772 ng/mL, far less than the estimated 1750 ng/mL IC50 reported for ivermectin against SARS-CoV-2 in vitro.",Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32891630/),[ng] / [ml],772,251352,DB00602,Ivermectin
,32891630,IC50,"The simulated ivermectin lung exposures reached a maximum concentration of 772 ng/mL, far less than the estimated 1750 ng/mL IC50 reported for ivermectin against SARS-CoV-2 in vitro.",Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32891630/),[ng] / [ml],1750,251353,DB00602,Ivermectin
,22075041,C(max),"The results showed that the C(max) (15.94 ng/mL) of ivermectin in combination product was 9.01 times higher than the single product, while the AUC(INF) (1925.61 ng h/mL) was 6.02 times higher.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),[ng] / [ml],15.94,251590,DB00602,Ivermectin
,22075041,AUC(INF),"The results showed that the C(max) (15.94 ng/mL) of ivermectin in combination product was 9.01 times higher than the single product, while the AUC(INF) (1925.61 ng h/mL) was 6.02 times higher.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),[h·ng] / [ml],1925.61,251591,DB00602,Ivermectin
,22075041,C(max),"Meanwhile, the C(max) (1.48 μg/mL), AUC(INF) (17.08μgh/mL), t(1/2z) (20.25 h), TimeDur3 (42.01 h) and TimeDur4 (16.60 h) of praziquantel in combination product were improved with a factor of 5.48, 13.66, 8.58, 10.10 and 7.31 times when compared with the single product, respectively.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),[μg] / [ml],1.48,251592,DB00602,Ivermectin
,22075041,AUC(INF),"Meanwhile, the C(max) (1.48 μg/mL), AUC(INF) (17.08μgh/mL), t(1/2z) (20.25 h), TimeDur3 (42.01 h) and TimeDur4 (16.60 h) of praziquantel in combination product were improved with a factor of 5.48, 13.66, 8.58, 10.10 and 7.31 times when compared with the single product, respectively.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),[μgh] / [ml],17.08,251593,DB00602,Ivermectin
,22075041,t(1/2z),"Meanwhile, the C(max) (1.48 μg/mL), AUC(INF) (17.08μgh/mL), t(1/2z) (20.25 h), TimeDur3 (42.01 h) and TimeDur4 (16.60 h) of praziquantel in combination product were improved with a factor of 5.48, 13.66, 8.58, 10.10 and 7.31 times when compared with the single product, respectively.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),h,20.25,251594,DB00602,Ivermectin
,22075041,TimeDur3,"Meanwhile, the C(max) (1.48 μg/mL), AUC(INF) (17.08μgh/mL), t(1/2z) (20.25 h), TimeDur3 (42.01 h) and TimeDur4 (16.60 h) of praziquantel in combination product were improved with a factor of 5.48, 13.66, 8.58, 10.10 and 7.31 times when compared with the single product, respectively.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),h,42.01,251595,DB00602,Ivermectin
,22075041,TimeDur4,"Meanwhile, the C(max) (1.48 μg/mL), AUC(INF) (17.08μgh/mL), t(1/2z) (20.25 h), TimeDur3 (42.01 h) and TimeDur4 (16.60 h) of praziquantel in combination product were improved with a factor of 5.48, 13.66, 8.58, 10.10 and 7.31 times when compared with the single product, respectively.",Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075041/),h,16.60,251596,DB00602,Ivermectin
,31691813,relative bioavailability,"The final model described concentration-time profiles after fed and fasted dosing accurately, and estimated the food effect associated with relative bioavailability to 1.18 (95% CI 1.10-1.67).",The effect of food on the pharmacokinetics of oral ivermectin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691813/),,1.18,251825,DB00602,Ivermectin
,25689407,FECRT,Mean FECRT and efficacy for removal of adult H. contortus was 0% for IVM at 0.2 and 0.4 mg/kg.,Comparative pharmacokinetic and pharmacodynamic response of single and double intraruminal doses of ivermectin and moxidectin in nematode-infected lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25689407/),%,0,252006,DB00602,Ivermectin
>,25689407,FECRT,"For MXD, FECRT were >95% for both treatments, and efficacy against H. contortus was 85.1% and 98.1% for 0.2 and 0.4 mg/kg, respectively.",Comparative pharmacokinetic and pharmacodynamic response of single and double intraruminal doses of ivermectin and moxidectin in nematode-infected lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25689407/),%,95,252007,DB00602,Ivermectin
,1553807,maximum concentration,The mean (+/- sem) maximum concentration in plasma was 42.0 +/- 9.7 ng/ml 37.2 +/- 5.0 hours after administration and the area under the concentration-time curve was 3543 +/- 580 ng/ml hours.,Clinical and pharmacological properties of ivermectin in rabbits and guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553807/),[ng] / [ml],42.0,252035,DB00602,Ivermectin
,1553807,area under the concentration-time curve,The mean (+/- sem) maximum concentration in plasma was 42.0 +/- 9.7 ng/ml 37.2 +/- 5.0 hours after administration and the area under the concentration-time curve was 3543 +/- 580 ng/ml hours.,Clinical and pharmacological properties of ivermectin in rabbits and guinea pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553807/),[ng] / [h·ml],3543,252036,DB00602,Ivermectin
,1553807,concentration,The mean concentration 72 hours after its administration to four guinea pigs was 0.7 +/- 0.3 ng/ml.,Clinical and pharmacological properties of ivermectin in rabbits and guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553807/),[ng] / [ml],0.7,252037,DB00602,Ivermectin
,19000259,Cmax,A limited maternal-fetal transfer of ivermectin was evidenced by a low fetal Cmax (1.72 +/- 0.6 ng/mL) and AUC (89.1 +/- 11.4 ng.h/mL).,Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000259/),[ng] / [ml],1.72,252417,DB00602,Ivermectin
,19000259,AUC,A limited maternal-fetal transfer of ivermectin was evidenced by a low fetal Cmax (1.72 +/- 0.6 ng/mL) and AUC (89.1 +/- 11.4 ng.h/mL).,Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000259/),[h·ng] / [ml],89.1,252418,DB00602,Ivermectin
,19000259,clearance,While the fetal administration of ivermectin resulted in higher values of clearance (554.1 +/- 177.9 mL/kg) and lower values of t((1/2)beta) (8.0 +/- 1.4 h) and mean residence time (8.0 +/- 2.9 h) indicating that fetal-placental unit is highly efficient in eliminating the drug as well as limiting the transfer of ivermectin from the maternal to fetal compartment.,Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000259/),[ml] / [kg],554.1,252419,DB00602,Ivermectin
,19000259,t((1/2)beta),While the fetal administration of ivermectin resulted in higher values of clearance (554.1 +/- 177.9 mL/kg) and lower values of t((1/2)beta) (8.0 +/- 1.4 h) and mean residence time (8.0 +/- 2.9 h) indicating that fetal-placental unit is highly efficient in eliminating the drug as well as limiting the transfer of ivermectin from the maternal to fetal compartment.,Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000259/),h,8.0,252420,DB00602,Ivermectin
,19000259,mean residence time,While the fetal administration of ivermectin resulted in higher values of clearance (554.1 +/- 177.9 mL/kg) and lower values of t((1/2)beta) (8.0 +/- 1.4 h) and mean residence time (8.0 +/- 2.9 h) indicating that fetal-placental unit is highly efficient in eliminating the drug as well as limiting the transfer of ivermectin from the maternal to fetal compartment.,Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000259/),h,8.0,252421,DB00602,Ivermectin
,19410269,last detectable plasma concentration (t(last)),The last detectable plasma concentration (t(last)) of IVM was significantly later in Kilis goats (38.33 days) compared with Damascus goats (22.50 days).,Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,38.33,258574,DB00602,Ivermectin
,19410269,last detectable plasma concentration (t(last)),The last detectable plasma concentration (t(last)) of IVM was significantly later in Kilis goats (38.33 days) compared with Damascus goats (22.50 days).,Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,22.50,258575,DB00602,Ivermectin
,19410269,C(max),"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),[ng] / [ml],10.83,258576,DB00602,Ivermectin
,19410269,C(max),"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),[ng] / [ml],10.15,258577,DB00602,Ivermectin
,19410269,t(max),"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,2.75,258578,DB00602,Ivermectin
,19410269,t(max),"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,2.33,258579,DB00602,Ivermectin
,19410269,area under the concentration-time curve-AUC,"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),[d·ng] / [ml],110.26,258580,DB00602,Ivermectin
,19410269,area under the concentration-time curve-AUC,"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),[d·ng] / [ml],73.38,258581,DB00602,Ivermectin
,19410269,terminal half-life-t(1/2lambdaz),"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,5.65,258582,DB00602,Ivermectin
,19410269,terminal half-life-t(1/2lambdaz),"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,3.81,258583,DB00602,Ivermectin
,19410269,plasma residence time-MRT,"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,9.31,258584,DB00602,Ivermectin
,19410269,plasma residence time-MRT,"Although, there were no significant differences on C(max) (10.83 ng/ml vs. 10.15 ng/ml) and t(max) (2.75 days vs. 2.33 days) values; the area under the concentration-time curve-AUC (110.26 ng.d/ml vs. 73.38 ng.d/ml) the terminal half-life-t(1/2lambdaz) (5.65 days vs. 3.81 days) and the mean plasma residence time-MRT (9.31 days vs. 6.35 days) were significantly different in Kilis goats compared with Damascus goats, respectively.",Breed-related plasma disposition of ivermectin following subcutaneous administration in Kilis and Damascus goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19410269/),d,6.35,258585,DB00602,Ivermectin
,17199426,bioavailability,"After SC administration, noncompartmental analysis revealed that bioavailability of ivermectin is nearly complete (98.20%), has a slow mean absorption time of 0.96 days, and reaches a maximum plasma concentration of 19.55 ng/mL at 3.13 days.",Bioavailability of a commercial formulation of ivermectin after subcutaneous administration to sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199426/),%,98.20,259854,DB00602,Ivermectin
,17199426,mean absorption time,"After SC administration, noncompartmental analysis revealed that bioavailability of ivermectin is nearly complete (98.20%), has a slow mean absorption time of 0.96 days, and reaches a maximum plasma concentration of 19.55 ng/mL at 3.13 days.",Bioavailability of a commercial formulation of ivermectin after subcutaneous administration to sheep. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199426/),d,0.96,259855,DB00602,Ivermectin
,17199426,maximum plasma concentration,"After SC administration, noncompartmental analysis revealed that bioavailability of ivermectin is nearly complete (98.20%), has a slow mean absorption time of 0.96 days, and reaches a maximum plasma concentration of 19.55 ng/mL at 3.13 days.",Bioavailability of a commercial formulation of ivermectin after subcutaneous administration to sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199426/),[ng] / [ml],19.55,259856,DB00602,Ivermectin
,29346388,half-life,Pharmacokinetic parameters showed a half-life between 81 and 91 h in the different treatment groups.,Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29346388/),h,81 and 91,264791,DB00602,Ivermectin
,28115181,overall clinical drug efficacies,"The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ).",Resistant nematodes in cattle: Pharmaco-therapeutic assessment of the ivermectin- ricobendazole combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115181/),%,48,264947,DB00602,Ivermectin
,28115181,overall clinical drug efficacies,"The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ).",Resistant nematodes in cattle: Pharmaco-therapeutic assessment of the ivermectin- ricobendazole combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115181/),%,94,264948,DB00602,Ivermectin
,28115181,overall clinical drug efficacies,"The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ).",Resistant nematodes in cattle: Pharmaco-therapeutic assessment of the ivermectin- ricobendazole combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115181/),%,98,264949,DB00602,Ivermectin
,19892381,C(max),A significantly higher (p<0.01) C(max) (36.7+/-7.52 ng/ml) value was obtained at a delayed (p<0.05) T(max) (48.0+/-0.0 h) in light compared to heavy (C(max): 8.0+/-0.80 ng/ml; at 34.0 h) body weight sheep.,Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19892381/),[ng] / [ml],36.7,265138,DB00602,Ivermectin
,19892381,T(max),A significantly higher (p<0.01) C(max) (36.7+/-7.52 ng/ml) value was obtained at a delayed (p<0.05) T(max) (48.0+/-0.0 h) in light compared to heavy (C(max): 8.0+/-0.80 ng/ml; at 34.0 h) body weight sheep.,Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19892381/),h,48.0,265139,DB00602,Ivermectin
,19892381,C(max),A significantly higher (p<0.01) C(max) (36.7+/-7.52 ng/ml) value was obtained at a delayed (p<0.05) T(max) (48.0+/-0.0 h) in light compared to heavy (C(max): 8.0+/-0.80 ng/ml; at 34.0 h) body weight sheep.,Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19892381/),[ng] / [ml],8.0,265140,DB00602,Ivermectin
,19892381,AUC,"The NTX AUC value in ""low bw"" (1188.5+/-122.6 microg day/ml) was significantly lower (p<0.05) than that obtained in the ""high bw"" (oldest) animals (1735.0+/-155.8 microg day/ml).",Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19892381/),[d·μg] / [ml],1188.5,265141,DB00602,Ivermectin
,19892381,AUC,"The NTX AUC value in ""low bw"" (1188.5+/-122.6 microg day/ml) was significantly lower (p<0.05) than that obtained in the ""high bw"" (oldest) animals (1735.0+/-155.8 microg day/ml).",Combined subcutaneous administration of ivermectin and nitroxynil in sheep: age/body weight related changes to the kinetic disposition of both compounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19892381/),[d·μg] / [ml],1735.0,265142,DB00602,Ivermectin
,24144515,Cmax,"Cmax (ng/ml) for moxidectin injection, oral and pour-on were 71.8, 8.3 and 0.4, respectively, and for abamectin injection, oral and pour-on were 62.1, 30.3 and 10.0, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),[ng] / [ml],71.8,265974,DB00602,Ivermectin
,24144515,Cmax,"Cmax (ng/ml) for moxidectin injection, oral and pour-on were 71.8, 8.3 and 0.4, respectively, and for abamectin injection, oral and pour-on were 62.1, 30.3 and 10.0, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),[ng] / [ml],8.3,265975,DB00602,Ivermectin
,24144515,Cmax,"Cmax (ng/ml) for moxidectin injection, oral and pour-on were 71.8, 8.3 and 0.4, respectively, and for abamectin injection, oral and pour-on were 62.1, 30.3 and 10.0, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),[ng] / [ml],0.4,265976,DB00602,Ivermectin
,24144515,Cmax,"Cmax (ng/ml) for moxidectin injection, oral and pour-on were 71.8, 8.3 and 0.4, respectively, and for abamectin injection, oral and pour-on were 62.1, 30.3 and 10.0, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),[ng] / [ml],62.1,265977,DB00602,Ivermectin
,24144515,Cmax,"Cmax (ng/ml) for moxidectin injection, oral and pour-on were 71.8, 8.3 and 0.4, respectively, and for abamectin injection, oral and pour-on were 62.1, 30.3 and 10.0, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),[ng] / [ml],30.3,265978,DB00602,Ivermectin
,24144515,Cmax,"Cmax (ng/ml) for moxidectin injection, oral and pour-on were 71.8, 8.3 and 0.4, respectively, and for abamectin injection, oral and pour-on were 62.1, 30.3 and 10.0, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),[ng] / [ml],10.0,265979,DB00602,Ivermectin
,24144515,Area under the curve (AUC),"Area under the curve (AUC) estimates for moxidectin injection, oral and pour-on were 106.6, 12.9 and 6.1, respectively, and for abamectin injection, oral and pour-on were 162.7, 57.5 and 74.3, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),,106.6,265980,DB00602,Ivermectin
,24144515,Area under the curve (AUC),"Area under the curve (AUC) estimates for moxidectin injection, oral and pour-on were 106.6, 12.9 and 6.1, respectively, and for abamectin injection, oral and pour-on were 162.7, 57.5 and 74.3, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),,12.9,265981,DB00602,Ivermectin
,24144515,Area under the curve (AUC),"Area under the curve (AUC) estimates for moxidectin injection, oral and pour-on were 106.6, 12.9 and 6.1, respectively, and for abamectin injection, oral and pour-on were 162.7, 57.5 and 74.3, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),,6.1,265982,DB00602,Ivermectin
,24144515,Area under the curve (AUC),"Area under the curve (AUC) estimates for moxidectin injection, oral and pour-on were 106.6, 12.9 and 6.1, respectively, and for abamectin injection, oral and pour-on were 162.7, 57.5 and 74.3, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),,162.7,265983,DB00602,Ivermectin
,24144515,Area under the curve (AUC),"Area under the curve (AUC) estimates for moxidectin injection, oral and pour-on were 106.6, 12.9 and 6.1, respectively, and for abamectin injection, oral and pour-on were 162.7, 57.5 and 74.3, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),,57.5,265984,DB00602,Ivermectin
,24144515,Area under the curve (AUC),"Area under the curve (AUC) estimates for moxidectin injection, oral and pour-on were 106.6, 12.9 and 6.1, respectively, and for abamectin injection, oral and pour-on were 162.7, 57.5 and 74.3, respectively.",Reduced efficacy of moxidectin and abamectin in young red deer (Cervus elaphus) after 20 years of moxidectin pour-on use on a New Zealand deer farm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24144515/),,74.3,265985,DB00602,Ivermectin
,8224326,limit of detection,The limit of detection of the assay is 1 ng per g tissue.,Determination of ivermectin residues in the tissues of Atlantic salmon (Salmo salar) using HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8224326/),[ng] / [g],1,269170,DB00602,Ivermectin
,8224326,half-life,"The half-life of 22,23-dihydroavermectin B1a was similar in all tissues studied, ranging from 89 to 98 degree days.",Determination of ivermectin residues in the tissues of Atlantic salmon (Salmo salar) using HPLC with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8224326/),d·degree,89 to 98,269171,DB00602,Ivermectin
,22638921,AUC(inf),"The main pharmacokinetic parameters of eprinomectin B1a were: AUC(inf), 124 ± 24 day ng/mL; T (1/2), 5.2 ± 0.9 days; and C (max), 9.7 ± 2.2 ng/mL.",Reevaluation of efficacy against nematode parasites and pharmacokinetics of topical eprinomectin in cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638921/),[d·ng] / [ml],124,270005,DB00602,Ivermectin
,22638921,T (1/2),"The main pharmacokinetic parameters of eprinomectin B1a were: AUC(inf), 124 ± 24 day ng/mL; T (1/2), 5.2 ± 0.9 days; and C (max), 9.7 ± 2.2 ng/mL.",Reevaluation of efficacy against nematode parasites and pharmacokinetics of topical eprinomectin in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638921/),d,5.2,270006,DB00602,Ivermectin
,22638921,C (max),"The main pharmacokinetic parameters of eprinomectin B1a were: AUC(inf), 124 ± 24 day ng/mL; T (1/2), 5.2 ± 0.9 days; and C (max), 9.7 ± 2.2 ng/mL.",Reevaluation of efficacy against nematode parasites and pharmacokinetics of topical eprinomectin in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638921/),[ng] / [ml],9.7,270007,DB00602,Ivermectin
,8786219,Peak excretion levels,"Peak excretion levels of 0.36 mg/kg (grain-fed) and 0.09 mg/kg (pasture-fed) of ivermectin were recorded at 6 and 8 days post-injection (dpi), respectively.",Effect of diet on the excretion profile of ivermectin in cattle faeces. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786219/),[mg] / [kg],0.36,271199,DB00602,Ivermectin
,8786219,Peak excretion levels,"Peak excretion levels of 0.36 mg/kg (grain-fed) and 0.09 mg/kg (pasture-fed) of ivermectin were recorded at 6 and 8 days post-injection (dpi), respectively.",Effect of diet on the excretion profile of ivermectin in cattle faeces. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786219/),[mg] / [kg],0.09,271200,DB00602,Ivermectin
,33139276,50% of maximum effect,"For the monotherapy arm and the arm including the combination with oxantel pamoate, E max models adequately described the correlation between dADT exposure and probability of being cured, with required exposures to achieve 50% of maximum effect of 39.6 and 15.6 nmol/ml·h, respectively.",Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33139276/),[nM] / [h·ml],39.6,271315,DB00602,Ivermectin
,33139276,50% of maximum effect,"For the monotherapy arm and the arm including the combination with oxantel pamoate, E max models adequately described the correlation between dADT exposure and probability of being cured, with required exposures to achieve 50% of maximum effect of 39.6 and 15.6 nmol/ml·h, respectively.",Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33139276/),[nM] / [h·ml],15.6,271316,DB00602,Ivermectin
,3838773,terminal half-life,"When given intravenously, ivermectin was very slowly eliminated with a terminal half-life of 178 h and a volume of distribution at steady state of 5.3 l/kg indicating sequestration in a temporary depot.","Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838773/),h,178,272691,DB00602,Ivermectin
,3838773,volume of distribution at steady state,"When given intravenously, ivermectin was very slowly eliminated with a terminal half-life of 178 h and a volume of distribution at steady state of 5.3 l/kg indicating sequestration in a temporary depot.","Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838773/),[l] / [kg],5.3,272692,DB00602,Ivermectin
,3838773,peak plasma concentration,"Intra-abomasal administration resulted in rapid absorption, a peak plasma concentration of 60.6 ng/ml at 4.4 h, and 100% bioavailability.","Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838773/),[ng] / [ml],60.6,272693,DB00602,Ivermectin
,3838773,bioavailability,"Intra-abomasal administration resulted in rapid absorption, a peak plasma concentration of 60.6 ng/ml at 4.4 h, and 100% bioavailability.","Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838773/),%,100,272694,DB00602,Ivermectin
,3838773,peak concentration,"However, intraruminal administration produced a much lower peak concentration (17.6 ng/ml at 23.5 h) and bioavailability (25.1%).","Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838773/),[ng] / [ml],17.6,272695,DB00602,Ivermectin
,3838773,bioavailability,"However, intraruminal administration produced a much lower peak concentration (17.6 ng/ml at 23.5 h) and bioavailability (25.1%).","Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838773/),%,25.1,272696,DB00602,Ivermectin
,25188004,water solubility,"The water solubility of IVM in SPC-SDC-MMs (4.79 ± 0.02 mg/mL) was improved by 1200-fold, comparing with free IVM (0.004 mg/mL).","Subcutaneously injected ivermectin-loaded mixed micelles: formulation, pharmacokinetics and local irritation study. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188004/),[mg] / [ml],4.79,273632,DB00602,Ivermectin
,25188004,water solubility,"The water solubility of IVM in SPC-SDC-MMs (4.79 ± 0.02 mg/mL) was improved by 1200-fold, comparing with free IVM (0.004 mg/mL).","Subcutaneously injected ivermectin-loaded mixed micelles: formulation, pharmacokinetics and local irritation study. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188004/),[mg] / [ml],0.004,273633,DB00602,Ivermectin
